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Abstract 
In this thesis I investigated two aspects of glycobiology. In the first, I investigated 
the potential of !-GalCer analogues to be used in cancer immunotherapy. Two 4-
deoxy !-GalCer analogues, with either a sphinganine or a sphingosine base, were 
synthesised using a convergent strategy. The !-GalCer sphinganine derivative 
was synthesised in 14 steps from D-arabinose, and in an overall 13% yield. The !-
GalCer sphingosine analogue was synthesised in 13 steps also in 13% yield. 
Biological analysis revealed that both 4-deoxy analogues possessed comparable 
activity to !-GalCer in mice, however demonstrated significantly reduced hNKT 
cell activity. The reduced activity was attributed to species-specific differences in 
iNKT cell glycolipid recognition rather than reduced CD1d presentation. From 
these results we suggest that glycolipids developed for potent CD1d-iNKT cell 
activity in humans should contain a ceramide base with the 4-hydroxyl present.  
 
The second part of this thesis focused on protecting group free methodology for 
the synthesis of sugar mimetics that have proven potential as glycosidase 
inhibitors. In this work I developed an efficient, high yielding and 
diastereoselective strategy for the synthesis of a number of five and six membered 
azasugars. This strategy utilises two novel reaction methodologies. The first 
enabled the stereoselective formation of cyclic carbamates from olefinic amines, 
the transition states controlling the stereoselectivity during this reaction are 
discussed. The second reaction facilitated the synthesis of primary amines without 
the need for protecting groups, the scope of this reductive amination methodology 
is also investigated. The five membered azasugars 1,4-dideoxy-1,4-imino-D-
xylitol, 1,4-dideoxy-1,4-imino-L-lyxitol, 1,4-dideoxy-1,4-imino-L-xylitol and 
1,2,4-trideoxy-1,4-imino-L-xylitol were prepared in 5 steps, in good overall yields 
(57%, 55%, 54% and 48% respectively), and without the need for protecting 
groups. The six membered azasugar DGJ was prepared over six steps in 33% 
yield using similar methodology. The synthesised compounds were also tested for 
anti-tubercular activity using a BCG alamar blue assay. 
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Preface 
This thesis is composed of seven chapters that describe the chemistry and biology 
of glycoconjugates and carbohydrates that can inhibit the metabolism of this 
important class of compound. In chapter one, an introduction into the studies 
undertaken in chapters two through seven is given. Here the reader is introduced 
to the iNKT cell ligand !-GalCer (1, Figure 1). In addition the therapeutic value 
of azasugars as glycosidase inhibitors is presented. 
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Figure 1. The iNKT cell ligand !-GalCer. 
 
The three major goals of this thesis were firstly, to understand the glycolipid 
structural components required for potent iNKT cell activation. Specifically we 
wanted to understand the importance of the 4-hydroxyl for glycolipid activity. 
Secondly, to develop methodology that enabled azasugars to be synthesised 
without using protecting groups. Thirdly, to investigate the anti-tubercular activity 
of compounds described in chapters four to six. 
 
Chapters two and three focus on understanding the importance of the 4-hydroxyl 
for iNKT cell activity. In chapter two, the syntheses of two 4-deoxy !-GalCer 
analogues, 2 and 3 (Figure 2), are described. The 4-deoxy analogues 2 and 3 were 
each synthesised in 13% yield over 14 and 13 steps respectively. In chapter four 
the biological activity of these 4-deoxy analogues, compared to !-GalCer was 
investigated. I found that the 4-hydroxyl was not a requirement for potent iNKT 
cell activity in mice, however, was vital for human iNKT cell activation. 
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Figure 2. The two 4-dexyo !-GalCer analogues synthesised in chapter two. 
 
Chapters four to six focus on developing methodology for the protecting group 
free synthesis of azasugars. In chapter four, two new reaction methodologies were 
developed that enable azasugars to be synthesised without using protecting 
groups. These reactions were a reductive amination, to synthesis primary amines 
directly from aldehydes, and a stereoselective carbamate annulation. The scope of 
the reductive amination was investigated in chapter five. In general this 
methodology was widely applicable to the synthesis of a variety of primary 
amines from aldehyde precursors. In chapter six the scope and application of the 
carbamate annulation for the synthesis of five and six membered azasugars was 
investigated. When the methodology was used to synthesise five membered 
azasugars the carbamate annulation was stereoselective (>20:1 d.r. in all reactions 
carried out). When the methodology was extended to six membered azasugars the 
diastereoselectivity was reduced. Overall the protecting group free methodology 
was employed to synthesise five azasugars from carbohydrate starting materials. 
The azasugars synthesised and the overall yields obtained for their synthesis are 
depicted in figure 3. 
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Figure 3. Azasugars synthesised in chapters four and six using the protecting 
group free methodology developed in this thesis. 
 
In chapter seven the anti-tubercular activity of the compounds described in 
chapters four to six were investigated. In this chapter an established BCG growing 
assay was optimised and used to examine the activity of the compounds. Most 
compounds did not exhibit inhibitory activity, however, 1-
(diphenylmethyl)amino-pent-4-ene-2,3-diol exhibited modest inhibitory activity.  
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Chapter 1: Introduction 
1.1 General introduction  
Glycans are vital components of all cells. Their role in biology, from energy 
storage to cellular recognition, makes them vital to the existence of life as we 
know it.1 Glycoconjugates are one of the most complex biopolymers, due to their 
vast monomeric structural diversity and the number of connection sites possessed 
by each individual unit. As our understanding of the glycome and the biological 
functions of carbohydrates increases, so does our ability to harness their potential 
for the treatment of disease.2 
 
The study of modern carbohydrate chemistry began in 1891, with Emil Fischer’s 
assignments of the relative configurations of the monosaccharides.3,4 Prior to this, 
glucose and galactose were recognised as similar but distinct sugars, yet very little 
was known about their structure.5 Emil Fischer’s work was fundamentally 
important to the field of carbohydrate chemistry and in 1902 he was awarded the 
Nobel Prize in Chemistry for his work on sugars and purines.6,7 Over the next 50 
years, the field of carbohydrate chemistry continued to evolve and flourish, with 
some of the most significant achievements being: the discovery of the first 
naturally occurring branched chain sugar, hamamelose (K. Freudenberg); 
investigations into the cyclic/acyclic nature of hydroxylated aldehydes and 
research into glycosidase enzymes (B. Helferich); and the application of 
methylation analysis to analyse disaccharides (N. Haworth).5 
 
In the 1950s, newly introduced chromatographic and NMR techniques made it 
possible to follow the progress of complex carbohydrate reactions, and during this 
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period of sugar research the importance of the carbocation intermediate, during 
glycosylation reactions, was realised and exploited, thus enabling more controlled 
structural modifications of carbohydrates to be made. A number of sugar 
analogues were synthesised during this period including C-glycosidic, branched 
chain, unsaturated derivatives and carbohydrates with amino-, thiol-, or halogeno-
substituents replacing one or more of the hydroxyl groups on the carbohydrate 
ring. The syntheses of these modified carbohydrates was largely driven by the 
discovery that many modified sugars were not only metabolites, produced by 
microorganisms, but also, in many instances, were biologically active.5  
 
Glycobiology 
As our structural and chemical understanding of carbohydrates has grown, so too 
has our comprehension of the role that carbohydrates play in biological systems. 
Since the late 19th century, the first insights into the role of carbohydrates during 
fermentation marked the beginning of the glycobiology field.8,9 However, due to 
the highly complex nature of glycoconjugates, this field has often been 
overshadowed by genomic and proteomic research.10 Despite this, we now 
understand much about the function of carbohydrates in energy storage, 
intercellular adhesion, signal transduction and viral and bacterial cell-surface 
recognition. Glycans enable cellular recognition and communication, they help to 
distinguish prokaryotes from eukaryotes, and form major components of cell 
walls and peptidoglycans. Many eukaryote and prokaryote cells contain a 
glycocalyx, which sits outside the plasma membrane and consists of a myriad of 
carbohydrate rich molecules (Figure 1.1). These carbohydrate molecules are like 
chemical keys, carrying the information required for events such as regulated 
intercellular interactions.11 As biopolymers, glycoconjugates are one of the most 
complex, and the majority of these are bound to proteins (glycoproteins) or to 
lipid backbones (glycolipids). These carbohydrates, which protrude into the 
surrounding environment, provide binding sites for other cells, pathogens, 
antibodies and lectins (carbohydrate binding proteins). 
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Figure 1.1. Cellular glycocalyx. Glycoproteins and glycolipids protrude from the 
cellular membrane into the surrounding environment. They provide binding sites 
for pathogens, such as viruses and bacteria, other cells, antibodies, and lectins. 
 
The classical ABO blood group antigens provide an elegant example of the 
importance of extracellular glycans. Each of the classified antigens within the 
ABO blood group system are oligosaccharides found at the termini of 
glycoproteins, glycolipids and soluble oligosaccharides (Table 1.1).11 These 
antigens were first discovered on the surface of erythrocytes (red blood cells), 
however, they are also displayed by other tissues and human secretions. The ABO 
classification is based on the presence or absence of two antigens, A and B, on the 
erythrocyte surface.12 In addition, there are two antibodies (gamma globulin 
proteins) anti-A and anti-B, which always occur in the plasma when the 
corresponding antigen is missing. If an oligosaccharide is not modified to the A or 
B type structures, the phenotype is called O and the surface antigen H. These 
antigens are recognised by an antibody called anti-H.11 It is this knowledge which 
enables us to understand why, for example, a person of blood group O cannot 
receive blood from a person with type A blood, as the anti-A antibodies will cross 
react with the A antigens in the received blood, resulting in agglutination. 
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Table 1.1. The ABO blood group system.11 
Phenotype of 
Erythrocytes 
Minimal determinant saccharide 
(Blood group antigen) 
Antibodies found 
in plasma 
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Another important class of carbohydrate-specific binding protein are the lectins. 
Lectins selectively and reversibly bind saccharides, however, they do not possess 
catalytic activity nor are they products of an immune response.13 This 
heterogeneous group of oligomeric proteins has been implicated in diverse 
biological functions including cell adhesion, cell recruitment, intracellular 
 5 
trafficking and immune recognition. Lectins occurring in animals consist of three 
subgroups, the S-type lectins, the C-type lectins and the P-type lectins.11 C-type 
lectins are further classified into endocytic lectins, collectins and selectins. One 
group of important endocytic lectins are the mannose-binding proteins. These are 
soluble lectins present in mammalian serum and liver, which bind to 
oligomannosides on infectious microorganisms, resulting in the activation of the 
compliment system (made up of over 25 proteins), and the subsequent lysis of 
invading pathogens.13 
 
Glycosphingolipids (GSLs), an important class of glycolipid, are components of 
essentially all types of animal and plant cell membranes. There are six series of 
glycosphingolipid that all contain a sphingoid base, most frequently ceramide (1, 
Figure 1.2), but possess different core oligosaccharides.14 The class sphingoid 
base encompasses over 100 different lipid amino alcohols with the three major 
categories in mammalian cells being sphingosine, phytosphingosine and 
sphinganine.15 These core structures can be derivatized with an N-acyl fatty acid 
chain (that can vary in length) to give ceramide (1), phytoceramide (2) and 
dihydroceramide (3), respectively.  
HN
O
OH
HO 12
n
Ceramide
1
Sphingosine
HN
O
OH
HO 12
n
Phytoceramide
2
Phytosphingosine
OH
HN
O
OH
HO 12
n
Dihydroceramide
3
Sphinganine
 
Figure 1.2. Three major categories of sphingoid base found in mammalian cells. 
 
The six series of glycosphingolipids are composed of five more simple categories, 
di-gal, ganglio-, globo-, lacto- and neolacto-, and a sixth hybrid series (Figure 3). 
All contain a !-glycosidic linkage between the carbohydrate at the reducing end 
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and the ceramide moiety. In all except the di-gal series, this sugar is a glucose 
residue. The ganglio-, globo-, lacto- and neolacto-series are further derivatized 
with a 1,4-!-linked galactose residue. The ganglio-series contains a 1,4-!-linked 
galactose residue, whereas the globo-series possess a 1,4-"-linked galactose 
residue, and the lacto- and neolacto-series a 1,3-!-linked N-acetylglucoseamine 
sugar. The roles of GSLs on the cell surface can be roughly divided into two 
functions: 1) involvement in cell adhesion or recognition processes through 
interactions with other GSLs or lectins on neighbouring cells, and 2) influencing 
signal transduction through receptor proteins on the cell surface.16 GSLs are found 
at increased concentrations on the apical membranes of cells that line the inside of 
the stomach, intestines and respiratory tract. These membranes form a barrier 
between the body and the external world, and are the place of first contact for 
many pathogens. Consequently, bacteria, viruses and protozoans have evolved to 
exploit GSLs to aid in virluence.16 For example, the exotoxins excreted by Vibrio 
cholerae are known to bind to ganglioside GM1, and botulism toxin binds to 
gangliosides GD1b and GT1b.14 In addition, some bacteria have GSL-binding 
lectins that may mediate infectivity. GSLs can regulate gene expression via two 
proposed mechanisms: lipid-lipid interactions, where the bioactive GSL alters 
membrane structure and/or the interactions of membrane proteins with the 
membrane bilayer; or lipid-protein interactions, where changes in GSLs modulate 
the functions of proteins.17 Some GSLs mediate signal transduction through the 
formation of ‘glycosynapses’. These are GSL rich, cholesterol independent 
membrane micro domains that contain tetraspanin, growth factor receptor, and 
cytoplasmic protein kinases.14 Another key function of GSLs is their involvement 
in immune responses. Notably, the GSLs "-galactosylceramide ("-GalCer) and 
isoglobotrihexosylceramide (iGb3) are presented by the CD1d molecule to 
invariant natural killer T (iNKT) cells. This process and the cascade events that 
result, following T cell activation, are discussed in more detail in section 1.2. 
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Carbohydrate based drugs 
With the increase in the discovery of carbohydrate-related drug targets, the 
pharmaceutical potential of carbohydrates has been explored.18-20 One particularly 
important area of carbohydrate based drugs has been in the development of 
glycosidase inhibitors.5 Glycosidase enzymes catalyse the hydrolytic cleavage of 
carbohydrates. They have a vital role in a wide range of biological processes 
including intestinal digestion, the post translational modification of glycoproteins, 
lysosomal catabolism of glycoconjugates and in the mediation of some viral 
infections.21 If glycosidases do not function correctly, a number of diseases can 
result from the defective processing of carbohydrates. The inhibition of 
glycosidases can thus provide a valuable therapy for the treatment of diseases 
such as diabetes, cancer and influenza.21,22 
 
Type II diabetes is caused by the body’s inability to respond to insulin, which 
results in a reduced ability to store glucose as the glycogen polysaccharide. This, 
in turn, leads to increased blood sugar levels.23 Though there is no cure for 
diabetes, blood sugar levels can be controlled through the use of glycosidase 
inhibitors that prevent the breakdown of carbohydrate polysaccharides.24 
Glycogen phosphorylase is responsible for the breakdown of glycogen into the 
glucose monomers and DAB (1,4-dideoxy-1,4-imino-D-arabinitol, 4, Figure 1.4), 
a potent inhibitor of glycogen phosphorylase, is currently being investigated for 
the treatment of type II diabetes.25 Another strategy for treating type II diabetes is 
via the regulation of carbohydrate absorption. This can be achieved by inhibiting 
intestinal glucosidase enzymes that break down dietary polysaccharides (e.g. 
starch) to smaller sugar units for absorption. Glyset, also known as miglitol (5, 
Figure 1.4), is one such anti-diabetic drug currently on the market. Miglitol 
inhibits !-glucosidases from the pancreas and small intestine,18 preventing the 
hydrolysis of 1,4-!-linked carbohydrates found in complex polysaccharides such 
as starch. 
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Figure 1.4. Prominent glycosidase inhibitors. 
  
Cancerous tumours express unusual complex carbohydrate structures resulting 
from abnormalities in the N-glycosylation pathway, and tumours that express 
greater numbers of aberrant glycosides are associated with poor clinical 
outcomes.26 The inhibition of key enzymes involved in N-glycosylation, such as 
Golgi !-mannosidase II (dGMII), has shown potential in cancer treatment.27 In 
particular, swainsonine (6, Figure 1.4)28 is a very effective inhibitor of murine cell 
invasion. Swainsonine acts by inhibiting Golgi !-mannosidase II, blocking the 
expression of 1,6-branched complex-type N-linked oligosaccharides. These N-
linked oligosaccharides are over expressed after malignant transformation and are 
required for effective tumour cell invasion. Swainsonine also enhances the natural 
anti-tumour defences of the body through stimulation of the immune system.29  
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Purine nucleoside phosphorylases (PNPs) are required by humans for the 
recycling of deoxyguanosine. T cell immune deficiency syndrome occurs as a 
result of a genetic deficiency of PNP,30 an observation that has made human PNP 
a target for the treatment of over activated T cells in disease such as T cell 
leukaemia and T cell related autoimmune disease. A number of synthetic high 
affinity transition state analogues have been developed as PNP inhibitors. 
Amongst the first generation inhibitors, Immucillin-H (7) and DADMe-
Immucillin-H (8, Figure 1.4) are the most notable with Pico-molar inhibition of 
PNP. These azasugar derivatives are currently in clinical trials for the treatment of 
leukemia.31  
 
Lysosomal storage disorders (LSDs) are a group of about 50 inherited metabolic 
disorders characterised by lysosomal dysfunction, and are usually a consequence 
of a single enzyme deficiency that is required for metabolism. Gaucher’s disease, 
a type of LSD, results from deficient glucocerebrosidase activity leading to the 
accumulation of glucosylceramide in cells, particularly white blood cells, and in 
some organs including the spleen, liver, kidneys and brain.2 This can lead to 
problems such as liver malfunction, severe neurological complications and sclera 
(the growth of tissue over the eye). Enzyme replacement therapy can be used for 
some, but not all forms of the disease, and because of this, enzyme inhibitors, 
which reduce glucosylceramide levels, hold much promise as therapies for 
Gaucher’s disease. Miglustat (9, Figure 1.4) is a glycosidase inhibitor that can be 
used to treat Gaucher’s disease.18 Miglustat inhibits glucosylceramide synthase 
thereby resulting in a global reduction of GSL levels and reduced GSL 
accumulation (Figure 1.5). 
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Figure 1.5. Inhibition of glucosylceramide synthase with Miglustat leads to a 
global reduction in glycosphingolipids via the reduced biosynthesis of 
glucosylceramide. 
 
Fabry’s disease, also a LSD, is caused by a deficiency in !-galactosidase A. This 
enzyme hydrolyses the terminal galactose residue from Gb3.32 A deficiency in this 
enzyme leads to the accumulation of Gb3 and other related glycolipids within 
lysosomes. In the end stages of the disorder, renal disease and life-threatening 
cardiovascular or cerebrovascular complications limit life expectancy. 1-
Deoxygalactonojirymicin (DGJ, 10) is currently being investigated for its ability 
to treat Fabry’s disease.32,33 Some forms of Fabry’s disease are caused by mis-
folded enzymes. The firm binding between DGJ and the mutant !-galactosidase A 
shifts the folding and stability of the enzyme in favour of the proper conformation 
and allows for a smooth escape of the enzyme from the ER for trafficking to the 
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lysosomal compartment. Once in the lysosome !-galactosidase A maintains its 
proper function. Though DGJ is an !-galactosidase A inhibitor, remarkably, in the 
treatment of Fabry’s disease leads to an increase in !-galactosidase A levels 
within the cells of those with the mis-folded enzyme. 
 
Another disease that can be treated by using a carbohydrate mimic is influenza. 
Influenza is an acute respiratory viral infection that affects millions of people each 
year. The influenza virus infects the respiratory epithelium by targeting sialic acid 
residues on glycoproteins and gangliosides. It uses two enzymes for this process: 
hemagglutinin, which enables the virus to attach to the host sialic acid and 
penetrate the plasma membrane; and neuraminidase, which enables the virus to 
detach itself after viral replication via sialic acid hydrolysis.5 Without 
neuraminidase, virus particles would not be able to escape the host cell surface 
and infect other cells. The inhibition of this enzyme therefore presents a valuable 
target for the treatment of influenza. Zanamivir (11, Figure 1.4) was the first 
neuraminidase inhibitor used for this purpose. Later in 2000 Tamiflu"(12) was 
developed.18,20 This neuraminidase inhibitor is more frequently used owing to its 
improved pharmacokinetic properties.  
 
By and large, the majority of glycosidase inhibitors discovered to date are 
azasugars (carbohydrates where the ring oxygen is replaced with a nitrogen atom). 
In view of this, azasugars have become popular synthetic targets and are 
frequently screened for their ability to inhibit glycosidases.10 A more thorough 
analysis of the history and synthesis of azasugars will be discussed in section 1.3.  
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1.2 Glycolipid adjuvants for cancer immunotherapy 
Over the last decade, interest in cancer vaccination has increased as our 
knowledge and understanding of the immune system has developed. At the start 
of the 20th century, cancer research focused predominantly on the development of 
new chemotherapeutic drugs,34 with some of the most successful drugs adding 
months to the lives of cancer patients. However, as most chemotherapeutics do 
not specifically target cancer cells, many have undesirable side effects.35-37 In 
light of this, therapeutic cancer vaccination strategies, in which the immune 
system is selectively activated to recognise and destroy tumour cells, are being 
developed to treat cancer. In 2010 the U.S. food and drug administration approved 
the first therapeutic cancer vaccine Provenge® for the treatment of prostate 
cancer.38 
 
Research into cancer vaccination began over 100 years ago with the work of 
William B. Coley. In 1892, Coley injected streptococcal bacteria into a patient 
with inoperable cancer to induce erysipelas (infection of the dermis) and stimulate 
the immune system.39,40 Coley observed that the malignant tumour reduced in size 
and he attributed this to the immune system destroying the cancer. Over the next 
40 years, Coley continued to investigate this form of cancer therapy and treated 
hundreds of patients with inoperable bone and soft-tissue sarcomas.41 Coley's 
therapy used a heat-treated streptococcal bacterium combined with a second 
bacterium called Serratia marcescens.42 This concoction became known as 
Coley’s Toxins and by the end of his career he had treated over 1,000 cancer 
patients. Although Coley's research generated widespread interest, it was 
criticised because his patient follow-up was poorly documented, 13 different toxin 
preparations were used, and his methods of administration were inconsistent. The 
growing popularity of radiation and chemotherapy coupled with the inability of 
others to reproduce his results, led to the demise of Coley's cancer 
immunotherapies and this avenue of research was largely ignored until the late 
20th century. 
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Antigen presentation 
Our knowledge of the immune system and how an antigen is presented has grown 
considerably since Coley’s time. Antigen presentation is a process by which 
antigen-presenting cells (APCs) enable T cells to recognise antigen. Antigens are 
presented by major histocompatibility complex (MHC) proteins on the surface of 
cells.43 There are two types of MHC complexes: MHC I, which presents 
intracellular antigens, and MHC II, which is only displayed by specialised 
immune cells and presents antigens that have been phagocytosed. Each person has 
a unique set of MHC proteins that enables their own cells to be distinguished from 
another person's. Nucleated cells are constantly presenting peptide on their MHC I 
complexes. If the peptide is a self-peptide, no immune response will be generated. 
Alternatively, if the peptide is foreign, this antigenic peptide will be recognised by 
immature antigen presenting cells (APCs). There are two categories of APCs, 
professional and non-professional. Compared to non-professional APCs, 
professional APCs internalise and display antigen more efficiently. The dendritic 
cell (DC) is a type of professional APC, which plays an important role in cancer 
immunotherapy.44  
 
During a primary immune response, immature DCs that have acquired antigen 
mature and migrate to the lymph node (Figure 1.6). Here they present the antigen 
on their MHC I receptors to the T cell receptor (TCR) on T cells. This interaction 
combined with cluster of differentiation (CD) 8 co-stimulation leads to T cell 
activation.45 Once the T cell is activated it divides and replicates, producing a 
number of T cells with the same TCR and the capacity to recognise the same 
specific antigen-MHC complex. These T cells migrate from the lymph node to the 
periphery seeking out cells that present the complementary antigen. The CD8+ T 
cells are then able to kill these foreign or defective cells (Figure 1.6).  
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Cancer immunotherapy 
The immune system can specifically identify and eliminate cancerous and/or 
precancerous cells on the basis of tumour-specific antigens induced by cellular 
stress.46 This process is called tumour immune surveillance.47 However, due to 
mechanisms not fully understood, a tumour cell is sometimes able to escape 
clearance.48 Once a tumour has developed, it is difficult for an immune response 
to be generated against it.49 There are two key reasons for this. First, tumour 
vasculature is incomplete and irregular making it difficult for immune cells to 
survey the tumour for antigen. Second, the tumour environment is highly 
immunosuppressive. This renders the majority of infiltrating immune cells 
inactive. The mechanisms contributing to the immunosuppressive 
microenvironment are not well understood, however a number of soluble 
suppressive factors such as TGF-!, VEGF, IL-10 and gangliosides have been 
implicated.49,50 
 
Cancer immunotherapy aims to stimulate a patient's immune system and restore 
the defective elements of the antigen presentation pathway thereby enabling the 
immune system to attack the malignant tumour cells responsible for the disease. 
There are several types of immunotherapy regimes, which can be broadly grouped 
into non-specific and specific immunotherapy. In these strategies, tumour antigen 
is provided to activate the anti-tumour response and/or boost the immune 
response. Some of the cancer vaccination strategies under investigation include: 
 
Non-specific Immunotherapy: 
• Toll-like receptor (TLR) activation – TLRs recognise danger signals 
produced by microbes.51 This immunotherapy regime attempts to alarm 
immune cells by providing the danger signals usually produced by 
pathogens.52  
• Administration of cytokines – Cytokines can modulate anti-tumour 
responses. For example, interleukin (IL)-2 has been shown to offset 
defective antigen recognition and stimulate tumour destruction by T or 
Natural Killer (NK) cells. Cytokines have been used on their own, or in 
combination with other immunotherapy regimes.53-55 
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• NK cell therapy – In this therapy, NK cells are administered with IL-2 to 
induce tumour regression. The reduced level of MHC expression on 
tumours makes them especially susceptible to lysis by NK cells.56 
 
Specific Immunotherapy 
ADOPTIVE TRANSFER. 
• Antibody adoptive transfer – Injection of prepared tumour-specific anti-
bodies that can kill the tumour directly or activate anti-body dependent 
cellular cytotoxicity. For example, the anti-body bevacizumab targets 
vasculature endothelial growth factor (VEGF) promoting 
angiogenesis.57,58 
• Adoptive cell transfer – Injection of cultured T cells pre-activated with 
tumour cells to target cancer antigens.59 
VACCINATION 
• Tumour cell vaccines – Vaccination with killed tumour cells mixed with a 
potent adjuvant.60 
• Tumour antigen vaccines – Administration of crude antigen mixtures (e.g. 
chaperone-peptide-rich complexes) extracted from tumours.60,61 
• Peptide vaccines – Injection of defined peptide antigens (e.g. gp100)62  
known to be expressed on tumours. These can bind to MHC I or II and be 
directly recognised by CD8 or CD4 T cells.63 
• Dendritic cell (DC) vaccines – DCs are harvested from the blood of a 
cancer patient and primed ex vivo with killed tumour cells before 
reinjection into the patient. This enables the immune system to recognise 
the cancer as foreign (discussed in subsequent paragraphs).64 
• Viral vectors and DNA vaccines – Delivery of naked DNA or viral vectors 
(e.g. adenovirus) encoding tumour antigen.60,65 
• Idiotype vaccines – Delivery of an antibody that mimics a natural tumour 
antigen. These vaccines can stimulate the body to produce an immune 
response against tumour cells.60 
 
Immunotherapy strategies are often combined to afford an improved treatment 
regime. For example, TLRs may be used in combination with DC vaccination.66 
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DC based cancer immunotherapy 
The DC based cancer immunotherapy regime provides DCs with tumour antigen 
for presentation and initiation of the anti-tumour response (Figure 1.7).67 In this 
therapy, a portion of a patient's tumour is surgically removed. A blood sample is 
also taken from the patient and from this sample, immature DCs are isolated. 
Apoptosis is induced in the cancer cells ex vivo and the isolated DCs are primed 
using the dead cancer cells. This process loads the DC MHC I proteins with 
antigen from the tumour cells. Following maturation, the DCs are re-injected into 
the patient.  The activated DCs prime the patient's immune response to target and 
kill cancer cells. 
 
 
Figure 1.7. The DC cancer vaccination process. After surgical removal of 
tumour cells, the cells are killed and mixed with DCs from the patient's blood. 
These DCs then present the tumour antigen and, after maturation, are re-injected 
into the patient where they elicit an anti-tumour immune response. 
 
Priming of the immune response occurs via MHC I presentation of antigen to 
CD8+ T cells in the lymph node. This generates a cancer cell specific anti-tumour 
immune response because only those CD8+ T cells with the correct receptor for 
binding to the specific cancer antigens (presented by the DC) are activated. 
Several cytokines, including IL-12 produced by the DCs, are also required for T 
cell activation.  Once activated, the CD8+ T cells migrate from the lymph node 
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and travel around the body to find and destroy tumour cells presenting the specific 
peptide antigen. By activating the DCs ex vivo, the defective tumour vasculature 
and the immunosuppressive tumour environment are by-passed. This is because 
the apoptosed cancer cells are given directly to the DCs thereby improving the 
availability of the antigen. This ex vivo DC activation also enhances maturation 
and antigen presentation. Despite these benefits, the anti-tumour immune 
response generated is often too weak to reproducibly eliminate and prevent the 
reoccurrence of the cancer. By increasing the strength of the immune response, 
this therapy could be greatly improved.68 One way an immune response can be 
enhanced is via the activation of Natural Killer T (NKT) cells.  
 
NKT cells 
NKT cells are a distinct population of T lymphocytes with enormous therapeutic 
potential in the treatment of cancers and autoimmune disorders. They are 
powerful regulators of the immune system and their activation results in a cascade 
of events ultimately leading to an enhanced immune response. NKT cells 
constitute approximately 0.2 per cent of all peripheral blood T cells51,69 and share 
properties of both T cells and Natural Killer (NK) cells as they express both a 
semi-invariant T cell receptor (TCR) and NK cell markers.70 In contrast to the 
traditional T cell, the TCR of NKT cells recognises the carbohydrate portion of 
glycolipids presented by the ‘MHC class I like’ cluster of differentiation (CD)1d 
molecule. CD1d is a member of the CD 1 family of glycoproteins71 and is 
displayed on the surface of APCs including DCs, B cells and macrophages.72 The 
CD1d receptor has a hydrophobic region that binds to the lipid portion of a 
glycolipid antigen exposing the carbohydrate region to NKT cells.73 "-
Galactosylceramide ("-GalCer, KRN7000, 13, Figure 1.8) is currently the most 
powerful glycolipid known to bind to CD1d and activate iNKT cells. This 
glycolipid is composed of a galactose head group and a ceramide lipid tail with a 
phytosphingosine base. The hydrophobic region of CD1d is composed of two 
binding pockets. The phytosphingosine chain of "-GalCer binds to the F’ pocket 
(alternatively termed the C’ by Cerundolo and co-workers)73 and the longer acyl 
chain is anchored in the A’ pocket. 
 20 
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Figure 1.8. The well studied iNKT cell ligand "-GalCer. 
 
Although there are subtypes of CD1d-dependant NKT cells, the best characterised 
expresses a semi-invariant T cell receptor. These type 1 or semi-invariant NKT 
(iNKT) cells are conserved across the majority of the mammalian population and 
are found in both humans and mice. They express an invariant "-chain combined 
with a limited, but not invariant, TCR !-chain. The TCR expressed by murine 
iNKT cells consists of an "-chain encoded by a V!14-J!18 rearranged gene that 
is preferentially associated with a !-chain encoded by V"8.2, V"2, or V"7.74 
Human iNKT cells also express an invariant TCR, however, the "-chain is 
encoded by the V!24-J!18 gene mainly associated with the V"11 !-chain. 
Human and mouse iNKT cells are highly cross-reactive and mouse iNKT cells 
can recognise human CD1d as well as mouse CD1d, and human iNKT cells can 
also recognise both CD1d homologues.75 The unprecedented degree of 
conservation in this T cell recognition system suggests that it is fundamentally 
important. Furthermore, the highly conserved TCR of iNKT cells makes them an 
ideal target to activate for improved cancer immunotherapy regimes.  
 
 
A number of glycolipids have been studied for their ability to bind to CD1d and 
activate iNKT cells. To date, "-GalCer (13, Figure 1.8) is the most potent and 
well-studied iNKT cell ligand. Activation of iNKT cells by "-GalCer leads to the 
immediate production of cytokines and an enhanced immune response.76 Upon 
activation, iNKT cells produce a host of cytokines such as interferon (IFN)-#, IL-
4, and to a lesser extent, IL-2 and tumour necrosis factor (TNF)-" (Figure 9). 
iNKT cell activation also leads to the trans activation of DCs and B cells which 
upregulate several maturation markers including CD80 and CD86 in response.77 
CD80 (also called  B7.1) and CD86 (B7.2) are co-stimulatory molecules that bind 
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to CD28 on T cells enhancing the TCR mediated activation of T cells.78 Overall, 
this process leads to an enhanced CD8+ T cell anti-tumour immune response with 
each of the cytokines playing a different role. IFN-! and IL-4 both increase IL-12 
production by DCs, and in turn, IL-12 increases the activity of CD8+ cells and 
stimulates NK cells. IL-2 stimulates the growth of CD8+ T cells and TNF-" is 
able to induce apoptosis and inflammation.  
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Synthetic glycolipids for iNKT cell activation 
The discovery of !-GalCer as a powerful CD1d binding lipid began in the 1990s 
when Kirin Pharmaceuticals isolated agelasphin-9b (14, Figure 1.10) from the 
marine sponge Agelas mauritianus.79,80 In 1995, a series of analogues were 
synthesised.81 These varied in fatty acid chain length, lipid chain length, and 
functional group substitution, with the goal being to identify a glycolipid that was 
easier to synthesise yet did not compromise on biological activity to any great 
extent. In murine studies it was discovered that 15 (Figure 1.10) was the most 
“desirable candidate for clinical application”81 due to its reduced structural 
complexity and improved tumour growth inhibition. Overall, it was found that 
longer ceramide lipid tail lengths improved activity, and the optimal lengths 
suggested in this study were C-18 for the lipid tail and C-24 or longer for the fatty 
acid chain. Several analogues were then tested for their ability to induce 
lymphocyte proliferation in human umbilical cord blood.81 When using human 
cells the activity of 15 was significantly reduced, and the importance of the 4-
hydroxyl on the lipid chain was discovered. This work eventually led to the 
selection of 13 (Figure 1.8) for future studies and in 1997 !-GalCer was identified 
as a potent iNKT cell ligand.82 
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Figure 1.10. !-Galactosylceramides isolated and synthesised in the development 
of the potent iNKT cell ligand KRN7000. 
 
Several groups have synthesised structural analogues of !-GalCer (13) to better 
understand which components are required for CD1d presentation and iNKT cell 
activation. The ceramide portion has been modified in a number of ways. These 
include the addition of aromatic residues,83,84 changes to lipid length, saturation 
and hydroxylation pattern85 and variations in the connectivity between the 
unfunctionalised lipid and the phytosphingosine backbone.86 Biological evaluation 
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of these analogues has shown that the CD1d molecule is able to accommodate a 
variety of lipid tails, and that the structure of these can alter iNKT cell activation, 
probably through a combination of affinity (of the lipid for CD1d) and the angle 
of carbohydrate presentation to the iNKT cell.87-91 
 
McCarthy et al. measured the rate at which !-GalCer, and analogues thereof (16, 
Figure 1.11), dissociated from CD1d. These !-GalCer analogues varied in the 
length and saturation of the ceramide lipid. They found that the length of both 
lipid chains (phytosphingosine and acyl) affected the stability of the glycolipid-
CD1d complex. They then investigated the binding affinity of the TCR for the 
human CD1d glycolipid complexes.87 Here, they found a unique role for the 
phytosphingosine lipid chain (which occupies the CD1d F’ channel) in 
modulating the TCR binding affinity to the hCD1d-lipid complex. Only 
alterations in the phytosphingosine length effected TCR affinity. It was concluded 
that incomplete occupation of the CD1d F’ channel results in conformational 
changes at the TCR recognition surface, reducing the affinity of the iNKT cell 
TCR for the CD1d-glycolipid complex. These results demonstrate the importance 
of the !-GalCer lipid lengths, and indicate that the C-26 acyl chain and the C-18 
ceramide base are optimal lengths for potent iNKT cell binding and activation. 
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Figure 1.11. !-GalCer analogues synthesised and tested for their ability to 
activate iNKT cells. 
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Tsuji and co-workers discovered that the C-glycoside analogue of !-GalCer (!-C-
GalCer, 17, Figure 1.11) was a more potent activator of mouse iNKT cells (than 
13), as it stimulated prolonged cytokine production.88,89 Two explanations were 
proposed for this improved activity. First, the C-glycoside analogue may persist 
longer due to its intrinsic resistance to enzyme mediated hydrolytic degradation. 
Second, this unnatural mimetic may have altered receptor-binding properties. The 
activity of this analogue was then investigated toward human cells. However, it 
was found to be a less potent agonist for human iNKT cells.90 Tsuji and co-
workers then investigated E-alkene linked glycolipids and found that some of 
these analogues were more potent activators of human, rather than murine, iNKT 
cells.91 
 
In addition to the synthesis of !-GalCer analogues with structural modifications to 
the ceramide portion, some groups have synthesised analogues with additional 
carbohydrate residues attached to the galactose head group. For example, Besra 
and co-workers synthesised the galactosyl (!1"2) galactosyl ceramide derivative 
18 (Figure 1.11).92 Interestingly, this analogue could only activate iNKT cells 
once it had been processed by APCs to !-GalCer.  
 
 
Isoglobotrihexosylceramide (iGb3) 
Isoglobotrihexosylceramide (iGb3, 19, Figure 1.12) is the only other class of 
glycolipid known to bind to CD1d and activate iNKT cells. iGb3 mediated iNKT 
cell activation produces a similar cytokine profile to !-GalCer, although at a 
reduced level.93 Its ability to bind to the TCR of iNKT cells demonstrates the 
unique ability of this TCR to recognise chemically diverse ligands presented by 
CD1d.94 iGb3 belongs to the family of glycolipids termed globosides, which are 
characterised as those having a sphingosine ceramide lipid tail attached via a #-
linkage to a lactose disaccharide equipped with a 1,4-!-linked galactose unit at 
the terminal position. This combination forms the most simple globoside core, 
termed Gb3 (Figure 3, pg 7). The most well-established role of globosides is to 
serve as cell surface antigens, such as blood group antigens95 or tumour associated 
antigens.17,96 Globosides also mediate cell adhesion and may be involved in signal 
transduction within cells. iGb3 differs from the standard globo-series in that the 
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attachment of the terminal galactose is at the 3'' rather than the 4'' position of the 
lactose moiety. This seemingly minor change enables the activation of iNKT 
cells. Gb3, by contrast, is unable to induce cytokine production by iNKT cells.93 
iGb3 is a lysosomal glycosphingolipid with previously unknown function. 
Accordingly, there has been considerable debate as to whether iGb3 is the ligand 
by which the invariant TCR of iNKT cells is selected upon.69,97 However, it seems 
unlikely that this glycolipid is critical to the development of iNKT cells as 
illustrated in studies where iNKT cell development was normal in mice deficient 
in the enzyme iGb3 synthase.98 In addition, it has been argued that humans do not 
have iGb3 because they lack any functional iGb3-synthase enzymes.99  
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Figure 1.12. Isoglobotrihexosylceramide (iGb3) 
 
A few iGb3 analogues have been synthesised and tested to gain insight into the 
critical elements required for iNKT cell activation, and to determine whether an 
enhanced response can be generated with this class of molecule. Chen et al. 
investigated a series of deoxy analogues in which the hydroxyl groups of the 
terminal galactose were systematically removed.100 The activities of the four iGb3 
analogues were tested against murine iNKT cells and the level of IL-2 measured. 
This structure activity relationship study illustrated that the 2''' and 3''' hydroxyl 
groups appear to be critical for the recognition of iGb3 by iNKT cells. It was also 
suggested that modifications to the 4''' and 6''' positions of iGb3 should not 
diminish stimulatory activity. In 2009 Xia et al. synthesised the iGb3 analogues 
phytosphingosine 20 and sphinganine 21 (Figure 1.13) and investigated their 
ability to stimulate human iNKT cells.101 They discovered that the 
phytosphingosine analogue was 100 times more active than iGb3 itself (when 
tested using human iNKT cells). Savage and co-workers synthesised the !-
anomers of both iGb3 (22, Figure 1.13) and Gb3 (23).102 These glycolipids were 
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effective iNKT cell antigens in both the human and murine settings and did not 
require lysosomal processing to the monoglycosylceramides for stimulation in 
mice.  
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Figure 1.13. iGb3 analogues. 
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Species-specific activity of !-GalCer analogues 
Despite the high degree of cross reactivity between human and mouse iNKT cells, 
there is accumulating evidence to suggest that glycolipid activity can be species-
specific. In particular, the 4-hydroxyl on the ceramide lipid chain appears to be 
important for potent glycolipid activity in humans, but not in mice. As previously 
mentioned, sphinganine glycolipid 15 (Figure 1.10, pg 23) demonstrated potent 
activity in mice, however this did not correspond to human iNKT cell activity.81 
In later studies, Kronenberg and co-workers investigated the activity of several 
glycosphingolipids, including !-GalCer (13) and analogue 15, and observed that 
13 was able to expand human iNKT cells from peripheral blood mononuclear 
cells (PBMCs), while sphinganine glycolipid 15 could not.103 They suggested this 
species-specific activity was due to differences in mouse and human CD1d 
structure. In the human system, studies by Xia et al. demonstrated that the 
phytosphingosine analogue of iGb3 (20, Figure 1.13) was 100 times more active 
than iGb3 itself (19, Figure 1.12).101 However, a recent article by Dubreuil and 
co-workers challenged this species-specific activity and suggested that 13 and 15 
induced comparable human iNKT cell activation.104 
 
Our interests lie in identifying the optimal iNKT cell glycolipid for use in cancer 
immunotherapy. Accordingly, the goal of this work is to identify the importance 
of the 4-hydroxyl on the lipid of !-GalCer for activity in humans. Sphinganine 15 
is a more attractive glycolipid adjuvant (cf. !-GalCer (13)) in the clinical setting, 
because removal of the 4-hydroxyl reduces the complexity and length of the 
synthetic strategy. It has been suggested that the 4-hydroxyl is not important for 
glycolipid activity.104 In addition, we wish to compare the mouse and human 
models for investigating glycolipid activity. Mouse models are frequently used to 
determine the activity of a glycolipid in the context of iNKT cell activation. While 
these models are invaluable tools, and indeed, played a major role in the discovery 
of !-GalCer, it is important to identify the limitations of these models. In the 
original work by Morita et al. the C-26 acyl chain was found to be the optimum 
length for potent activity, however, the sphinganine !-GalCer analogue 15 
synthesised only contained a C-24 acyl chain.81 Thus, to more fully understand the 
influence of the 4-hydroxyl on species-specific glycolipid activity, we want to 
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synthesise !-GalCer sphinganine analogue 24 (Figure 1.14), with the C-26 acyl 
chain, and investigate its activity in mice and humans. In addition, the !-GalCer 
sphingosine analogue 25 (Figure 1.14) has not been synthesised and tested for 
activity. Sphingosine 25 provides an extra target to investigate the importance of 
the 4-hydroxyl for human iNKT cell activation. Together, studies investigating the 
activities of 24 and 25 will enable us to more fully understand the glycolipid 
structural elements required for potent iNKT cell activation in humans. 
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Figure 1.14. Target !-GalCer lipid analogues. 
 
Synthesis of !-GalCer analogues 
A number of elegant strategies for the synthesis of !-GalCer have been 
reported.81,104-110 We combined aspects of these strategies to develop an efficient 
route that allowed for the convergent synthesis of glycolipids 24 and 25 via a 
common late stage building block. For the synthesis of 24 and 25, we propose to 
use the donor developed by Wong and co-workers which contains a benzylidene 
acetal at the 4- and 6-hydroxyls and which leads to !-selective coupling.105 As the 
lipid acceptor a sphingosine azide was chosen. While it is possible to couple the 
complete ceramide lipid, amides reduce the nucleophilicity of the primary 
hydroxyl and reduce the yield of the glycosylation reaction.107 The lipid acceptor 
will be synthesised by modifying the strategy developed by Schmidt and co-
workers,111 whereby the hydroxy aldehyde used in the key Wittig metathesis will 
be prepared using a more efficient strategy, as reported by David et al.112 
Alternative deprotection strategies will then be employed to synthesise 24 and 25 
from a common late stage precursor.  
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1.3 The history and synthesis of azasugars 
Azasugars are structural analogues of traditional carbohydrates, where the ring 
oxygen is replaced with a nitrogen atom. Since the discovery of nojirimycin in 
1966,113 these sugar mimics have attracted considerable attention due to their 
ability to specifically and effectively inhibit carbohydrate-processing enzymes. 
Azasugars are found as secondary metabolites in a wide variety of plants and 
microorganisms and can be divided into the five classes: pyrrolidines, piperidines, 
indolizidines, pyrrolizidines and nortropanes (Figure 1.15). Pyrrolidines and 
piperidines are the most simple and are constructed of five or six membered rings, 
respectively. Indolizidines and pyrrolizidines are bicyclic structures that contain 
five – six (indolizidines) or five – five membered (pyrrolizidines) 1,2 fused rings. 
Nortropanes, also bicyclic structures, contain 2,6 fused five – six membered rings. 
Representative structures of each azasugar class are shown (Figure 1.15), 
however, as this thesis concerns the synthesis of piperidines and pyrrolidines, our 
attention will focus on these two classes of azasugars.  
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Figure 1.15. Representative structures of the five azasugar classes. 
 
Nojirimycin (26) was the first naturally occurring azasugar isolated.113,114 This six 
membered azasugar, or piperidine, was first extracted from Streptomyces 
roseochromogenes in 1966 and was found to possess anti-microbial activity. 
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Later, nojirimycin was also isolated from Streptomyces nojiriensis (from where it 
acquired the name nojirimycin).114 In addition to anti-microbial activity, 
nojirimycin is a potent inhibitor of !- and #-glucosidases. Ten years after the 
discovery of nojirimycin, deoxynojirimycin (DNJ, 27), originally named 
moranoline, was isolated from Mulberry trees,115 though it had been previously 
synthesised in 1966116 and 1968114 prior to its isolation. Fagomine (28) was first 
isolated from buckwheat seeds in 1974 (Fagopyrum esculentum Moench)117 and 
was first synthesised by Fleet et al. in 1985.118 Fagomine, a 1,2-dideoxy azasugar, 
is an inhibitor of mammalian !-glucosidase and #-galactosidase119,120 and was 
reported to have anti-hyperglycemic effects in diabetic mice.121 Due to the 
instability of azasugars with an anomeric hydroxyl (e.g. 26) there has been more 
interest in the activity of C-1 deoxy azasugars (e.g. 27 and 28). The five 
membered azasugars, or pyrrolidines, were first discovered in 1976 when 2,5-
dihydroxymethyl-3,4-dihydroxypyrrolidine (DMDP, 29) was isolated from the 
leaves of Derris elliptica.122 However, DMDP’s ability to inhibit glycoprotein 
processing enzyme glucosidase I was not discovered until several years later.123 
 
Azasugars as enzyme inhibitors  
As eluded to in section 1.1, carbohydrate processing enzymes play an important 
role in a wide range of diseases22,124 including cancer,125 Gaucher’s disease,126 
viral and bacterial infection, and diabeties,21 and accordingly, the development of 
specific and selective glycosidase inhibitors has become the target of many 
synthetic chemists. Arguably, the most valuable property of azasugars is their 
ability to inhibit glycosidase enzymes and it is this property that has been 
exploited during the development of a number of azasugar drugs. Glycosidases 
catalyse the hydrolysis of glycosidic linkages, releasing smaller sugar units 
(Scheme 1.1). The transition state of this reaction involves a positively charged 
oxocarbenium ion. At physiological pH, the nitrogen atom of the azasugar is 
protonated and this charged species resembles the oxocarbenium ion transition-
state formed during carbohydrate hydrolysis.  
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Scheme 1.1. General scheme illustrating the mechanism by which positively 
charged azasugars are able to mimic the glycosyl cation formed during 
carbohydrate hydrolysis. 
 
In addition to their use as glycosidase inhibitors, azasugars have the potential to 
act as glycosyltransferase inhibitors. Glycosyltransferase enzymes catalyse the 
transfer of a monosaccharide donor to a glycosyl acceptor (Scheme 1.2) and are 
involved in the biosynthesis glycoconjugates such as of polysaccharides, 
glycoproteins and glycolipids. During the coupling reaction, a glycosyl cation 
transition state is formed. Once again, it is the positively charged ring nitrogen 
that is able to mimic the positively charged glycosyl cation formed during 
carbohydrate transfer.  
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Scheme 1.2. Azasugar inhibition of glycosyltransferases. 
 
Of particular interest to us is the potential use of azasugar mimics to treat 
tuberculosis (Tb). M. tuberculosis, the causative agent of Tb, has a thick outer cell 
wall that plays a critical role in the intrinsic resistance of mycobacteria to 
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antibiotics, chemical injury and the immune response.127 One of the key features 
of this cell wall is that it contains large arabinogalactan (AG) polysaccharide 
components, which contains linear galactan chains and branched arabinose motifs. 
The arabinogalactan polysaccharide is constructed by arabinosyltransferase 
(AraT) enzymes that use arabinofuranosyl-1-monophosphoryldecaprenol (DPA) 
as the monomeric donor substrate. The AraT enzyme family catalyse the addition 
of the DPA donor to the growing arabinogalactan polysaccharide. During this 
coupling reaction, the donor carbohydrate goes through a positively charged 
glycosyl cation transition state (Scheme 1.2). Therefore, azasugars hold much 
promise for the treatment of Tb. 
 
Despite their valuable inhibitory properties, only a few azasugars have been 
widely studied for their therapeutic potential. This is largely due to the limited 
availability of many azasugars and the complexity of their synthesis.128 
Methodology that enables azasugars to be synthesised in a fast and efficient 
manner is highly advantageous for full assessment of their inhibitory properties. 
 
Synthetic routes to five and six membered azasugars 
A number of routes have been developed for the synthesis of azasugars. These 
utilise a variety of key synthetic transformations including aldol and Wittig 
reactions, Michael additions, reductive aminations, substitution reactions, ring-
closing metathesis, dihydroxylation, and pericyclic reactions. There are a number 
of excellent articles that review the total synthesis of azasugars.129-134 A few 
recent synthetic routes are summarised below. 
 
In 2009, Poisson and co-workers developed an efficient non-chiral pool total 
synthesis of DNJ (27) in 11 steps with an overall yield of 24% (Scheme 1.3).135 
The key reactions in this synthesis were a one-pot ring closing metathesis and 
subsequent hydroboration. The route began with Sharpless asymmetric 
epoxidation of alcohol 30, followed by sodium hydroxide promoted 
rearrangement to give epoxide 31. Reaction of 31 with benzoyl isocyanate, 
followed by base promoted cyclisation gave carbamate 32 in a 77% yield. This 
material was converted to protected diol 33 through Boc protection, followed by 
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carbamate cleavage and benzylidene protection. N-Alkylation of 33 with iodide 
34 provided diene 35, ready for the one-pot Grubbs metathesis and hydroboration 
step. The two-step one-pot conversion of diene 35 into protected azasugar 36 
occurred smoothly (70% yield) and allowed for the final deprotection and total 
synthesis of DNJ (27). While this approach involves a number of steps, the overall 
yield is competitive with the sequence being the most efficient of the non-chiral-
pool approaches for the synthesis of DNJ. 
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Scheme 1.3. Total synthesis of DNJ.135 
 
In the same year Vankar and co-workers developed a route for the synthesis of six 
membered L-azasugars (Scheme 1.4).136 Their synthesis of L-allo-
deoxynojirimycin (43) was performed in 13 steps, with an overall 20% yield. As 
the starting material, protected galactal 37 was used. Conversion of the primary 
hydroxyl to the trichloroacetimidate enabled the key 3,3-sigmatropic 
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rearrangement to install the protected amine functionality at the anomeric position 
and gave amide 38. Reduction of amide 38 followed by Boc protection gave linear 
amine 39 in a 75% yield over the two steps. Next mesylation, followed by Boc 
deprotection enabled intramolecular SN2 cyclisation, induced by K2CO3, to give 
protected azasugar 40. Amine protection followed by osmium tetroxide 
dihydroxylation gave diol 41, which was cleaved using sodium periodate. The 
resulting ketone was reduced and the hydroxyl protected to give tribenzyloxy 
protected azasugar 42. Final deprotection with H2 on Pd/C followed by acid 
mediated hydrolysis gave L-allo-deoxynojirimycin (43). The primary advantages 
of this synthesis are that it enables L-azasugars to be accessed from D-
carbohydrates. In addition, by varying the carbohydrate starting material, 
azasugars with different stereochemistries can be synthesised. Some of the 
disadvantages, however, include the use of osmium tetroxide, which is highly 
poisonous even at low exposure levels, and the requirement for complicated 
starting materials, which are difficult to obtain.  
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Scheme 1.4. Methodology for the synthesis of L-allo-deoxynojirimycin.136 
 
In 2006, a synthesis of the rare five membered L-azasugar 1,4-dideoxy-1,4-imino- 
L-ribitol (49) was published (Scheme 1.5).137 This azasugar was synthesised in 9 
steps from D-glucosamine, in an overall 21% yield. D-Glucosamine 44 was 
subjected to diazotransfer followed by benzylidene protection to give 
azidoglucose 45 in a 75% yield. Next, anomeric protection and stereochemical 
inversion of the hydroxyl at the 3-position gave benzoyloxy-D-alloside 46. Benzyl 
protection of the 3-hydroxyl followed by reductive opening of the benzylidene 
protecting group gave azido-3,4-dibenzyloxy-D-alloside 47, which was converted 
to linear diol 48 via benzoyl deprotection and subsequent reduction using sodium 
borohydride in methanol. Target azasugar 49 was obtained through periodate 
cleavage followed by hydrogenation using palladium on charcoal.  
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Scheme 1.5. Synthesis of 1,4-dideoxy-1,4-imino-L-ribitol.137 
 
Fernández-Mayoralas and co-workers developed an elegant synthesis of five and 
six membered azasugars using a proline derived chiral catalyst to direct the 
stereochemistry of the key aldol reaction.138 In this work, (S)-proline was 
immobilised on a mesoporous silicate and the use of this catalyst in the aldol 
reaction of aldehyde 50 and ketone 51 resulted in anti-selective aldol product 52 
(Scheme 1.6). Subsequent one-pot reduction/cyclisation of azide 52 led to the 
formation of five membered azasugar 53. Although the starting aldehyde is not 
commonly commercially available, it can be relatively easily synthesised from 
tartaric acid, and thus this route provides efficient methodology for the 
preparation of azasugars.  
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Scheme 1.6. Chiral catalysed aldol methodology for the synthesis of azasugars.138 
 
An area of growing concern for the synthetic organic chemist is the ability to 
develop more efficient routes through reducing the number of protecting group 
manipulations used in a sequence.139 A protection/deprotection event introduces 
two additional steps, and incurs costs from additional reagents and waste disposal. 
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With this in mind, Lindström et al. completed an efficient protecting group free 
synthesis of azasugar 57 in water.140 The synthesis commenced with a modified 
Sharpless asymmetric dihydroxylation of 1,6-dibromodiene 54. Hydrolysis of the 
allylic bromide gave diol 55, and subsequent stereoselective epoxidation using 
peroxotungstate catalyst K2[W2O3(O2)4(H2O)2] gave 56 in a 97% yield over the 
two steps. Nucleophilic displacement of the bromide by ammonia led to 
spontaneous intramolecular ring-opening of the epoxide to afford azasugar 57 in 
an 88% yield. Overall, the total synthesis was performed in four steps in an 
impressive 60% total yield.  
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Scheme 1.7. The asymmetric synthesis of a five membered azasugar in water.140 
 
Proposed strategy for the protecting group free synthesis of 
azasugars 
By and large, the vast majority of strategies utilised for the synthesis of azasugars 
employ standard protecting group manipulations. The use of protecting groups has 
the disadvantage of requiring organic solvents for reaction, work-up and 
purification.139 In addition, extensive protecting group manipulations lead to 
lengthy syntheses requiring both protection and deprotection, resulting in reduced 
atom economy141 and hence reaction efficiency. In view of this, we investigated a 
protecting group free synthesis of azasugars to enable their efficient preparation 
and facilitate biological testing. 
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In our protecting group free strategy, we proposed that azasugars (58, Scheme 
1.8) could be prepared via an iodine promoted carbamate annulation to give 
carbamates 59, which could be subsequently hydrolysed to give the desired 
azasugars. We postulated that the linear alkenylamines (60) would be accessible 
via Vasella reductive amination of methyl iodofuranosides 61,142,143 which can be 
prepared in two steps from the parent monosaccharides.144 To achieve this 
protecting group free strategy, two reactions were developed: the one pot iodine 
mediated carbamate annulation reaction and the Vasella reductive amination to 
form primary amines from aldehydes. We also hoped that the complete synthesis 
would be amenable to chemistry in aqueous media. 
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Scheme 1.8. Proposed retrosynthesis for the formation of five membered 
azasugars via cyclic carbamates. 
 
In developing the one pot iodine promoted carbamate annulation reaction we 
wanted the cyclisation to be stereoselective. The use of electrophiles to promote 
nucleophilic addition to allylic alcohols has been well documented and when an 
internal nucleophile is used, the ‘cis’ product is formed preferentially (Scheme 
1.9).145,146 Here the stereochemistry of the allylic alcohol directs the 
stereochemical outcome of the cyclisation. It was anticipated that similar stereo 
control could be extended en route to the desired carbamate. In addition to 
controlling the stereochemistry of the cyclisation, we also wanted to form the 
cyclic carbamate in situ.  
X
OH
I2, base
X = N or O
X
HO
I
 
Scheme 1.9. Stereochemical outcome of iodine promoted cyclisations utilising an 
internal nucleophile. 
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It has previously been reported that cyclic carbamates can be prepared, in modest 
yield, from the reaction of acyclic amines equipped with a halogen leaving group 
and either tetraethylammonium carbonate147 or sodium carbonate148 (Scheme 
1.10). In view of this, we postulated that carbamate building block 59 (Scheme 
1.8) could be prepared via an iodine promoted cyclisation/in situ carbonylation 
using NaHCO3 as both the base, for the halocyclisation, and the source of CO2 for 
the carbamate annulation reaction. 
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Scheme 1.10. Cyclic carbamate formation from acyclic amines equipped with a 
halogen leaving group. 
 
Key in our protecting group free strategy was also the ability to synthesise the 
unprotected linear alkenylamines (60, Scheme 1.8) from iodoglycosides (61) 
using a one-pot Vasella reductive amination with ammonia as the amine 
nucleophile. The Vasella reaction allows for the reductive fragmentation of 
haloglycosides with zinc yielding alkenals.149 In Vasella’s original work activated 
zinc and acetic acid were added to a solution of methyl bromoglucoside 62 in 
ethanol and the solution was stirred at reflux to give aldehyde 63 (Scheme 1.11). 
Magnesium, Zn/Cu and Zn/Ag were also investigated, however, no product was 
observed using these reagents. The Vasella reaction proceeds via oxidative 
insertion of zinc into the carbon-bromide bond, this is followed by reductive 
elimination with the loss of methoxide to give the aldehyde product. This 
methodology is generally applicable to the synthesis of alkenals from both 
pyranose150 and furanose151 precursors equipped with iodide,152,153 bromide154 or 
chloride155 substituents. We proposed to use the Vasella reaction to convert the 
methyl iodoglycosides (61) into alkenal substrates prior to reductive amination. 
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Scheme 1.11. Vasella reaction. 
 
Traditionally, protecting groups have been used when preparing primary amines 
via metal hydride reductive amination,156-158 so as to prevent over alkylation. In 
the typical reductive amination a carbonyl, usually a ketone or an aldehyde (64), 
reacts with an amine (65) to form an imine (66) that is subsequently reduced 
(often with NaCNBH3)159 to give the desired amine product 67 (Scheme 1.12). 
However, when R2 = H, multiple alkylation events typically occur (68) resulting 
in the formation of the undesired secondary (69) or tertiary (70) amine 
products.160-162 This over-alkylation is a consequence of the increased reactivity of 
the primary amine product 67 (when R2 = H) compared to ammonia (65, when R2 
= H).160,163,164 Though the formation of tertiary amines (70) can be reduced by 
increasing the number of amine equivalents and by adjusting the pH,160 it is 
difficult to prevent the formation of secondary amines. To avoid this problem, 
primary or ‘protected’ amines (65, R2 = alkyl, aryl) are commonly used as the 
amine source.156-158  
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Scheme 1.12. Reductive amination of aldehydes. 
 
Miriyala et al. recently developed alternative methodology for the synthesis of 
primary amines via selective reductive amination. Here, primary amines were 
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produced from ketones using ammonia and titanium(IV) isopropoxide-NaBH4.165 
Unfortunately, the extension of this methodology to aldehydes was ineffective and 
predominantly resulted in secondary amine formation. This decreased selectivity 
is a consequence of the reduced steric bulk and high reactivity of aldehydes, 
making them even more likely to give over-alkylated products when compared to 
ketones.163 The selective metal hydride reductive amination of aldehydes to 
primary amines has, therefore, continued to be a significant challenge in scientific 
research. 
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1.4 Thesis outline 
The work in this thesis focuses on the synthesis of glycolipids and azasugars that 
could be used to treat disease. Chapters 2 and 3 describe the synthesis and 
biological evaluation of !-GalCer lipid analogues to assess which lipid sphingoid 
base is required for potent iNKT cell activation in humans. In Chapter 4, 
methodology for the protecting groups free synthesis of azasugars is developed, 
and this work is expanded in Chapters 5 and 6. Chapter 5 focuses on further 
developing the reductive amination reaction using different iodoglycoside and 
aldehyde substrates, and Chapter 6 expands on the carbamate annulation 
methodology. In Chapter 7, the anti-tubercular activity of azasugars, and the 
azasugar building blocks is investigated.  
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Chapter 2: The Synthesis of !-GalCer Analogues 
2.1 Introduction 
The glycolipid !-GalCer (1, Figure 2.1) is a potent iNKT cell ligand that is used 
to boost anti-tumour immune responses during therapeutic cancer vaccination. 
The !-GalCer phytosphingosine lipid possesses a hydroxyl on the 4-position. To 
date the importance of this hydroxyl for human iNKT cell activation has been 
strongly debated. !-GalCer demonstrates potent activity toward both human and 
murine iNKT cells. In contrast, a number of studies have suggested that the 
activity of !-GalCer sphinganine analogue 2 (Figure 2.1) was significantly 
reduced in humans, although in mice, its activity was comparable to !-GalCer.1,2 
In 2008, Dubreuil and co-workers challenged this species-specific activity by 
reporting that 1 and 2 induced comparable human iNKT cell activation.2 To shed 
light on this and identify the optimal ceramide backbone for human iNKT cell 
activation, we wanted to synthesise the 4-deoxy !-GalCer analogues 2 and 3 
(Figure 2.1) containing the sphinganine and sphingosine ceramides. These would 
then be tested for their ability to activate both murine and human iNKT cells (see 
Chapter 3 for biological analysis). To date, the !-GalCer sphingosine analogue 3 
has not been synthesised and investigated for its ability to activate iNKT cells.  
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Figure 2.1. !-GalCer and the target sphinganine and sphingosine analogues. 
 
2.2 Synthesis of !-GalCer Analogues 
To synthesise sphinganine 2 and sphingosine 3 a convergent strategy was 
proposed whereby the late stage building block 4 could be converted into either 
glycolipid (Scheme 2.1). Here, hydrogenation reaction or birch reduction would 
give sphinganine 2 or sphingosine 3 respectively. The fully protected glycolipid 4 
could be accessed via the coupling of galactosyl donor 5 and mono-lipid acceptor 
6. Although it is possible to couple the complete ceramide lipid to a donor 
substrate, amides reduce the nucleophilicity of the primary hydroxyl, via 
hydrogen bond donation and thus reduce the yield of the glycosylation reaction.3,4 
Galactose donor 5 could in turn be prepared from D-galactose (7),5 and lipid 
acceptor 6 from aldehyde 8 and phosphorane 9 through the use of a Wittig 
reaction.6 Aldehyde 8 could be synthesised in 3 steps from D-arabinose (10),7 and 
phosphorane 9 prepared from commercially available bromotetradecane.  
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Scheme 2.1. Retrosynthesis of target sphinganine and sphingosine !-GalCer 
analogues. 
 
To prepare the desired trichloroacetimidate donor 5, D-galactose (7) was 
peracetylated then subjected to thiophenyl glycosylation followed by 
deacetylation using sodium methoxide to give thiogalactoside 11 (Scheme 
2.2). The C-4 and C-6 hydroxyls were then protected with a benzylidene tether 
so as to allow for selective !-glycosylation.5,8 Benzylation gave the fully 
protected dibenzylgalactoside 12 in 53% yield (two steps). The thioglycoside 
donor was then convereted to a trichloroacetimidate leaving group. While 
thioglycosides are good donors their activation required the use of NIS. The 
use of NIS with lipid acceptor 6 would be likely to result in intramolecular 
iodocyclisation to form the corresponding five membered ring. Hydrolysis of 
thioglycoside 12 using TFA and NIS9 only provided 71% yield of lactol 13. 
TLC analysis of the crude reaction mixture revealed the presence of a higher 
running product, which was isolated and characterised using 1H, 19F and 2D 
NMR spectroscopy. The reaction by-product was determined to be TFA 
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derivative 14, which gave a distinctive 1H NMR anomeric shift at 6.56 ppm (J 
= 3.6 Hz) and a signal in the 19F NMR at -75 ppm. To improve the yield of 
lactol formation, thioglycoside 12 was subjected to NBS in acetone and lactol 
13 was obtained in excellent (99%) yield.10 Conversion of the anomeric 
hydroxyl to a trichloroacetimidate leaving group then afforded final galactose 
donor 5 in 81% yield. 
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Scheme 2.2. Synthesis of trichloroacetimidate donor 5. 
 
The synthesis of lipid building block 6 commenced with NaBH4 reduction of D-
arabinose (10) to give the corresponding pentol which was subsequently protected 
with a benzylidene group to give triol 15 (Scheme 2.3).7 Sodium periodate 
cleavage of triol 15 gave aldehyde 8. This hydroxy aldehyde readily polymerised 
and accordingly it was important to react aldehyde 8 immediately to improve the 
yield of the Wittig reaction. Reaction of bromotetradecane (16) with PPh3 gave 
phosphonium salt 17 which could be crystallised using dry acetone and diethyl 
ether and stored under nitrogen. Wittig metathesis was then conducted to install 
the E-alkene and synthesise the full length C-18 ceramide backbone. First, 
phosphonium salt 17 was deprotonated using phenyllithium to give phosphorane 9 
as an orange solution. Reaction of aldehyde 8 with phosphorane 9 using the 
Schlosser modification11,12 as adapted by Schmidt and co-workers,6 then gave 
alkene 18 as a mixture of E and Z isomers (4:1, 77% yield). These isomers could 
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be separated at this stage using repeated silica gel column chromatography 
(DCM/Hexanes, 1/1, vv). Alternatively, the E/Z mixture of alkenes could be 
converted to hydroxyazide 6 (vide infra), which allowed for easier 
chromatographic separation of the isomers. 
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Scheme 2.3. Synthesis of lipid building block 6. 
 
Wittig reaction of an unstabilized ylide usually leads to the formation of the Z-
product. To explain the preferential formation of the E-alkene during the synthesis 
of lipid 18 it is important to consider the theory behind the Schlosser 
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modification. In this procedure an excess (3.6 eq.) of alkyllithium base is used, 
this leads to the formation of lithium halide complexes and allows the E-isomer to 
form (Scheme 2.4). When an ylide (II) reacts with an aldehyde (I) at low 
temperatures (-30 °C), it is presumed that a diastereomeric mixture of betaine-
lithium halide complexes is formed (IIIa and b). At -30 °C fragmentation of this 
complex to the alkene does not occur. Treatment of the complex with a strong 
base, such as phenyllithium, results in the formation of a "-oxide ylide complex 
(IV), which when protonated gives the more stable anti-betaine lithium halide 
complex (V). Once the anti-betaine lithium halide complex has formed the 
reaction is then warmed to room temperature, which releases the E-alkene (VI).  
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Scheme 2.4. Schlosser modification to the Wittig reaction affording E-alkenes. 
 
Having prepared the required alkene 18 the C-2 hydroxyl was then converted to a 
triflate leaving group to enable NaN3 SN2 substitution to give azidooctadecene 19. 
Initial attempts at carrying out this transformation on a small scale (100 mg) were 
unsuccessful and only a small quantity of product was observed. Several by 
products, including the putatively assigned ketone 21, were observed. It is likely 
that ketone 21 was formed via E2 elimination of the triflate intermediate to give 
diene 20. Hydrolysis of 20, would then result in the formation of ketone 21. When 
the scale of the reaction was increased to a minimum of 1.0 g of alkene 18 
azidooctadecene 19 was obtained in 77% yield, consistent with that reported by 
Schmidt and co-workers.6 With azidooctadecene 19 in hand the benzylidene 
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acetal was removed using pTsOH to give lipid diol 22 in 90% yield. Next we 
wanted to determine whether it was necessary to protect the secondary hydroxyl 
during coupling of the lipid building block to the carbohydrate donor. 
Accordingly lipid 22 was reacted with imidate donor 5 (Scheme 2.2), however, a 
1:1 mixture of 1-OH:3-OH coupled products were observed. Although primary 
hydroxyls are typically more reactive than secondary hydroxyls, in this example 
the 3-OH is at the allylic position. This increases the reactivity of the secondary 
hydroxyl rendering the nucleophilicity of two hydroxyls comparable. Thus trityl 
protection of the primary hydroxyl, benzyl protection of the allylic alcohol, and 
subsequent detritylation was necessary to complete the synthesis of the final lipid 
building block 6 ready for coupling. 
 
With the required galactose trichloroacetimidate donor 5 and lipid acceptor 6 in 
hand, a BF3.OEt2 mediated glycosylation reaction was attempted. This proceeded 
smoothly, and 1H NMR analysis revealed an anomeric coupling constant of 3.4 
Hz indicating that only the !-isomer 23 was formed in good (65%) yield (Scheme 
2.5). Staudinger reduction of the C-2 azide using PMe3, followed by coupling to 
hexacosanoic acid then gave key building block 4 in 83% yield over the two steps. 
Removal of the benzylidene protecting group, using acetic acid and water gave 
glycolipid 24, which was subjected to Pd(OH)2 to give !-GalCer sphinganine 2 in 
a 98% yield over two steps. Alternatively, Birch reduction of the fully protected 
glycolipid 4 gave !-GalCer sphingosine 3 in 97 % yield. Due to the amphiphilic 
nature of glycolipids 2 and 3 deuterated pyridine was used for NMR 
characterisation. The full characterisation data was in agreement with literature 
values for analogous glycolipids with shorter acyl chains (see appendix for NMR 
spectra of final glycolipids).13,14 
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Scheme 2.5. Total synthesis of !-GalCer analogues 2 and 3. 
 
2.3 Conclusion 
In this work, two !-GalCer analogues were synthesised from carbohydrate 
starting materials using a convergent strategy. !-GalCer sphinganine derivative 2 
was synthesised in 14 steps (longest linear sequence) from D-arabinose, and in an 
overall 13% yield. !-GalCer sphingosine analogue 3 was synthesised in 13 steps 
(longest linear sequence) also with an overall yield of 13%. 
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2.4 Experimental 
General procedure 
Unless otherwise stated all reactions were performed under a nitrogen 
atmosphere. THF (Lab-Scan) was distilled from LiAlH4 prior to use. BF3.OEt2 
(Janssen Chimica), diethyl ether (Merck), H2O, PhBr (Aldrich), and pyridine 
(Fischer Scientific), were distilled prior to use. Hexanes (Panreac), DMF (Acros), 
TES (Aldrich), NaH (Avocado), BnBr (Fluka), TrCl (Acros), NaN3 (BDH), 
pTsOH (Fluka), Tf2O (Sigma-Aldrich), Li (Aldrich), 1-bromotetradecane (Fluka), 
NaIO4 (M&B), benzaldehyde (Unilab), NaBH4 (Aldrich), D-arabinose (Acros), D-
galactose (Sigma), NaOAc (Riedel-de Haën), Ac2O (Fluka), SnCl4 (Aldrich), 
PhSH (Koch-Light Laboratories), NaOMe (Chimica), Bn(OMe)2 (Aldrich),  NBS 
(Aldrich), Acetone (Pure Science), NCCCl3 (Aldrich), DBU (Merck), PMe3 
(Aldrich), EDCI (Sigma), Hexacosanoic acid (Acros), Pd/OH (Aldrich), Na 
(Aldrich), NH3 (BOC gasses), toluene (Panreac), MeOH (Pure Science), EtOAc 
(Pure Science), and Petroleum ether (Pure Science) EtOH (absolute, Pure 
Science), AcOH (Ajax Finechem), DCM (Panreac), TFA (Aldrich) PPh3 (Merck), 
and NaOH (Pure Science) were used as received. All solvents were removed by 
evaporation under reduced pressure. Reactions were monitored by TLC-analysis 
on Macherey-Nagel silica gel coated aluminium sheets (0.20 mm, silica gel 60) 
with detection by UV-absorption (254 nm), by spraying with 20% H2SO4 in EtOH 
followed by charring at ~150 °C, by dipping in I2 in silica, or by spraying with a 
solution of ninhydrin in EtOH followed by charring at ~150 °C. Column 
chromatography was performed on Pure Science silica gel (40-63 micron). 
Dowex® W50-X8 acidic resin (Sigma) and Dowex® 1X4-50 basic resin (Sigma) 
were used for ion exchange chromatography. High-resolution mass spectra were 
recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer using 
positive electro-spray ionisation. Optical rotations were recorded using a Perkin-
Elmer 241 polarimeter at the sodium D-line. Infrared spectra were recorded as 
thin films using a Bruker Tensor 27 FTIR spectrometer, equipped with an 
Attenuated Total Reflectance (ATR) sampling accessory, and are reported in 
wave numbers (cm-1). Nuclear magnetic resonance spectra were recorded at 20 °C 
in D2O, CDCl3, CD3OD or pyridine-d6 using either a Varian Unity-INOVA 
operating at 300 MHz or a Varian Unity operating at 500 MHz. Chemical shifts 
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are given in ppm (") relative to tetramethylsilane. NMR peak assignments were 
made using COSY, HSQC and HMBC experiments.  
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OAcAcO
AcO SPh
 Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-!-D-
galactopyranoside. To a solution of 1,2,3,4,6-penta-O-acetyl-!-D-
galactopyranoside (15.0 g, 38.45 mmol, co-evaporated twice with dry toluene), in 
dry DCM (150 mL) at 0 °C, thiophenol (4.75 mL, 5.08 g, 46.14 mmol) followed 
by tin(IV) chloride (0.45 mL, 1.0 g, 3.85 mmol) were added and the resulting 
mixture stirred for 3 h. The reaction was quenched with 3M aq. KF (100 mL) and 
the organic layer was washed with water (100 mL), sat. aq. NaHCO3 (100 mL), 
and brine (100 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The resulting oil was purified by flash chromatography mixed with 10% 
crushed KF (Petroleum ether/EtOAc, 2/1, v/v) to give phenyl 2,3,4,6-tetra-O-
acetyl-1-thio-!-D-galactopyranoside as a colourless oil (99%, 16.75 g, 38.07 
mmol). ["]23D = +4.0 (c = 1.0, CHCl3); IR (film) 3060, 2917, 2849, 2400, 2000, 
1747, 1583, 1480, 1439, 1369, 1200, 1054, 917, 736, 702 cm-1; 1H NMR (500 
MHz, CDCl3) ! 7.51 (m, 2H, CH-o Ph), 7.31 (m, 3H, CH-m Ph), 5.41 (d, J3,4 = 
3.4 Hz, 1H, H-4), 5.24 (t, J1,2 = J2,3 = 10.0 Hz, 1H, H-2), 5.05 (dd, J3,4 = 3.4, J2,3 = 
10.0 Hz, 1H, H-3), 4.72 (d, J1,2 = 10.0 Hz, 1H, H-1), 4.18 (dd, J5,6a = 7.1, J6a,6b = 
11.4 Hz, 1H, H-6a), 4.11 (dd, J5,6b = 6.2, J6a,6b = 11.4 Hz, 1H, H-6b), 3.94 (dd, 
J5,6b = 6.2, J5,6a = 7.1 Hz, 1H, H-5), 2.11 (s, 3H, OAc-CH3), 2.09 (s, 3H, OAc-
CH3), 2.04 (s, 3H, OAc-CH3), 1.97 (s, 3H, OAc-CH3); 13C NMR (125 MHz, 
CDCl3) ! 170.4, 170.2, 170.1, 169.4 (OAc-C=O), 132.5 (CH-o Ph) 132.5 (C-i Ph), 
128.9 (CH-m Ph), 128.2 (CH-p Ph), 86.6 (C1), 74.4 (C5), 72.0 (C3), 67.22, 67.20 
(C2 and C4), 61.6 (C6), 20.8 (OAc-CH3),  20.7 (OAc-CH3), 20.64 (OAc-CH3), 
20.59 (OAc-CH3); HRMS(ESI) m/z calcd. for [C20H24O9S+Na]+: 463.1033, obsd.: 
463.1034. 
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 Phenyl 1-thio-!-D-galactopyranoside (11). To a solution of 
phenyl 2,3,4,6-tetra-O-acetyl-1-thio-!-D-galactopyranoside (33.0 g, 74.98 mmol) 
in MeOH (375 mL), NaOMe was added slowly until the solution reached a pH of 
11. The reaction mixture was stirred 4 h, neutralised with Dowex H+, filtered and 
concentrated under reduced pressure. The resulting oil was crystallized from 
EtOH/Petroleum ether to afford 11 as white fluffy crystals (99%, 20.2 g, 74.23 
mmol). Mp 106.2 – 107.0 °C. ["]21D = -37.0 (c = 0.1, MeOH); IR (film) 3383, 
2895, 1583, 1480, 1439, 1057, 865, 743, 692 cm-1; 1H NMR (500 MHz, CD3OD) 
! 7.56-7.53 (m, 2H, CH-o Ph), 7.31-7.27 (m, 2H, CH-m Ph), 7.24-7.22 (m, 1H, 
CH-p Ph), 4.60 (d, J1,2 = 9.7 Hz, 1H, H-1), 3.91 (bs, 1H, H-4), 3.77 (dd, J5,6a = 
7.0, J6a,6b = 11.5 Hz, 1H, H-6a), 3.72 (dd, J5,6b = 5.5, J6a,6b = 11.5 Hz, 1H, H-6b), 
3.60 (t, J1,2 = J2,3 = 9.7 Hz, 1H, H-2), 3.56 (dd, J5,6b = 5.5, J5,6a = 7.0 Hz, 1H, H-5), 
3.49 (dd, J3,4 = 3.0, J2,3 = 9.5 Hz, 1H, H-3); 13C NMR (125 MHz, CD3OD) ! 
135.9 (C-i SPh) 131.9 (CH-o Ph), 129.8 (CH-m Ph), 127.9 (CH-p Ph), 90.2 (C1), 
80.5 (C5), 76.2 (C3), 70.9 (C2), 70.3 (C4), 62.6 (C6); HRMS(ESI) m/z calcd. for 
[C12H16O5S+Na]+: 295.0611, obsd.: 295.0613. 
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Phenyl 4,6-O-benzylidene-1-thio-!-D-galactopyranoside. To 
a solution of thioglycoside 11 (3.0 g, 11.03 mmol, co-evaporated twice with dry 
DMF, 30 mL) dissolved in dry DMF (180 mL) under a nitrogen atmosphere, 
benzaldehyde dimethyl acetal (11.5 mL, 76.6 mmol) was added followed by 
pTsOH (1.0 g, 5.1 mmol). The reaction mixture was stirred overnight at rt then 
neutralised with triethylamine and concentrated under reduced pressure. The 
residue was redissolved in EtOAc (150 mL) and washed with water (150 mL), sat. 
aq. NaHCO3 (150 mL) and brine (150 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. Crystallisation from EtOAc/petroleum ether 
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afforded phenyl 4,6-O-benzylidene-1-thio-!-D-galactopyranoside as fluffy white 
crystals (66%, 2.62 g, 7.28 mmol). Mp 154-156 °C; ["]22D = -34.5 (c = 1.0, 
CHCl3); IR (film) 3401, 3061, 2976, 2869, 1583, 1480, 1451, 1439, 1362, 1098, 
1070, 1041, 1027, 925, 898, 866, 734, 696 cm-1; 1H NMR (500 MHz, CDCl3) ! 
7.70 (m, 2H, aromatic), 7.40-7.29 (m, 8 H, aromatic), 5.52 (s, 1H, CH-Ph), 4.52 
(d, J1,2 = 9.0 Hz, 1H, H-1), 4.40 (d, J6a,6b = 12.5 Hz, 1H, H-6a) 4.22 (d, J3,4 = 1.5 
Hz, 1H, H-4), 4.05 (dd, J5,6b = 1.0, J6a,6b = 12.5 Hz, 1H, H-6b), 3.71-3.70 (m, 2H, 
H-2, and H-3), 3.57 (bs, 1H, H-5), 2.60 (s, 1H, HO-3), 2.58 (d, 1H, J = 8.5 Hz, 
HO-2); 13C NMR (125 MHz, CDCl3) ! 137.5, 130.6 (quaternary C), 133.8, 129.4, 
129.0, 128.3, 126.5 (10 x aromatic C), 101.4 (PhCHO2), 87.0 (C1), 75.3 (C4), 
73.8 (C2), 70.1 (C5), 69.3 (C6), 68.8 (C3); HRMS(ESI) m/z calcd. for 
[C19H20O5S+Na]+: 383.0924, obsd.: 383.0927. 
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 Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-!-D-
galactopyranoside (12). To a solution of phenyl 4,6-O-benzylidene-1-thio-!-D-
galactopyranoside (2.0 g, 5.55 mmol) in dry DMF (25 mL) at 0 °C was added 
BnBr (2.27 g, 1.6 mL, 13.3 mmol) followed by NaH (as a 60% mineral oil 
dispersion, 0.72 g, 18.0 mmol). The resulting solution was warmed to room 
temperature and stirred overnight, excess NaH was quenched using MeOH, and 
the solvent was removed under reduced pressure. The syrup was redissolved in 
diethyl ether (100 mL) and washed twice with water (100 mL) and brine (100 
mL), dried over MgSO4, filtered and concentrated under reduced pressure. The 
product was crystallised from EtOAc/petroleum ether to afford 12 as white fluffy 
crystals (80%, 2.39 g, 4.42 mmol). Mp 171.2-171.9 °C; ["]22D = -18.9 (c = 1.0, 
CHCl3); IR (film) 2817, 2849, 1977, 1584, 1453, 1399, 1092, 1057, 1026, 815, 
759, 732, 696 cm-1; 1H NMR (500 MHz, CDCl3) ! 7.73-7.71 (m, 2H, CH-o 
PhCHO2), 7.55-7.53 (m, 2H, CH-o SPh), 7.43-7.19 (m, 16H, aromatic H), 5.50 (s, 
1H, PhCHO2), 4.72 (m, 4H, Bn-2 and Bn-3), 4.63 (d, J1,2 = 9.3 Hz, 1H, H-1), 4.39 
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(d, J6a,6b = 12.5 Hz, 1H, H-6a), 4.17 (d, J3,4 = 3.4 Hz, 1H, H-4), 4.01 (dd, J5,6a = 
1.3, J6a.6b = 12.5 Hz, 1H, H-6b), 3.91 (t, J1,2 = J2,3 = 9.3 Hz, 1H, H-2), 3.64 (dd, 
J3,4 = 3.4, J2,3 = 9.3 Hz, 1H, H-3), 3.44 (bs, 1H, H-5); 13C NMR (125 MHz, 
CDCl3) ! 138.5, 138.1, 137.9 (3 x quaternary C), 132.8 (CH-o SPh), 132.7, 129.1, 
128.9, 128.4, 128.4, 128.24, 128.19, 127.8, 127.7, 127.5, 126.6 (aromatic C), 
101.4 (PhCHO2), 86.5 (C1), 81.4 (C3), 75.5 (2-OCHPh), 75.4 (C2), 73.7 (C4), 
71.9 (3-OCH2Ph), 69.9 (C5), 69.4 (C6); HRMS(ESI) m/z calcd. for 
[C33H32O5S+Na]+: 563.1863, obsd.: 563.1871. 
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2,3-Di-O-benzyl-4,6-O-benzylidene-D-galactose (13). To a 
solution of thioglycoside 12 (500 mg, 0.925 mmol) in acetone (18.5 mL) and 
water (1.85 mL) NBS (576 mg, 3.24 mmol) was added and the reaction was 
stirred at room temperature for 15 min. The reaction mixture was diluted with 
EtOAc (45 ml), and washed sat. aq. Na2S2O3 (50 mL), water (50 mL) and brine 
(50 mL), dried over MgSO4 filtered and concentrated under reduced pressure. The 
resulting oil was purified by gradient flash chromatography (Petroleum 
ether/EtOAc, 5/1 to 0/100, v/v) then crystallised (Petroleum ether/EtOAc, 2/1, 
v/v) to give 13 as fluffy white crystals (94%, 390 mg, 0.870 mmol). Rf = 0.08 
(Petroleum ether/EtOAc, 5/1, v/v). Mp = 165.5 – 166.4 °C; [!]D24 = +41.0 (c = 
1.0, CHCl3). IR (film) 3408, 3064, 3032, 2865, 1454, 1400, 1364, 1249, 1097, 
1052, 1027, 996, 909, 732, 697 cm-1.  1H NMR (500 MHz, CDCl3) " 7.57-7.53 
(m, 3H, aromatics), 7.43-7.29 (m, 12H, aromatics), 5.50 (s, 1H, CH-benzylidene), 
5.38 (s, 1H, H-1), 4.93-4.86 (m, 1H, CHaHb Bn-2), 4.82-4.76 (m, 2H, Bn-3), 4.73-
4.69 (m, 1H, CHaHb Bn-2), 4.24 (d, J6a,6b = 12.5 Hz, 1H, H-6a), 4.23 (s, 1H, H-4), 
4.07 (dd, J1,2 = 3.4, J2,3 = 9.7 Hz, 1H, H-2), 4.03 (d, J6a,6b = 12.5 Hz, 1H, H-6b), 
3.98 (dd, J3,4 = 3.4, J2,3 = 9.7 Hz, 1H, H-3), 3.88 (s, 1H, H-5), 2.90 (s, 1H, 1-OH);  
13C NMR (125 MHz, CDCl3) " 138.5, 138.2, 137.8, 128.9, 128.7, 128.6, 128.5, 
128.45, 128.39, 128.21, 128.18, 128.14, 128.1, 128.9, 128.8, 128.7, 126.3 
(aromatics), 101.1 (CH-benzylidene), 92.2 (C1), 75.73 (C2), 75.71 (C3), 74.3 
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(C4), 73.9 (CH2Bn-2), 71.8 (CH2Bn-3), 69.5 (C6), 62.8 (C5); HRMS (ESI) m/z 
calcd. for [C27H28O6+Na]+: 471.1778, obsd.: 471.1774.  
 
O
BnO
O
O
BnO
Ph
O CCl3
NH  2,3-di-O-benzyl-4,6-O-benzylidene-!-D-galactosyl 
trichloroacetimidate (5). To a solution of lactol 13 (370 mg, 0.826 mmol, co-
evaporated 3 x dry toluene) in dry DCM (4 mL) was added trichloroacetonitrile 
(826 µL, 1.19 g, 8.26 mmol) followed by 1,8-diazabicycloundec-7-ene (185 µL, 
1189 mg, 1.24 mmol) and the resulting brown solution stirred 4 h at rt. The 
solution was concentrated under reduced pressure and purified by gradient flash 
chromatography (Petroleum ether/EtOAc/NEt3, 95/5/1 to 1/1/0, v/v/v) to give 
trichloroacetimidate 5 as a colourless oil (81%, 394 mg, 0.661 mmol). Rf = 0.69 
(Petroleum ether/EtOAc, 1/2, v/v); Mp = 140.8 – 142.1 °C; [!]D24 = +93.0 (c = 
1.0, CHCl3). IR (film) 3339, 3065, 2907, 2864, 1671, 1497, 1456, 1368, 1290, 
1249, 1175, 1120, 1098, 1027, 968, 846, 794, 738, 697 cm-1. 1H NMR (500 MHz, 
CDCl3) " 8.58 (s, 1H, H-N), 7.55-7.53 (m, 3H, aromatics), 7.40-7.28 (m, 15H, 
aromatics), 6.65 (d, J1,2 = 3.4 Hz, 1H, H-1), 5.53 (s, 1H, CH-benzylidene), 4.84 
(d, JHaHb = 11.9 Hz, 1H, CHaHb Bn-3), 4.81 (d, JHaHb = 8.8 Hz, 1H, CHaHb Bn-2), 
4.79 (d, JHaHb = 8.8 Hz, 1H, CHaHb Bn-2), 4.77 (d, JHaHb = 11.9 Hz, 1H, CHaHb 
Bn-3), 4.31-4.27 (m, 3H, H-2, H-4 and H-6a), 4.09 (dd, J3,4 = 3.5, J2,3 = 10.0 Hz, 
1H, H-3), 4.02 (dd, J5,6b = 1.5, J6a, 6b = 12.7 Hz, 1H, H-6b), 3.85 (s, 1H, H-5); 13C 
NMR (125 MHz, CDCl3) " 161.0 (C=NH), 138.4, 138.3, 137.6, 129.0, 128.3, 
128.26, 128.2, 128.0, 127.7, 127.5, 127.4, 126.4 (aromatics), 101.1 (CH-
benzylidene), 95.6 (C1), 91.4 (CCl3), 75.1 (C2), 74.7 (C3), 74.5 (C4), 73.1 
(CH2Bn-2), 72.2 (CH2Bn-3), 69.1 (C6), 65.3 (C5). HRMS(ESI) m/z calcd. for 
[C29H28NO6Cl3+Na]+: 614.0874, obsd.: 614.0872.  
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 2,4-O-Benzylidene-D-threose (8). To a solution of 1,3-O-benzylidene-
D-arabinitol 157 (5.17 g, 21.52 mmol) in methanol (100 mL) was added NaIO4 
(5.07 g, 23.67 mmol) in water (50 mL). The reaction was stirred 20 min at rt, at 
which point the reaction was deemed complete by TLC analysis (Rf = 0.47, 
EtOAc). The solution was filtered, to remove the white precipitate, and 
concentrated under reduced pressure. The residue was dissolved in water (50 mL) 
and extracted four times with 100 mL EtOAc, dried over MgSO4, filtered and 
concentrated under reduced pressure. The resulting oil was co-evaporated three 
times with dry toluene and used immediately. 
 
Ph3P
Br
12
Tetradecyltriphenylphosphoniumbromide (17). A solution of 
PPh3 (9.5 g, 36.0 mmol) in bromotetradecane (10.75 mL, 10.0 g, 36.0 mmol) was 
heated to 140 °C under dry conditions, and stirred for 5 h. The solution was 
cooled to approximately 40 °C, and the product crystallised by the addition of 50 
mL dry acetone followed by 120 mL dry diethyl ether to give phosphorane salt 17 
as white crystals (14.98 g, 27.1 mmol, 75%). 
 
O
OH
O
Ph
12
 (2R,3R,4E)-1,3-O-Benzylidene-4-octadecen-1,2,3-triol (18). 
To a solution of PhBr (15.20 g, 96.85 mmol) in dry diethyl ether (45 mL) at 0 °C 
Li (1.35g, 195 mmol) was added in small pieces. The solution was stirred at rt 
until all Li metal dissolved (~3 h). To phosphorane salt 17 (14.5 g, 26.9 mmol) in 
dry toluene (210 mL) under an atmosphere of nitrogen at -30 °C, the 
phenyllithium base was added via a cannula needle. The reaction mixture was 
stirred 30 min at -30 °C, before the addition of aldehyde 8 (5.17 g, 21.5 mmol) in 
dry THF (30 mL). The reaction was stirred 1 h at -30 °C, then left to warm up 
slowly over night. After 18 h the reaction was quenched by the addition of 
methanol (100 mL) and water (50 mL) and stirred a further 1 h. The layers were 
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then separated, the organic layer was washed with brine (200 mL), dried over 
MgSO4, filtered, concentrated under reduced pressure. The resulting oil was 
purified by gradient flash chromatography (Petroleum ether/EtOAc, 100/0 to 10/1, 
v/v) to give 18 as a waxy solid. (4:1 mixture, E:Z, 77%, 6.39 g, 16.5 mmol). The 
isomers could be separated at this stage using a long (~60 cm) gradient flash 
column (DCM/Hexanes, 1/1 to 3/2, v/v). Rf = 0.01 (Petroleum ether/EtOAc, 9/1, 
v/v); [!]D21 = -12.0 (c = 0.4, CHCl3). IR (film) 3578, 3434, 3012, 2923, 2853, 
1454, 1395, 1359, 1310, 1216, 1130, 1087, 1027, 887, 849, 813, 755, 698 cm-1. 
1H NMR (500 MHz, CDCl3) " 7.54-7.51 (m, 2H, aromatics), 7.41-7.36 (m, 3H, 
aromatics), 5.88 (ddd, J3,5 = 1.0, J5,6 = 6.7, J4,5 = 15.5 Hz, 1H, H-5), 5.67 (ddt, J3,4 
= 6.2, J4,5 = 15.5, J4,6a = J4,6b = 1.3 Hz, 1H, H-4), 5.63 (s, 1H, CH-benzylidene), 
4.43 (d, J3,4 = 6.2 Hz, 1H, H-3), 4.26 (dd, J1a,2 = 2.0, J1a,1b = 11.8 Hz, 1H, H-1a) 
4.10 (dd, J1b,2 = 1.3, J1a,1b = 11.8 Hz, 1H, H-1b), 3.55 (br-d, J2,OH = 10.0 Hz, 1H, 
H-2), 2.65 (d, J2,OH = 10.0 Hz, 1H, 2-OH), 2.09 (ddd, J4,6 = 1.3, J5,6 = 6.7, J6,7 = 
14.1 Hz, 2H, H-6a and H-6b), 1.39 (m, 2H, H-7), 1.27 (m, 20H, H-8 to H-17), 
0.87 (t, J17,18 = 7.0 Hz, 3H, H-18); 13C NMR (125 MHz, CDCl3) " 137.9 (C5), 
135.3, 129.0, 128.3, 126.1, (aromatics), 125.9 (C4), 101.5 (benzylidene-CH), 80.7 
(C3), 72.4 (C1), 66.4 (C2), 32.5 (C6), 31.9, 29.69, 29.68, 29.66, 29.6, 29.5, 29.4, 
29.3, 29.0, 22.7 (C7 to C17), 14.1 (C18); HRMS(ESI) m/z calcd. for 
[C25H40O3+Na]+:411.2870, obsd.: 411.2871. 
 
O
N3
O
Ph
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12
 (2S,3R,4E)-2-Azido-1,3-O-benzylidene-4-octadecen-1,3-diol 
(19). To a solution of 18 (1.360 g, 3.51 mmol) (co-evaporated three times with 
dry toluene, 8 mL) in freshly distilled DCM (9.5 mL) with dry pyridine (707 µL, 
8.76 mmol) at -15 °C under nitrogen, Tf2O (737 µL, 4.38 mmol) was added 
slowly drop wise over 30 min. The solution was stirred an additional 15 min at -
15 °C before the slow addition (over 2 min) of dry DMF (35 mL). NaN3 (0.913 g, 
14.05 mmol) was then added in one portion and the reaction slowly warmed to 
room temperature and stirred for 5 h, at which point TLC analysis deemed the 
reaction complete. The reaction was quenched with water (100 mL) and extracted 
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with petroleum ether (three times 30 mL). The organic layers were combined, 
washed brine (100 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The resulting oil was purified by gradient flash chromatography 
(Petroleum ether/EtOAc, 100/1 to 50/1, v/v) to give 19 as a waxy solid (77%, 1.11 
g, 2.69 mmol). Rf = 0.39 (Petroleum ether/EtOAc, 9/1, v/v); [!]D23 = -15.62 (c = 
1.0, CHCl3). IR (film) 3344, 2924, 2853, 2107, 1456, 1395, 1274, 1214, 1115, 
1026, 970, 907, 731, 696 cm-1. 1H NMR (500 MHz, CDCl3) " 7.49-7.46 (m, 2H, 
aromatics), 7.38-7.34 (m, 4H, aromatics), 5.99 (dt, J4,5 = 15.4, J5,6a = J5,6b = 6.9 
Hz, 1H, H-5), 5.59 (ddt, J3,4 = 7.5, J4,5 = 15.4, J4,6a = J4,6b = 1.2 Hz, 1H, H-4), 5.50 
(s, 1H, CH-benzylidene), 4.35 (dd, J1a,2 = 5.2, J1a,1b = 10.8 Hz, 1H, H-1a), 4.07 
(dd, J3,4 = 7.5, J2,3 = 9.4 Hz, 1H, H-3), 3.63 (t, J1a,1b = J1b,2 = 10.8 Hz, 1H, H-1b), 
3.48 (ddd, J1a,2 = 5.2, J2,3 = 9.4, J1b,2 = 10.8 Hz, 1H, H-2), 2.12 (ddd, J4,6 = 1.2, J5,6 
= 6.9, J6,7 = 14.0 Hz, 2H, H-6a and H-6b), 1.43 (m, 2H, H-7), 1.35 – 1.24 (m, 
20H, H-8 to H-17), 0.89 (t, J17,18 = 6.9 Hz, 3H, H-18); 13C NMR (125 MHz, 
CDCl3) " 137.9 (C5), 137.3, 129.1, 128.3, 126.2 (aromatics), 125.8 (C4), 101.1 
(CH-benzylidene), 81.8 (C3), 69.1 (C1), 57.5 (C2), 32.5 (C7), 31.9, 29.68, 29.66, 
29.59, 29.5, 29.4, 29.2, 28.7, 22.7 (C8 to C17), 14.1 (C18); HRMS(ESI) m/z 
calcd. for [C25H39O2N3+Na]+: 436.2934, obsd.: 436.2932. 
O O
12
Ph
HO
 1-O-(!-hydroxybenzylidene)-4-octadecen-3-one (21). 
1H NMR (500 MHz, CDCl3) " 7.42-7.23 (m, 5H, aromatics), 6.87 (dt, J4,5 = 16.0, 
J5,6a = J5,6b = 6.7 Hz, 1H, H-5), 6.16 (dt, J4,5 = 16.0, J4,6a = J4,6b = 1.6, 1H Hz, H-
4), 5.47 (s, 1H, CH-benzylidene), 4.14 (dt, J1a,1b = 12.0, J1a,2a  = J1a,2b = 6.7 Hz, 
1H, H-1a), 3.97 (dt, J1a,1b = 12.0, J1b,2a  = J1b,2b = 6.7 Hz, 1H, H-1b), 2.91 (m, 2H, 
H-2a and H-2b), 2.22 (m, 2H, H-6a and H-6b), 1.41 (m, 2H, H-7), 1.27-1.18 (m, 
20H, H-8 to H-17), 0.87 (t, J17a,18 = J17b,18 = 6.8 Hz, 3H, H-18). 
 
OH
HO
N3
12
 (2S,3R,4E)-2-Azido-4-octadecen-1,3-diol (22). To a 
solution of 19 (715 mg, 1.72 mmol) in DCM (4 mL), MeOH (19 mL), H2O (150 
µL), propane-1,3-diol (95 µL, 1.72 mmol), and pTsOH (~75 mg) were added. The 
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solution was stirred four days at rt then quenched using sat. aq. NaHCO3. The 
methanol was removed under reduced pressure, and the resulting bi-layer was 
diluted using EtOAc (50 mL) and washed sat. aq. NaHCO3 (50 mL) and brine (50 
mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The 
resulting oil was purified by gradient flash chromatography (Petroleum 
ether/EtOAc, 20/1 to 1/1, v/v) to give 22 as a white solid (90%, 505 mg, 1.55 
mmol). Rf = 0.43 (Petroleum ether/EtOAc, 1:1, v/v); [!]D23 = -29.4 (c = 1.0, 
CHCl3). IR (film) 3357, 2922, 2853, 2098, 1466, 1266, 1059, 1005, 971, 908, 735 
cm-1. 1H NMR (500 MHz, CDCl3) " 5.82 (dt, J4,5 = 15.3, J5,6a = J5,6b = 6.7 Hz, 1H, 
H-5), 5.53 (ddt, J3,4 = 7.3, J4,5 = 15.3, J4,6a = J4,6b = 1.4, 1H Hz, H-4), 4.24 (dd, J2,3 
= 6.5, J3,4 = 7.3 Hz, 1H, H-2), 3.77 (m, 2H, H-1a and H-1b), 3.50 (m, 1H, H-2), 
2.06 (ddd, J4,6 = 1.4, J5,6 = 6.7, J6,7 = 14.5 Hz, 2H, H-6a and H-6b), 1.38 (m, 2H, 
H-7), 1.27 (m, 20H, H-8 to H-17), 0.87 (t, J17a,18 = J17b,18 = 6.8 Hz, 3H, H-18); 13C 
NMR (125 MHz, CDCl3) " 136.1 (C5), 128.0 (C4), 73.8 (C3), 66.7, (C2), 62.6 
(C1), 32.3 (C6), 31.9, 29.70, 29.68, 29.67, 29.66, 29.60, 29.5, 29.4, 29.2, 28.9, 
22.7 (C7 to C17), 14.1 (C18); HRMS(ESI) m/z calcd. for [C18H35O2N3+Na]+: 
348.2621, obsd.: 348.2624. 
 
OH
TrO
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12
 (2S,3R,4E)-2-azido-1-O-trityl-4-octadecen-1,3-diol. To a 
solution of 22 (653 mg, 2.01 mmol), in pyridine (10 mL), TrCl (785 mg, 2.82 
mmol) was added and the solution was stirred 48 h at rt. The reaction mixture was 
then concentrated, and redissolved in diethyl ether (30 mL). The organic layer 
was washed with sat. aq. NH4Cl (30 mL), sat. aq. NaHCO3 (30 mL), and brine (30 
mL), dried over MgSO4, filtered and concentrated under reduced pressure. The 
resulting oil was purified by gradient flash chromatography (Petroleum 
ether/EtOAc, 100/0 to 20/1, v/v) to give (2S,3R,4E)-2-azido-1-O-trityl-4-
octadecen-1,3-diol (97%, 1.10 g, 1.95 mmol). Rf = 0.45 (Petroleum ether/EtOAc, 
3/3, v/v); [!]D23 = -5.98 (c = 1.0, CHCl3). IR (film) 3374, 2729, 2810, 2096, 1597, 
1415, 1220, 1047, 858, 746, 668 cm-1. 1H NMR (500 MHz, CDCl3) " 7.47-7.45 
(m, 5H, aromatics), 7.34-7.24 (m, 10H, aromatics), 5.67 (dtd, J3,5 = 0.9, J5,6a = 
J5,6b = 6.6, J4,5 = 15.4 Hz, 1H, H-5), 5.34 (ddt, J3,4 = 7.2, J4,5 = 15.4, J4,6a = J4,6b = 
1.4 Hz, 1H, H-4), 4.21 (ddd, J3,5 = 0.9, J2,3 = 5.4, J3,4 = 7.2 Hz, 1H, H-3), 3.53 (t, 
 69 
J1,2 = J2,3 = 5.4, 1H, H-2), 3.31 (d, J1,2 = 5.4 Hz, 2H, H-1a and H-1b), 1.96 (m, 2H, 
H-6). 1.32-1.25 (m, 22H, H-7 to H-17), 0.89 (t, J17a,18 = J17b,18 = 6.9 Hz, 3H, H-
18); 13C NMR (125 MHz, CDCl3) " 143.5 (C5), 135.4, 128.6, 127.9, 127.6, 127.2, 
127.1 (aromatics and C4), 87.4 (Tr-C-OR), 73.1 (C3), 65.8 (C2), 63.4 (C1), 32.3, 
31.9, 29.71, 29.69, 29.67, 29.60, 29.5, 29.4, 29.3, 29.2, 28.9, 22.7 (C6 to C17), 
14.1 (C18); HRMS(ESI) m/z calcd. for [C37H49O2N3+Na]+: 590.3717, obsd.: 
590.3723. 
 
OBn
TrO
N3
12
 (2S,3R,4E)-2-azido-3-O-benzyl-1-O-trityl-4-octadecen-
1,3-diol. To a solution of (2S,3R,4E)-2-azido-1-O-trityl-4-octadecen-1,3-diol 
(1.10 g, 1.94 mmol) in dry DMF (11 mL) at 0 °C was added BnBr (283 µL, 407 
mg, 2.33 mmol) followed by NaH (as a 60% mineral oil dispersion, 108 mg, 2.53 
mmol). The resulting solution was warmed to rt and stirred overnight, excess NaH 
was quenched using MeOH, and the solvent was removed under reduced pressure. 
The syrup was redissolved in diethyl ether (50 mL) and washed twice with water 
(50 mL) and brine (50 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The resulting oil was purified by gradient flash chromatography 
(Petroleum ether/EtOAc, 20/1 to 10/1, v/v) to give (2S,3R,4E)-2-azido-3-O-
benzyl-1-O-trityl-4-octadecen-1,3-diol as a colourless oil (95%, 1.21 g, 1.84 
mmol). Rf = 0.46 (Petroleum ether/EtOAc, 5:1, v/v); [!]D23 = -12.0 (c = 1.0, 
CHCl3). IR (film) 2924, 2853, 2097, 1490, 1449, 1066, 907, 731, 695, 617 cm-1. 
1H NMR (500 MHz, CDCl3) " 7.54 - 7.17 (m, 20H, aromatics), 5.66 (dt, J4,5 = 
15.4, J5,6a = J5,6b = 6.7 Hz, 1H, H-5), 5.33 (ddt, J3,4 = 8.5, J4,5 = 15.4, J4,6a = J4,6b = 
1.2 Hz, 1H, H-4), 4.56 (d, JHa,Hb = 12.1 Hz, 1H, CHaHb Bn-3), 4.29 (d, JHa,Hb = 
12.1 Hz, 1H, CHaHb Bn-3), 3.89 (dd, J2,3 = 5.9, J3,4 = 8.5 Hz, 1H, H-3), 3.61 (ddd, 
J1b,2 = 4.9, J2,3 = 5.9, J1a,2 = 6.3 Hz, 1H, H-2), 3.28 (dd, J1a,2 = 6.3, J1a,1b = 9.6 Hz, 
1H, H-1a), 3.24 (dd, J1b,2 = 4.9, J1a,1b = 9.6 Hz, 1H, H-1b), 2.04 (ddd, J4,6 = 1.2, 
J5,6 = 6.7, J6a,6b = 14.3 Hz, 2H, H-6a and H-6b) 1.35-1.27 (m, 22H, H-7 to H-17), 
0.89 (t, J17a,18 = J17b,18 = 7.0 Hz, 3H, H-18); 13C NMR (125 MHz, CDCl3) " 143.7 
(C5), 138.1, 137.9, 128.73, 128.66, 128.3, 127.8, 127.52, 127.46, 127.4, 127.08, 
127.06, 127.0, (aromatics), 125.9 (C4), 87.0 (Tr-C-OR), 79.4 (C3), 77.3 (CH2-
Bn), 65.0 (C2), 63.2 (C1), 32.3 (C6), 31.9, 29.72, 29.71, 29.68, 29.64, 29.5, 29.4, 
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29.2, 29.0, 22.7 (C7 to C17), 14.1 (C18); HRMS(ESI) m/z calcd. for 
[C44H55O2N3+Na]+: 680.4186, obsd.: 680.4193.  
 
OBn
HO
N3
12
(2S,3R,4E)-2-Azido-3-O-benzyl-4-octadecen-1,3-diol (6). 
To a solution of (2S,3R,4E)-2-azido-3-O-benzyl-1-O-trityl-4-octadecen-1,3-diol 
(1.18 g, 1.79 mmol) in DCM (10 mL) with triethylsilane (569 µL, 416 mg, 3.58 
mmol) trifluoroacetic acid (TFA) was added slowly drop wise until the addition of 
TFA no longer turned the solution yellow. The mixture was then quenched using 
sat. aq. NaHCO3, and the organic layer further diluted using 20 mL DCM. The 
aqueous and organic layers were separated, and the organic layer was washed 
once more with sat. aq. NaHCO3 (30 mL), followed by brine (30 mL), then dried 
over MgSO4, filtered and concentrated. The resulting oil was purified by gradient 
flash chromatography (Petroleum ether/EtOAc, 100/0 to 17/1, v/v) to give 6 as a 
colourless oil (78%, 578 mg, 1.39 mmol). Rf = 0.58 (Petroleum ether/EtOAc, 5/1, 
v/v); [!]D20 = -66.8 (c = 1.0, CHCl3). IR (film) 3410, 3065, 2958, 2923, 2852, 
2132, 2096, 1720, 1454, 1304, 1206, 1027, 973, 733, 697 cm-1. 1H NMR (500 
MHz, CDCl3) " 7.37 – 7.28 (m, 5H, aromatics), 5.79 (dt, J4,5 = 15.5, J5,6a = J5,6b = 
6.9 Hz, 1H, H-5), 5.44 (ddt, J3,4 = 8.4, J4,5 = 15.5, J4,6a = J4,6b = 1.2 Hz, 1H, H-4), 
4.63 (d, JHa,Hb = 11.9 Hz, 1H, CHaHb Bn), 4.36 (d, JHa,Hb = 11.9 Hz, 1H, CHaHb 
Bn), 3.90 (dd, J2,3 = 6.1, J3,4 = 8.4 Hz, 1H, H-2), 3.73 (m, 2H, H-1a and H-1b), 
3.51 (ddd, J1a,2 = 4.8, J2,3 = 6.1, J1b,2 = 10.5 Hz, 1H, H-2), 2.11 (ddd, J4,6 = 1.2, J5,6 
= 6.9, J6,7 = 14.5 Hz, 2H, H-6a and H-6b), 1.49 (m, 2H, H-7), 1.29 (m, 20H, H-8 
to H-17), 0.88 (t, J17a,18 = J17b,18 = 6.7 Hz, 3H, H-18); 13C NMR (125 MHz, 
CDCl3) " 138.4 (C-5), 137.8, 128.5, 127.8 (aromatics), 126.1 (C4), 80.6 (C3), 
70.0 (C1), 66.0 (C2), 62.7 (CH2-Ph), 32.4 (C6), 31.9, 29.70, 29.69, 29.68, 29.67, 
29.63, 29.5, 29.4, 29.2, 29.0, 22.7 (C7 to C17), 14.1 (C18); HRMS(ESI) m/z 
calcd. for [C25H41O2N3+Na]+: 438.3091, obsd.: 438.3099. 
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 (2S,3R,4E)-2-Azido-3-O-benzyl-1-O-(2,3-di-O-
benzyl-4,6-O-benzylidene-!-D-galactopyranosyl)-4-octadecen-1,3-diol (23). 
Lipid acceptor 6 (65 mg, 0.157 mmol) was co-evaporated three times with dry 
toluene (3 mL) together with imidate donor 5 (158 mg, 0.267 mmol). The mixture 
was dissolved in dry THF (0.8 mL), and cooled to -20 °C. Freshly distilled 
BF3.OEt2 (40 µL, 23 mg, 0.157 mmol) was then added slowly drop wise, and the 
resulting solution was stirred at -20 °C for 2 h, at which point additional donor 5 
(78 mg, 0.131 mmol) in dry THF (0.3 mL) was added, and the solution was stirred 
an additional 2 h at -20 °C. After this time the mixture was diluted with EtOAc 
(15 mL) and was washed sat. aq. NaHCO3 (15 mL), and brine (15 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting oil was 
purified by gradient flash chromatography (Petroleum ether/EtOAc, 20/1 to 10/1, 
v/v) to give glycolipid 23 as a colourless oil (65%, 87 mg, 0.103 mmol). Rf = 0.46 
(Petroleum ether/EtOAc, 2/1, v/v,); [!]D24 = +26.0 (c = 1.0, CHCl3). IR (film) 
3065, 3032, 2925, 2853, 2096, 1737, 1496, 1400, 1340, 1245, 1154, 1049, 974, 
907, 729, 696 cm-1. 1H NMR (500 MHz, CDCl3) " 7.53-7.50 (m, 2H, aromatics), 
7.42-7.23 (m, 18H, aromatics), 5.71 (dt, J4,5 = 15.5, J5,6a = J5,6b = 6.7 Hz, 1H, H-
5), 5.47 (s, 1H, CH-benzylidene), 5.41 (ddt, J3,4 = 8.5, J4,5 = 15.5 Hz, 1H, H-4), 
4.95 (d, J1’,2’ = 3.4 Hz, 1H, H-1’), 4.86 (d, JHa,Hb = 12.0 Hz, 1H, CHaHb Bn-2’), 
4.82 (d, JHa,Hb = 12.4 Hz, 1H, CHaHb Bn-3’), 4.74 (d, JHa,Hb = 12.4 Hz, 1H, CHaHb 
Bn-3’), 4.65 (d, JHa,Hb = 12.0 Hz, 1H, CHaHb Bn-2’), 4.53 (d, JHa,Hb = 11.8 Hz, 
1H, CHaHb Bn-3), 4.25 (d, JHa,Hb = 11.8 Hz, 1H, CHaHb Bn-3), 4.19 (m, 2H, H-4’ 
and H-6’a), 4.08 (dd, J1’,2’ = 3.4, J2’,3’ = 10.1 Hz, 1H, H-2’), 4.01 (dd, J3’,4’ = 3.4, 
J2’,3’ = 10.1 Hz, 1H, H-3’), 3.97 (m, 1H, H-6’b), 3.93 (dd, J2,3 = 6.3, J3,4 = 8.5 Hz, 
1H, H-3), 3.80 (dd, J1a,2 = 3.8, J1a,1b = 10.7 Hz, 1H, H-1a), 3.66 (dd, J1b,2 = 6.3, 
J1a,1b = 10.7 Hz, 1H, H-1b), 3.63 (br s, 1H, H-5’), 3.53 (dt, J1a,2 = 3.8, J1b,2 = J2,3 = 
6.3 Hz, 1H, H-2), 2.10 (dd, J5,6 = 6.7, J6,7 = 14.6 Hz, 2H, H-6), 1.41 (m, 2H, H-7), 
1.29 (m, 20H, H-8 to H-17), 0.88 (t, J17,18 = 6.9 Hz, 3H, H-18); 13C NMR (125 
MHz, CDCl3) " 138.9 (C5), 138.2, 137.8, 128.9, 128.4, 128.29, 128.28, 128.1, 
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127.74, 127.73, 127.6, 127.55, 127.52, 126.4 (aromatics), 126.2 (C4), 101.1 (CH-
benzylidene), 99.3 (C1’), 79.1 (C3), 75.8 (C3’), 75.5 (C2’), 74.7 (C5’), 73.5 
(CH2Bn-2’), 72.2 (CH2Bn-3’), 70.0 (CH2Bn-3), 69.4 (C6’), 68.2 (C1), 64.1 (C2), 
63.0 (C4’), 32.4 (C6), 31.9, 29.71, 29.67, 29.5, 29.4, 29.2, 29.1, 22.7 (C7 to C17), 
14.1 (C18); HRMS(ESI) m/z calcd. For [C52H67O7N3+Na]+: 868.4871, obsd.: 
868.4873. 
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 (2S,3R,4E)-3-O-Benzyl-1-O-(2,3-di-O-benzyl-
4,6-O-benzylidene-!-D-galactopyranosyl)-2-hexacosylamido-4-octadecen-1,3-
diol (4). To a solution of azide 23 (86 mg, 0.102 mmol) in THF (0.4 mL), PMe3 
(1M in THF, 509 µL, 0.509 mmol) followed by NaOH (1M aqueous, 0.4 mL) was 
added and the resulting solution was stirred at rt overnight, then diluted with 
EtOAc (15 mL) and washed sat. aq. NaHCO3 (15 mL) and brine (15 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. The resulting oil 
was used without further purification. Rf = 0.31 (Petroleum ether/EtOAc, 2:1, 
v/v); To (2S,3R,4E)-2-amino-3-O-benzyloxy-1-O-(2,3-di-O-benzyloxy-4,6-O-
benzylidene -!-D-galactopyranosyl)-4-octadecene-1,3-diol (84 mg 0.102 mmol, 
co-evaporated three times with dry toluene, 3 mL) in dry DCM (0.5 mL), 
hexacosanoic acid (101 mg, 0.255 mmol), was added followed by EDCI (49 mg, 
0.255 mmol), and a catalytic amount of DMAP. The reaction mixture was stirred 
overnight at rt, then concentrated under reduced pressure. The resulting oil was 
purified by gradient flash chromatography (Petroleum ether/EtOAc, 10/1 to 2/1, 
v/v) to give 4 as a colourless oil (83% over the two steps, 101 mg, 0.0844 mmol). 
Rf = 0.44 (Petroleum ether/EtOAc, 2:1, v/v); [!]D20 = +37.5 (c = 1.0, CHCl3). IR 
(film) 3298, 3032, 2956, 2918, 2850, 1641, 1542, 1468, 1453, 1343, 1159, 1099, 
1054, 696 cm-1. 1H NMR (500 MHz, CDCl3) " 7.53-7.51 (m, 2H, aromatics), 
7.42-7.24 (m, 18H, aromatics), 5.82 (br d, J2,NH = 9.1 Hz, 1H, N-H), 5.59 (dt, J4,5 
= 15.3, J5,6a = J5,6b = 6.8 Hz, 1H, H-5), 5.46 (s, 1H, CH-benzylidene), 5.34 (ddt, 
J3,4 = 8.3, J4,5 = 15.3, J4,6a = J4,6b = 1.3, Hz, 1H, H-4), 4.92 (d, J1’,2’ = 3.5 Hz, 1H, 
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H-1’), 4.83 (d, JHa,Hb = 11.5 Hz, 1H, CHaHb Bn-2’), 4.78 (d, JHa,Hb = 12.2 Hz, 1H, 
CHaHb Bn-3’), 4.74 (d, JHa,Hb = 12.2 Hz, 1H, CHaHb Bn-3’), 4.59 (d, JHa,Hb = 11.5 
Hz, 1H, CHaHb Bn-2’), 4.54 (d, JHa,Hb = 11.8 Hz, 1H, CHaHb Bn-3), 4.23 (d, JHa,Hb 
= 11.8 Hz, 1H, CHaHb Bn-3), 4.17 (m, 3H, H-2, H-4’ and H-6’a), 4.04 (dd, J1’,2’ = 
3.5, J2’,3’ = 10.0 Hz, 1H, H-2’), 3.94 (m, 2H, H-3’ and H-6’b), 3.90 (dd, J1a,2 = 5.5, 
J1a,1b = 11.1 Hz, 1H, H-1a), 3.83 (dd, J2,3 = 6.7, J3,4 = 8.3 Hz, 1H, H-3), 3.75 (dd, 
J1b,2 = 3.8, J1a,1b = 11.1 Hz, 1H, H-1b), 3.57 (br s, 1H, H-5’), 2.00 (m, 4H, H-6 and 
H-!), 1.67 (m, 2H, H-7), 1.52 (m, 2H, H-#), 1.25 (m, 64H, H-8 to H-17, H-$ to 
H-(%-1)), 0.88 (t, J17,18 = J%-1,% = 6.8 Hz, 6H, H-18 and H-%); 13C NMR (125 
MHz, CDCl3) " 172.6 (C-carbonyl), 138.7 (C-5), 138.6, 138.4, 137.8, 137.1, 
128.9, 128.4, 128.34, 128.32, 128.1, 127.9, 127.8, 127.74, 127.69, 127.62, 127.60, 
127.1, 126.3 (C-aromatics and C-4), 101.0 (CH-benzylidene), 99.6 (C-1’), 79.6 
(C-3), 76.0 (C-3’), 75.7 (C-2’), 74.4 (C-4’), 73.7 (CH2Bn-2’), 71.7 (CH2Bn-3’), 
70.1 (CH2Bn-3), 69.5 (C-6’), 67.6 (C-1), 62.9 (C-5’), 52.5 (C-2), 36.9 (C-!), 32.3 
(C-6), 31.9, 29.74, 29.72, 29.70, 29.69, 29.67, 29.63, 29.55, 29.51, 29.4, 29.30, 
29.28, 25.8, 22.7. (C-7 to C-17 and C-# to C-(%-1)), 14.1 (C-18 and C-%); 
HRMS(ESI) m/z calcd. for [C78H119O8N+Na]+: 1220.8828, obsd.: 1220.8823. 
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 (2S,3R,4E)-3-O-Benzyl-1-O-(2,3-di-O-benzyl-!-
D-galactopyranosyl)-2-hexacosylamido-4-octadecen-1,3-diol (24). A solution 
of fully protected glycolipid 4 (68 mg, 0.056 mmol) in 4:1 acetic acid/H2O (2.5 
mL) and THF (1 mL) was heated to 75 °C and stirred 24 h, the mixture was then 
cooled and concentrated under reduced pressure. The resulting oil was purified by 
gradient flash chromatography (Petroleum ether/EtOAc, 5/1 to 0/100, v/v) to give 
24 as a colourless oil (100%, 64 mg, 0.56 mmol). Rf = 0.32 (Petroleum 
ether/EtOAc, 1/1, v/v); [!]D18 = -18.9 (c = 1.0, CHCl3). IR (film) 3395, 3303, 
2919, 2850, 1740, 1641, 1539, 1469, 1346, 1216, 1157, 1049, 762, 695 cm-1. 1H 
NMR (500 MHz, CDCl3) " 7.37-7.25 (m, 15H, aromatics), 5.90 (br d, J2,NH = 9.5 
Hz, 1H, N-H), 5.65 (dt, J4,5 = 15.4, J5,6a = J5,6b = 6.8 Hz, 1H, H-5), 5.37  (ddt, J3,4 
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= 8.1, J4,5 = 15.4, J4,6a = J4,6b = 1.3, Hz, 1H, H-4), 4.84 (d, J1’,2’ = 3.0 Hz, 1H, H-
1’), 4.78 (d, JHa,Hb = 11.4 Hz, 1H, CHaHb Bn-2’), 4.76 (d, JHa,Hb = 11.9 Hz, 1H, 
CHaHb Bn-3’), 4.70 (d, JHa,Hb = 11.4 Hz, 1H, CHaHb Bn-2’), 4.60 (d, JHa,Hb = 11.9 
Hz, 1H, CHaHb Bn-3’), 4.57 (d, JHa,Hb = 11.8 Hz, 1H, CHaHb Bn-3), 4.24 (d, JHa,Hb 
= 11.8 Hz, 1H, CHaHb Bn-3), 4.24 (m, 1H, H-2), 4.03 (d, J3’,4’ = 2.3 Hz, 1H, H-
4’), 3.96 (dd, J1a,2 = 6.3, J1a,1b = 11.4 Hz, 1H, H-1a), 3.83 (m, 4H, H-3, H-2’, H-3’, 
and H-6’a), 3.73 (m, 3H, H-1b, H-5’, and H-6’b), 2.04 (m, 4H, H-6 and H-!), 
1.52 (m, 2H, H-7), 1.36 (m, 2H, H-#), 1.28 (m, 64H, H-8 to H-17, H-$ to H-(%-
1)), 0.88 (t, J17,18 = J%-1,% = 6.8 Hz, 6H, H-18 and H-%); 13C NMR (125 MHz, 
CDCl3) " 172.9 (C-carbonyl), 138.4, 138.3, 138.0 (C-aromatics), 137.0 (C-5), 
128.5, 128.42, 128.38, 128.0, 127.84, 127.76, 127.6, (C-aromatics), 126.8 (C-4), 
99.4 (C-1’), 79.7 (C-3), 77.4 (C-2’), 75.8 (C-3’), 73.4 (CH2Bn-3’), 72.6 (CH2Bn-
2’), 70.1 (CH2Bn-3), 69.6 (C-5’), 68.7 (C-4’), 68.5 (C-1), 63.0 (C-6’), 52.6 (C-2), 
36.9 (C-!), 32.4 (C-6), 31.9, 29.74, 29.73, 29.71, 29.69, 29.68, 29.67, 29.59, 
29.53, 29.46, 29.38, 29.37, 29.35, 29.30, 29.25, 25.7, 22.7 (C-7 to C-17 and C-# 
to C-(%-1)), 14.1 (C-18 and C-%); HRMS(ESI) m/z calcd. for [C71H115O8N3+Na]+: 
1132.8515, obsd.: 1132.8513. 
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 (2S,3R)-1-O-(!-D-galactopyranosyl)-2- 
hexacosylamidooctadecan-1,3-diol (2). To a solution of diol 24 (37 mg, 0.033 
mmol) in EtOH/DCM (2 mL, 1/1, v/v), was added Pd(OH)2 (0.5 mg, 0.0033 
mmol), and H2. The mixture was stirred at 400 kPa for 18 h, at which point TLC 
analysis showed complete consumption of starting material. The reaction mixture 
was filtered through celite, and concentrated under reduced pressure. The 
resulting oil was purified by gradient flash chromatography (DCM/MeOH, 99/1 to 
9/1, v/v) to give target glycolipid 2 as an amorphous white solid (100%, 28 mg, 
0.033 mmol). Rf = 0.22 (EtOAc/MeOH, 4/1, v/v); [!]D21 = +49.5 (c = 0.2, 
pyridine). IR (film) 3352, 2917, 2850, 1734, 1717, 1699, 1636, 1558, 1507, 1466, 
1033 cm-1. 1H NMR (500 MHz, pyridine-d6) " 8.93 (br d, J2,NH = 8.6 Hz, 1H, N-
H), 5.79 (d, J1’,2’ = 3.7 Hz, 1H, H-1’), 5.07 (m, 1H, H-2), 4.99 (dd, J1’,2’ = 3.7, 
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J2’,3’ = 9.9 Hz, 1H, H-2’), 4.05 (d, J3’,4’ = 3.3 Hz, 1H, H-4’), 4.87 (t, J5,6 = 5.5 Hz, 
1H, H-5’), 4.82-4.79 (m, 2H, H-1a, and H-3’), 4.77-4.72 (m, 2H, H-6’a and H-
6’b), 4.69 (dd, J1b,2 = 5.6, J1a,1b = 10.5 Hz, 1H, H-1b), 4.63-4.59 (m, 1H, H-3), 
2.81 (t, J!,# = 7.3 Hz, 2H, H-!), 2.23-2.13 (m, 4H, H-4 and H-#), 1.89-1.57 (m, 
70H, H-5 to H-17 and H-$ to H-(%-1)), 1.20 – 1.16 (m, 6H, H-18 and H-%); 13C 
NMR (125 MHz, pyridine-d6) " 173.6 (C-carbonyl), 102.2 (C-1’), 73.2 (C-5’), 
72.0 (C-3), 71.7 (C-3’), 71.1 (C-4’), 70.6 (C-2’), 69.8 (C-1), 62.8 (C-6’), 55.0 (C-
2), 36.9 (C-!), 35.2, 32.24, 32.23, 30.3, 30.2, 30.14, 30.13, 30.09, 30.05, 30.03, 
29.95, 29.86, 29.74, 29.71, 26.7, 26.5, 23.1, 23.0 (C-4 to C-17 and C-# to C-(%-
1)), 14.4 (C-18 and C-%); HRMS(ESI) m/z calcd. for [C50H99O8N+Na]+: 
864.7263, obsd.: 864.7266. 
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 (2S,3R,4E)-1-O-(!-D-galactopyranosyl)-2- 
hexacosylamido-4-octadecen-1,3-diol (3). To a solution of fully protected 
glycolipid 4 (11 mg, 0.00919 mmol) in 0.5 mL THF, NH3 (L) was added, 
followed by the careful addition of Na (s) until the blue colour remained. The 
solution was stirred for 1 h under refluxing NH3, then allowed to warm to rt and 
the excess NH3 was evaporated. The solution was neutralised by the addition of 
Dowex H+, filtered and concentrated under reduced pressure. The resulting 
powder was purified by gradient flash column chromatography (DCM/MeOH, 
99/1 to 9/1, v/v) to give sphingosine glycolipid 3 as an amorphous white solid 
(97%, 7.5 mg, 0.089 mmol). Rf = 0.16 (EtOAc/MeOH, 9/1, v/v); [!]D21 = +42.5 (c 
= 0.3, pyridine). IR (film) 3348, 2948, 2837, 1653, 1450, 1412, 1217, 1113, 1016 
cm-1. 1H NMR (500 MHz, CDCl3/CD3OD, 9/1, v/v) " 5.46 (dt, J4,5 = 15.4, J5,6a = 
J5,6b = 6.9 Hz, 1H, H-5), 5.18 (dd, J3,4 = 7.1, J4,5 = 15.4 Hz, 1H, H-4), 4.61 (d, 
J1’,2’ = 3.8 Hz, 1H, H-1’), 3.81 (t, J2,3 = J3,4 = 7.1, 1H, H-3), 3.79 – 3.69 (m, 1H, 
H-2), 3.67 (m, 1H, H-4’), 3.54 – 3.46 (m, 7H, H-1a, H-1b, H-2’, H-3’, H-5’, H-
6’a, and H-6’b), 1.92 (t, J!,# = 7.8 Hz, 2H, H-!), 1.76 (dd, J5,6 = 6.9, J6,7 = 14.2 
Hz, 2H, H-6), 1.32 (m, 2H, H-#), 1.11 – 1.00 (m, 66H, H-7 to H-17, H-$ to H-(%-
1)), 0.62 (t, J17,18 = J%-1,% = 6.9 Hz, 6H, H-18 and H-%); 13C NMR (125 MHz, 
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CDCl3/CD3OD, 9/1, v/v) " 174.8 (C-carbonyl), 134.1 (C-5), 129.2 (C-4), 99.8 (C-
1’), 72.0 (C-3), 70.7 (C-2’, or C-3’ or C-5’), 70.1 (C-2’, or C-3’ or C-5’), 69.4 (C-
4’), 69.0 (C-2’, or C-3’ or C-5’), 67.3 (C-1), 61.6 (C-6’), 53.7 (C-2), 36.3 (C-!), 
32.3 (C-6), 31.8, 29.59, 29.55, 29.47, 29.4, 29.2, 29.17, 25.9, 22.5 (C-7 to C-17 
and C-# to C-(%-1)), 13.7 (C-18 and C-%); HRMS(ESI) m/z calcd. for 
[C50H97O8N+Na]+: 862.7106, obsd.: 862.7109. 
 77 
2.5 References 
(1) Brossay, L.; Naidenko, O.; Burdin, N.; Matsuda, J.; Sakai, T.; Kronenberg, 
 M. J. Immunol. 1998, 161, 5124-5128. 
(2) Lacône, V.; Hanault, J.; Pipelier, M.; Blot, V.; Lecourt, T.; Rocher, J.; 
 Turcot-Dudois, A.-L.; Marionneau, S.; Douillard, J.-Y.; Clément, M.; Le 
 Pendu, J.; Bonneville, M.; Micouin, L.; Dubreuil, D. J. Med. Chem. 2009, 
 52, 4960-4963. 
(3) Sabò, L.; Li, Y.; Polt, R. Tetrahedron Lett. 1991, 32, 585-588. 
(4) Morales-Serna, J. A.; Boutureira, O.; Díaz, Y.; Matheu, M. I.; Castillón, S. 
 Carbohydr. Res. 2007, 342, 1595-1612. 
(5) Plettenburg, O.; Bodmer-Narkevitch, V.; Wong, C.-H. J .Org. Chem. 
 2002, 67, 4559-4564. 
(6) Zimmermann, P.; Schmidt, R. R. Liebigs Ann. Chem. 1988, 663-667. 
(7) David, S.; Estramareix, B.; Fischer, J.-C.; Thérisod, M. J. Chem. Soc. 
 Perkin Trans. 1 1982, 2131-2137. 
(8) Lee, A.; Farrand, K. J.; Dickgreber, N.; Hayman, C. M.; Jürs, S.; Hermans, 
 I. F.; Painter, G. F. Carbohydr. Res. 2006, 341, 2785-2798. 
(9) Dinkelaar, J.; Witte, M. D.; van den Bos, L. J.; van der Marel, G. A. 
 Carbohydr. Res. 2006, 341, 1723-1729. 
(10) Motawia, M. S.; Marcussen, J.; Møller, B. L. J. Carbohydr. Chem. 1995, 
 14, 1279-1294. 
(11) Schlosser, M.; Christmann, K.-F. Angew. Chem. Int. Edit. 1965, 4, 689-
 690. 
(12) Schlosser, M.; Christmann, K.-F. Angew. Chem. Int. Edit. 1966, 5, 126. 
(13) Du, W.; Kulkarni, S. S.; Gervay-Hague, J. Chem. Comm. 2007, 2336-
 2338. 
(14) Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; 
 Yamaji, K.; Koezuka, Y.; Kobayashi, E.; Fukushima, H. J. Med. Chem. 
 1995, 38, 2176-2187. 
 
 
 
 79 
 
 
 
 
 
 
 
Chapter 3: Biological Testing of !-GalCer 
Analogues 
3.1 Introduction 
There has been considerable interest in synthesising structural analogues of !-
GalCer (1, Figure 3.1) to understand which components are required for CD1d 
presentation and iNKT cell activation.1-3 In particular, it is important to 
understand which structural elements are required for human iNKT cell 
activation. To more fully understand the influence of the 4-hydroxyl on species-
specific glycolipid activity, we investigated the ability of !-GalCer analogues 2 
and 3 to activate both murine and human iNKT cells.  
 
O
HO
OH O
O
HN
HO
HO
OH
24
12
OH
!-GalCer
1
O
HO
OH O
O
HNHO
HO
OH
24
12
!-GalCer analogue
with sphinganine lipid
2
O
HO
OH O
O
HNHO
HO
OH
24
12
!-GalCer analogue
with sphingosine lipid
3  
Figure 3.1. Glycolipids tested for their ability to activate iNKT cells. 
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3.2 Results 
To determine the ability of !-GalCer analogues 2 and 3 to activate iNKT cells we 
investigated their in vivo activity in mice by measuring the expression of the co-
stimulatory molecule CD86 on splenic DC and B cells and by assessing 
intracellular iNKT cell IL-4 and IFN-" cytokine levels in a similar manner to 
established literature protocols.4,5 The first assay is based on the observation that 
CD86 is upregulated in response to iNKT cell interaction with DC and B cells. 
Therefore CD86 expression is an indirect measure of iNKT cell activation. The 
ability of each glycolipid to activate murine or human iNKT cells in vitro was 
also determined by measuring iNKT cell proliferation as well as IL-2 and IFN-" 
cytokine production. These are well-established measures for determining iNKT 
cell glycolipid activity.6-9 iNKT cells secrete IL-2 and IFN-" in response to !-
GalCer activation. IL-2 mediates the differentiation and survival of cytotoxic T 
cells and IFN-" possesses anti-tumour properties, thus increased production of 
these cytokines is a good measure of potent anti-tumour iNKT cell activity. 
 
To determine B cell and DC CD86 up-regulation mice were injected with !-
GalCer (1), sphinganine 2, or sphingosine 3 and sacrificed 1 day later. 
Splenocytes were isolated and the CD86 expression on B cells (B220+) and DCs 
(CD11c+) was measured using flow cytometry (Figure 3.2a). No significant 
difference in B cell or DC activation was observed between 1 and 2, however, a 
significant (p<0.05) decrease in both B cell and DC maturation was observed in 
response to glycolipid 3. To confirm the involvement of CD1d in this response, 
CD1d-/- mice were injected with !-GalCer (1), 2, or 3, and the CD86 expression 
on B cells and DCs was measured (Figure 3.2b). CD86 up-regulation was not 
observed in CD1d-/- mice, indicating that the immune response elicited involved 
CD1d. To more specifically assess the activity of the glycolipid analogues, 
intracellular iNKT cell cytokine levels were investigated in vivo. Mice were 
injected with !-GalCer (1), 2, or 3, sacrificed 3 h later and the splenocytes 
removed. The levels of intracellular iNKT IL-4 and IFN-" were then determined 
using flow cytometric analysis (Figure 3.2c). All three analogues induced similar 
levels of IL-4. In contrast, sphingosine analogue 3 demonstrated a significant 
(p<0.05) reduction in IFN-" production compared to both !-GalCer and 2.  
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Figure 3.2. !-GalCer analogues 2 and 3 are able to activate murine iNKT 
cells through CD1d presentation. a) C57BL/6 mice were injected intravenously 
with 200 ng of 1 (n = 3), 2 (n = 3) or 3 (n = 3) and spleens were removed 20 h 
after injection for antibody labelling and flow cytometry. The expression of CD86 
on CD11c+ dendritic cells and B220+ B cells was assessed. Mean fluorescence 
intensities (MFI) ± SD are presented; b) 200 ng of 1 (n = 2), 2 (n = 2) or 3 (n = 2) 
was injected into wild type (C57BL/6) and CD1d-/- mice, and spleens were 
removed 20 h after injection for antibody labelling and flow cytometry. The 
spleen of an untreated CD1d-/- mouse was used as a control. The expression of 
CD86 on CD11c+ dendritic cells and B220+ B cells was assessed. Mean 
fluorescence intensities (MFI) ± SD are presented; c) C57BL/6 mice were injected 
with 200 ng of 1 (n = 2), 2 (n = 2) or 3 (n = 2) and the spleens removed 3 h after 
injection for antibody labelling, formaldehyde fixing, and flow cytometry. The 
percent of intracellular IL-4 and IFN-" in tetramer positive iNKT cells was 
assessed using flow cytometry. 
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Having demonstrated that the glycolipids activated murine iNKT cells through 
CD1d presentation, we then investigated their ability to stimulate human iNKT 
cells. Accordingly, human peripheral blood mononuclear cells (PBMCs), which 
include DCs, T cells, iNKT cells and B cells, were purified from whole blood. 
The healthy donor PBMCs were cultured for 7 days with decreasing 
concentrations of glycolipids 1, 2, or 3, or vehicle only. iNKT cell proliferation 
was measured using flow cytometric analysis (Figure 3.3). !-GalCer induced 
iNKT cell expansion at concentrations as low as 24 pg/mL. Analogues 2 and 3 
were approximately 1,000 times less active, and iNKT cell proliferation was only 
initiated at glycolipid concentrations of 25 ng/mL. This result suggested that 
analogues 2 and 3 were significantly less active in humans. However, this assay 
uses iNKT cell proliferation as a read out of iNKT cell activation. Therefore the 
result is not directly comparable to those obtained using the in vivo murine models 
(Figure 3.2). Accordingly, it was important to develop an assay that used the same 
read out for iNKT cell activation in both human and murine iNKT cells. 
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Figure 3.3. iNKT cell proliferation in whole PBMCs. 200,000 healthy donor 
PBMCs were cultured with titrated doses of either 1, 2 or 3 in cIMDM/5% human 
AB serum at 37 °C, 5% CO2. 50 U/mL recombinant human IL-2 was added at 24 
h. The cells were harvested at day 7 for antibody labelling and flow cytometry. 
The number of CD3+, CD1d tetramer+ CD19- iNKT cells was measured as a 
percentage of all live CD3+ cells (Rob Weinkove). 
 
To more directly compare glycolipid activity across the two species we used 
human and murine in vitro DC-iNKT cell assays and measured the supernatant 
IL-2 and IFN-" levels. Mouse DCs (mDCs) and mouse iNKT (mNKT) cells were 
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cultured together with decreasing concentrations of glycolipid 1, 2 or 3, and after 
24 h the supernatant IL-2 and IFN-" levels were measured (Figure 3.4a). All 
glycolipids induced IL-2 and IFN-" production to similar extents suggesting that 2 
and 3 had similar activity to !-GalCer in mice. An analogous experiment was 
conducted using human DCs (hDCs) and human iNKT (hNKT) cells (Figure 
3.4b). !-GalCer (1) concentrations as low as 1 ng/mL induced IL-2 production, 
however, no activity was observed with either 2 or 3. This result paralleled the 
observations using human PBMCs (Figure 3.3) and supports the idea that the 
sphinganine and sphingosine !-GalCer analogues (2 and 3) are less active in 
humans when compared to !-GalCer. To further understand the mechanism 
behind the observed species-specific differences, we incubated hDCs with mNKT 
cell. This would enable us to clarify whether the difference in activity was due to 
insufficient human CD1d presentation, lack of human iNKT cell TCR 
recognition, or a combination of both. hDCs and mNKT cells were cultured 
together with glycolipids 1, 2 or 3, and the supernatant IL-2 and IFN-" levels 
measured (Figure 3.4c). In this system, similar levels of IL-2 and IFN-" were 
observed in response to each glycolipid. This indicates that hDC are able to 
present the glycolipid analogues and suggests that it is the hNKT cell TCR that is 
unable to recognise the CD1d-bound 4-deoxy !-GalCer analogues.  
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Figure 3.4. The human iNKT cell TCR is unable to recognise the 4-deoxy 
glycolipid analogues. a) Production of IL-2 and IFN-" by the murine iNKT cells 
(DN32.D3) in the presence of titrated doses of 1, 2 or 3 presented by the murine 
DC cell line (DC2114); data representative of four individual experiments; error 
bars indicate SE of triplicate experiments; b) Production of IL-2 and IFN-" by 
human iNKT cells (V!24V"11 clone) in the presence of titrated doses of 1, 2 or 3 
(in triplicate) presented by human PBMC derived DCs; data representative of two 
individual experiments; error bars indicate SE; c) Production of IL-2 and IFN-" by 
murine iNKT cells (DN32.D3) in the presence of titrated doses of 1, 2 or 3 
presented by human PBMC derived DCs; error bars indicate SE of triplicate 
experiments. 
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3.3 Discussion 
In this work the 4-deoxy !-GalCer analogues 2 and 3 possessed species-specific 
iNKT cell activities. We confirmed that glycolipids 1, 2 and 3 are similarly active 
in mice (Figure 3.2 and Figure 3.4a), this was consistent with literature 
findings.6,10,11 We also demonstrated that sphinganine 2 was at least 1,000 times 
less active toward human iNKT cells than !-GalCer (1), highlighting the 
importance of the 4-hydroxyl for potent glycolipid activity in humans. To confirm 
this, we investigated the activity of sphingosine 3, which had not been previously 
tested. We found that the activity of 3 towards hNKT cells was 1,000 times less 
than that of 1. Again, this confirms the importance of the 4-OH for human iNKT 
cell activation and suggests that glycolipids developed for potent activity in 
humans should contain a ceramide base with the 4-hydroxyl present.  
 
The observation that 4-deoxy glycolipids possess species-specific activities is 
consistent with the work by Kronenberg and co-workers,6 however is in 
opposition to the work by Dubreuil and co-workers.12 Dubreuil and co-workers 
found that glycolipids 1 and 2 induced comparable human iNKT cell activation 
and suggested that the species-specific activity observed by other groups was due 
to the removal of the 4-hydroxyl decreasing solubility and hence activity. In our 
work glycolipid solubility is unlikely to play a major role as no difference was 
observed in the same samples when tested in mice. Studies by Xia et al. also 
demonstrated the importance of the 4-hydroxyl for potent hNKT cell activation. 
In their work the phytosphingosine analogue of iGb3 (Chapter 1.2, Figure 13, pg 
27) was synthesised and found to be 100 times more active than iGb3 itself.8 
These results support our observations, and suggest that the 4-hydroxyl is critical 
for potent hNKT cell activation. 
 
To elucidate the mechanism behind this species-specific activity we investigated 
human DC presentation to murine iNKT cells. We found that human DCs were 
able to present glycolipids 1, 2 and 3 almost equally well. This suggests that the 
reduced activity observed in the human system is not due to a lack of CD1d 
binding or DC presentation. In contrast, Kronenberg and co-workers attributed the 
decreased activity to insufficient human CD1d presenation.6 In their work mouse 
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B cells were transfected with human CD1d. These cells were cultured together 
with mNKT cells and either glycolipid 1 or an analogue of 2 (where the acyl chain 
was C-24). In this assay IL-2 production was significantly reduced using the 4-
deoxy analogue, thus Kronenberg and co-workers suggested the species-specific 
activity was due to insufficient human CD1d presentation. However, as only one 
glycolipid concentration was investigated it is likely that this is exacerbating the 
relatively small difference we also observe in hDC presentation to mNKT cells 
(Figure 3.4c). We found that this difference was not as significant as that observed 
using hDC and hNKT cells. In addition, the reduced activity observed by 
Kronenberg and co-workers could also be due to the use of the C-24 acyl chain, as 
studies in the literature suggests that the C-26 acyl chain is the optimal length for 
iNKT cell activation.13 
 
Our results suggest that structural differences in the iNKT cell TCR shape the 
species-specific activities of the 4-deoxy analogues. This is supported by recent 
studies in the literature, which suggest that changes to the TCR structure can alter 
glycolipid activity. In 2009, Joyce and co-workers demonstrated that a panel of 
murine iNKT cell hybridomas, each possessing different #-TCR-chains, produced 
varying amounts of IL-2, in response to stimulation by the same glycolipid.14 In 
addition, Tsuji and co-workers found that an E-alkene linked glycolipid was a 
more potent activator of human, rather than murine, iNKT cells.15 They 
determined that this preferential activity related to the binding affinity of the 
CD1d-glycolipid complex to the TCR and that differences in TCR structure were 
more important than differences in CD1d structure. 
 
In view of this, it seems likely that the human and mouse TCR homologues 
respond differently to the 4-deoxy glycolipids. In an attempt to explain the 
reasons for these differences in more detail we compared the structural data 
available for human and mouse CD1d-glycolipid binding, and TCR recognition. 
This would enable us to identify the key amino acid residues involved in 
maintaining the ternary complex. Both human and murine CD1d proteins employ 
the Asp80 residue to bind to the 3- and 4-hydroxyls of the phytosphingosine 
lipid.16-19 Crystal structures demonstrate that the orientation of the Asp80 residue 
is very similar in the two CD1d homologues (Figure 3.5).18 In our studies, 
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removing the 4-OH did not affect glycolipid binding to either human or mouse 
CD1d proteins as illustrated by mNKT cell cytokine production in response to 
both human and mouse DC presentation of 2 and 3 (Figure 3.4a and c). However, 
this chemical modification reduced the affinity of the human TCR for the CD1d-
glycolipid complex (Figure 3.4b).  
 
 
Figure 3.5. Structural alignment of the human (grey) and mouse (green) CD1d !-
GalCer (orange) binding sites. The position and orientation of the Asp80 residue 
that binds to the 3- and 4-hydroxyls is conserved. (Image used with permission 
from the Nature Publishing Group)18 
 
The prominent recognition force in the ternary complex (CD1d-glycolipid-TCR) 
is the H-bond network.16 The permanence of these interactions plays a vital role in 
the strength of the glycolipid response. In the human CD1d-glycolipid-TCR 
complex, one of the most important H-bonding interactions is between the 
Arg95! residues in the alpha chain of the hTCR, to the Asp80 residue of the 
CD1d protein.16,18,20 The Arg95! residue is in a different orientation in the mouse 
TCR,21 and while it may still be involved in the TCR-glycolipid-CD1d binding 
complex, it is likely to play less of a role in the H-bonding network.17 This 
structural information suggests that the mTCR can more easily compensate for the 
loss of the 4-hydroxyl on the phytosphingosine chain, and therefore the activity of 
!-GalCer vs. analogues 2 or 3 was comparable using the mTCR. In contrast, the 
hTCR is unable to accommodate changes at this position due to the vital Asp80 to 
Arg95!  H-bond. The Asp80 residue binds to both 3- and 4-hydroxyls and 
removal of the 4-hydroxyl may therefore alter the orientation of the Asp80 residue 
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and disrupt the crucial binding to Arg95!. Based on our results it appears that the 
affinity of the hTCR for the CD1d-glycolipid complex is reduced upon removal of 
the 4-hydroxyl. 
 
In the future, the importance of these H-bonding interactions could be confirmed 
by obtaining crystal structures of the ternary complexes with each of the 4-deoxy 
analogues. This would reveal changes to the CD1d-glycolipid-TCR H-bonding 
network upon removal of the glycolipid 4-hydroxyl. In addition the importance of 
the 4-hydroxyl on the activity of other glycolipids could be investigated.  
 
3.4 Conclusion 
In summary, !-GalCer, sphinganine analogue 2, and sphingosine analogue 3 
showed comparable activity in mice. The 4-deoxy analogues, 2 and 3, 
demonstrated significantly reduced hNKT cell activity. The reduced activity is 
attributed to species-specific differences in iNKT cell glycolipid recognition 
rather than reduced CD1d presentation. Our results suggest that differences in 
TCR structure influence the species-specific activities. From these results we 
suggest that glycolipids developed for potent CD1d-iNKT cell activity in humans 
should contain a ceramide base with the 4-hydroxyl present.  
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3.5 Experimental 
Mice  
Breeding pairs of the inbred strains C57BL/6 were obtained from The Jackson 
Laboratories and from the Animal Resource Centre. All mice were maintained in 
the Biomedical Research Unit of the Malaghan Institute of Medical Research. 
CD1d -/- mice, which are devoid of CD1d-restricted iNKT cells, were also used.22 
The experiments were approved by the NZ national animal ethics committee and 
performed according to established national guidelines.  
 
Solubilisation of glycolipids  
!-GalCer (Industrial Research Ltd, New Zealand) and synthesised glycolipids 
were tested to be endotoxin-free at a sensitivity of 0.125 EU/mL with an 
endotoxin kit (Pyrotell, Limulus Amebocyte Lysate). Each glycolipid (1 mg) was 
dissolved in 200 µL of CHCl3/MeOH/H2O (10:10:3), heated at 37 °C for 15 min 
followed by sonication for 10 min. The solution was then diluted to 200 µg/mL in 
0.5% Tween/phosphate-buffered saline (PBS) and left to sit at!4 °C overnight. 
The glycolipid was then heated at 80 °C for 5 min followed by sonication for 5 
min then cooled at 0 °C for 5 min (x2) and left to sit at 4 °C overnight. Aliquots of 
this stock solution were removed and further diluted to the appropriate 
concentrations used in each assay using sterile PBS. 
 
Antigen presenting cell maturation assay 
100 µL of glycolipid, diluted to 2 µg/mL, was administered i.v. to groups of 
C57BL/6 mice (n = 3) and spleens were removed 20 h later. Spleens were teased 
through a cell strainer, red blood cells (RBCs) lysed with RBC lysis buffer, and 
the remaining cells labeled with anti-bodies for CD11c (clone HL3; BD 
Pharmingen), B220 (clone RA3-6B2 conjugated to A488; BD Pharmingen) CD86 
(clone GL1 conjugated to PE; eBioscience) and propidium iodide (BD 
Pharmingen) and analysed by flow cytometry (BD FACSort). The same protocol 
was used to assess CD86 expression on CD11c+ and B220+ cells from CD1d-/- 
mice. 
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In vivo intracellular iNKT cell cytokine expression 
100 µL of glycolipid, diluted to 2 µg/mL, was administered i.v. to groups of 
C57BL/6 mice (n = 2) and spleens were removed 3 h later. Spleens were teased 
through a cell strainer, red blood cells (RBCs) lysed with RBC lysis buffer, and 
the remaining cells labeled with CD1d tetramer (human CD1d tetramer, clone 
51.1, conjugated to PE, eBioscience, loaded with !-GalCer, IRL), and antibodies 
for CD3 (clone 145-2C11 conjugated to FITC, eBioscience 11-0031-82), and 
B220 (clone RA3-6B2 conjugated to PerCP, BD Pharmingen), then fixed with 
formaldehyde (Sigma) at 4 °C over night. Wells were washed, then stained for 
intracellular IFN-" (clone XMG1.2, conjugated to APC, BD Pharmingen) or IL-4 
(clone 11B11 conjugated to APC, BD Pharmingen) and analysed by flow 
cytometry (BD FACSort). Rat IgG (clone R3-34 conjugated to APC, BD 
Pharmingen) was used as an isotype control. Spleens from naïve control mice 
were similarly processed. 
 
Human iNKT cell proliferation assay. 
PBMCs were collected from healthy human volunteers, stored in liquid nitrogen, 
and thawed on the day of use. PBMCs (200,000 cells per well) were cultured with 
four fold serial dilutions of glycolipid 1, 2, 3 or media only (negative control) in 
wells containing 200 µL cIMDM (5% human AB serum) and incubated at 37 °C, 
5% CO2. After 24 h, 50 U/mL human IL-2 was added. The cells were harvested 
on day 7 for antibody labelling for live/dead fixable blue (Invitrogen), CD3 (clone 
SK7 conjugated to FITC, BD 349201), CD1d (human CD1d tetramer, clone 51.1, 
conjugated to PE, eBioscience, loaded with !-GalCer, IRL), CD19 (clone SJ25C1 
conjugated to APC, BD 340437) and flow cytometry (BD LSRII SORP). 
 
Culturing Murine cell lines 
The murine CD8!+ dendritic cell line (DC2114)23 was cultured in a flask 
containing complete Iscove’s Modified Dulbecco’s Medium (cIMDM): IMDM + 
GlutaMax (Gibco), 5% foetal bovine serum (Sigma-Aldrich), 0.1% 2-
mercaptoethanol (Invitrogen), 1% penicillin-streptomycin (Invitrogen). The flask 
was incubated at 37 °C, 5% CO2. Once the cells reached 80% confluency, the 
media was removed, and the adherent cells treated with trypsin, then split. Cells 
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were used after at least one passage. 
 
The murine NKT hybridoma cells (DN32.D3)24 were also cultured in a flask 
containing cIMDM and incubated at 37 °C, 5% CO2. Once the cells reached 80% 
confluency, the non-adherent cells were removed and then split. Cells were used 
after at least one passage. 
 
Human monocyte derived Dendritic Cells 
PBMCs were collected from the blood of healthy human volunteers and 
suspended in Roswell Park Memorial Institute (RPMI) media (Gibco) containing 
1% autologous human serum, human IL-4 (500 U/mL, PeproTech) and human 
granulocyte-macrophage colony-stimulating factor (hGMCSF) (2,000 U/mL, 
PeproTech). Cells were cultured for 7 days at 37 °C, 5% CO2, and half the media 
was replaced every two days. At day 7, the non-adherent cells were gently 
decanted and washed three times (PBS) before use. 
 
Human iNKT cell clones 
Human V!24V"11 iNKT cell clones were received from Rod Dunbar and Anna 
Brooks (Auckland University, NZ) and stored in liquid nitrogen. Before use the 
cells were defrosted, and washed. The cells were then rested for 1 to 2 days in a 
24 well plate (2 million cells per well) with RPMI media containing 5% AB 
human serum (Invitrogen), human IL-2 (100 U/mL, in house*), human IL-7 (0.1 
mg/mL, PeproTech), and 1% penicillin-streptomycin (Invitrogen). After 1 to 2 
days cells were gently removed from the 24 well plate and washed 2 to 3 times to 
remove cytokines. 
 
In vitro dendritic and iNKT cell culture assay  
DCs (25,000 per well, human or murine) and iNKT cells (100,000 per well, 
human or murine) were cultured together with two or four fold dilutions of 
glycolipid 1, 2, or 3 (triplicate repeats) with 250 µL media (cIMDM for mDC 
with mNKT, or cRPMI for hDC with hNKT or hDC with mNKT), in a 96 well 
                                                 
* Recombinant human IL-2 was produced using stationary phase cultures of the 
IL2L6 cell line, generated by modifying the murine J558 parental line to secrete 
the full-length human IL-2 protein 
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plate. Media, DCs, and NKT cell only and media and NKT cells only wells were 
included as negative controls, each in triplicate. Cells were incubated overnight at 
37 °C, 5% CO2 and 2 x 110 µL supernatant removed. The supernatant IL-2 and 
IFN-" levels were then measured. IL-2 was measured by determining the 
proliferation of an IL-2 dependant T cell line (see below). IFN-" produced by 
murine iNKT cells was measured using BioPlex. IFN-" produced by human iNKT 
cells was measured using ELISA. 
 
Measuring IL-2 production 
Supernatant IL-2 was measured by determining the proliferation of the IL-2 
dependant murine T-helper cell-derived line (HT-2).  
 
 HT-2 cell culture 
HT-2 cells were cultured in a flask containing cIMDM in the presence of 
IL-2 (200 U/mL). Once cells reached 80% confluency, the non-adherent 
cells were removed and then split. Cells were used after at least one passage. 
Before use cells were washed thoroughly with PBS to remove IL-2.  
 
HT-2 cells were then plated out in a flat-bottom 96-well plate (5,000 cells per 
well) and 100 µL supernatant added. A standard curve was constructed by 
incubating HT-2 cells with known concentrations of IL-2 (200-0 U/mL in five 
fold dilution). HT-2 cells proliferation was measured using [3H]thymidine 
incorporation over the final 6 h, and measured with a beta-counter (Wallac). 
 
Statistical analysis 
Statistical significance was analysed using one-way analysis of variants 
(ANOVA) followed by Tukey’s Multiple Comparison Test to compare the means 
of every treatment group with every other treatment group. Statistical calculations 
were performed using Graphpad Prism® Version 5 statistical package (Graphpad 
Software Inc., San Diego, CA, USA). 
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Chapter 4: Protecting Group Free Synthesis of A 
Five Membered Azasugar1 
4.1 Introduction 
As noted inhibitors of glycosidases, azasugars have enormous potential in the 
treatment of diseases such as viral infection, bacterial infection, lysosomal storage 
disorders, cancer and diabetes (Chapter 1).2,3 However, due to their limited 
availability, only a few have been widely studied for their therapeutic potential. 
The ability to rapidly and efficiently synthesise azasugars provides the 
opportunity to evaluate their inhibitory properties and investigate their therapeutic 
potential. Although there have been a number of elegant strategies for the 
synthesis of five membered azasugars, the vast majority of these employ standard 
protecting group manipulations (see Chapter 1.3 and references cited therein). The 
focus of the work in this chapter is the development of methodology that allows 
for the protecting group free synthesis of five membered azasugars (I, Scheme 
4.1). Key to achieving this goal was the development of two synthetic 
transformations, a novel carbamate cyclisation (III to II), and the Vasella 
reductive amination to produce primary amines (IV to III). To develop this 
methodology we chose to synthesise 1,4-dideoxy-1,4-imino-D-xylitol, which is a 
weak glycogen phosphorylase b inhibitor4 that was first isolated in 19855,6,7 and 
has been synthesised several times before.8-11 
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Scheme 4.1. Retrosynthesis of target five membered azasugars. 
 
4.2 Results and Discussion 
Carbamate Annulation 
Our first representative synthesis of a five membered azasugar commenced with 
the conversion of D-xylose (1, Scheme 4.2) into its methyl furanoside via a Fisher 
glycosidation. Treatment of the crude product with iodine and triphenylphosphine 
gave methyl 5-iodofuranoside 2 in a 61% yield over two steps.12 Iodoglycoside 2 
was then refluxed with zinc and catalytic amount of acetic acid, according to the 
conditions of Vasella, and TLC analysis showed complete conversion of the 
starting material to a less mobile product. Attempts to isolate the aldehyde, 
however, proved problematic due to the propensity of hydroxy aldehydes to 
readily polymerise. In contrast, in situ imine formation using 
(diphenylmethyl)amine and subsequent reduction with sodium cyanoborohydride 
led to the smooth formation of amine 3 in a three-step, one-pot procedure. 
Deprotection of crude amine 3, using TFA and Et3SiH, gave linear amine 4 as the 
TFA salt in 93% over the two steps with a minimal use of protecting groups. 
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Scheme 4.2. Synthesis of cis-2,3-disubstituted 1,4-dideoxy-1,4-imino-D-xylitol 
using novel annulation methodology. 
 
With the olefinic amine 4 in hand, we set out to develop the carbamate annulation 
reaction and produce the azasugar ring via halocyclisation. We proposed that 
iodide 5 could be prepared according to literature procedures and then reacted in 
situ, with a CO2 source, to generate the desired carbamate. Initial attempts to 
produce cyclic iodide 5 using N-iodosuccinimide (NIS) gave a complex mixture 
of products that included the five membered iodoazasugars 5 and the six 
membered iodoazasugars 6, presumably formed from 5 via aziridine formation 
and subsequent opening of the three membered ring by the nucleophilic iodide.13 
In an attempt to overcome this problem, amine 4 was subjected to a solution of I2 
and NaHCO3 in water. This solution was stirred overnight at room temperature, at 
which point TLC analysis demonstrated complete consumption of starting 
material. Attempts to extract the product using standard work-up procedures were 
unsuccessful, as the product was more soluble in the aqueous layer than the 
organic layer. Instead, the reaction mixture was concentrated in vacuo and an 
NMR of the crude reaction mixture was taken directly. 1H NMR analysis revealed 
the presence of only one product, however, further analysis by 13C and 2D NMR 
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was not possible at this stage due to the high salt content of the sample. 
Purification of the product was complicated by the inability of the TLC dips (I2; 
ninhydrin; H2SO4; KMnO4; dragendorff – BiO(NO3), KI, AcOH, and H2O; and 
ceric ammonium molybdate – (NH4)6Mo7O24.4H2O, Ce(SO4)2, and H2SO4) to 
stain the product. This observation suggested that the product was not azasugar 5, 
as this product stained in ninhydrin and I2. Nevertheless, purification could be 
achieved using silica gel gradient column chromatography with the product 
consistently eluted from the column using a solution of 5% methanol in ethyl 
acetate.  
 
Extensive NMR (1H, 13C, COSY, HMBC, HSQC) analysis of the purified 
material revealed the product contained six carbon centres; one carbonyl (13C 
NMR ! 164.4 ppm), two methylene groups and three methine centres (see 
appendix). HMBC correlations from the carbonyl carbon to both methylene 
groups and to one methine centre indicated that the carbonyl was attached to the 
molecule. In addition, the protons on one of the methylene groups had 1H 
chemical shifts of 4.64 and 4.51, suggesting this CH2 was next to an ester like 
functional group. Mass spectrometric analysis indicated that the product had an 
exact m/z of 160.0605 suggesting the product had the chemical formula C6H9NO4. 
With this information, and further analysis of the NMR spectra the structure of the 
product was determined to be that of carbamate 7. This result was exciting as we 
had hoped to be able to prepare carbamate 7 from alkenylamine 4 using an iodine 
promoted cyclisation. This methodology enabled the carbamate to be formed 
directly from the alkenylamine, in addition only a single product was observed 
from the reaction of alkenylamine 4 with I2 and NaHCO3, indicating the reaction 
was stereoselective. In an attempt to understand the CO2 source, and check that 
the CO2 was not being absorbed from the air, the unprotected amine 4 was 
subjected to iodine in the presence of DBU, however, this did not lead to 
carbamate 7 and a complex mixture of products was observed. This result was 
similar to that observed using NIS implicating NaHCO3 as the CO2 source in this 
reaction.  
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Although the mechanism of the cyclisation reaction has not yet been proven, we 
propose that reaction of alkenylamine 9 with I2 activates the double bond, through 
formation of iodonium ion 10 (Scheme 4.3). This enables intramolecular 
nucleophilic attack by the internal amine to form the intermediate haloamine 11. 
The haloamine then reacts with CO2, from the NaHCO3, to form adduct 12, which 
displaces the iodide, forming target carbamate 13.  
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Scheme 4.3. Proposed mechanism for the formation of cyclic carbamates from 
alkenylamines. 
 
Another remarkable feature of the halocyclisation/carbonylation is that it proceeds 
with complete diastereo- and regioselectively to give the five-membered 3,4-cis 
products exclusively. The 3,4-cis configuration is in agreement with the 
observation that iodine promoted intramolecular cyclisations are often directed by 
the allylic hydroxyl to give the cis-product.14-16 The stereochemistry of carbamate 
7 was unequivocally proven by hydrolysis to form the desired 1,4-dideoxy-1,4-
imino-D-xylitol (8) in excellent yield (99%). The data matched that previously 
reported.17 (See Chapter 6 for discussions concerning the diastereoselectivity 
observed during the carbamate annulation reaction.) 
 
Reductive Amination 
Given the success of our carbamate annulation, we set out to develop 
methodology for the synthesis of alkenylamine 4 that avoids the use of protecting 
groups. It is well known that the use of ammonia or ammonium salts in reductive 
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amination reactions typically results in the formation of amine dimers, due to the 
lower nucleophilicity of ammonia compared to the primary amine product of the 
reductive amination (see Chapter 1.3). We proposed that by increasing the 
concentration of ammonia (or ammonium salt) preferential formation of primary 
amine 4 could be achieved. To explore this, we first investigated the influence that 
the ammonium salt had on the reductive amination reaction. To this end, a variety 
of amine salts were used including NH4Cl, (NH4)2CO3, NH4HCO3 and NH4OAc 
(Table 4.1, Entries 1-4). With the exception of the less soluble carbonate, the 
addition of 10 equivalents of salt gave very similar results with monomer being 
formed in modest yield (40%), and with mediocre selectivity (2:3, 4:14). Next, 
taking advantage of the greater solubility of NH4OAc in EtOH, we increased the 
concentration of NH4OAc in an attempt to improve monomer formation. An 
increase from 10 to 100 equivalents of NH4OAc proved beneficial with monomer 
4 being formed in a 1:1 ratio (Entry 5). Increasing the acetate concentration, 
through use of a saturated solution of NH4OAc in EtOH, again showed a marked 
improvement in the formation of the monomer, both in yield (60%) and selectivity 
(3:2, Entry 6). 
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Table 4.1. Reductive amination of furan 2. 
O
I
OMe
HO OH
Zn, NH4X
NaCNBH3
EtOH, reflux
18 h2 14
NH2
OH
OH
4
+
H
N
OH
OH OH
OH
 
Entry Conditionsa,b Ratio 4:14c Yield 
(monomer)d 
1 (NH4)2CO3 (10 eq.) 3:7 30% 
2 NH4Cl (10 eq.) 2:3 40% 
3 NH4HCO3 (10 eq.) 2:3 40% 
4 NH4OAc (10 eq.) 2:3 40% 
5 NH4OAc (100 eq.) 1:1 50% 
6 NH4OAc (sat.) 3:2 60% 
7 NH4OAc (sat.), AcOH (10 eq.) 4.5:5.5 45% 
8 NH3 (30% solution in H2O) — degradation 
9 NH3 (60 eq.), TFA (2 eq.) 5.5:4.5 55% 
10 NH3 (60 eq.), AcOH (7 eq.) 3:2 60% 
11 NH4OAc (sat.), NH3 (10 eq.) 4:1 80% 
12 NH4OAc (sat.), NH3 (60 eq.) >20:1 95%e 
aAll reactions were performed by the addition of activated Zn (5 eq.), amine (as 
indicated) and NaCNBH4 (2 eq.) to a solution of the iodofuranoside in ethanol (20 
mL/mmol). bNH3 was added as a 30% solution in H2O. cRatios calculated from the 
integral values of the corresponding 1H NMR signals (4:14). dMolar yields. eIsolated 
yield. 
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As monomer 4 is both more nucleophilic, but also more basic than ammonia, we 
postulated that the correct balance between free ammonia and protonated 
monomeric amine would be critical in optimising the formation of amine 4. To 
explore this, a series of experiments were performed whereby the ammonia to 
ammonium salt ratio was altered. First, the addition of acetic acid to a saturated 
solution of NH4OAc (Entry 7) led to a reduction in both yield and selectivity 
compared to ammonium acetate alone (cf. Entry 6). This suggested that a more 
basic reaction medium was required. Use of 30% aqueous ammonia, as the amine 
source, with various concentrations of acids was then assessed. Without acid 
(Entry 8), degradation of starting material occurred and no product could be 
detected. The use of TFA or acetic acid (Entries 9 and 10) led to product 
formation, albeit without significant improvements in monomer yield. In contrast, 
adding ammonia (10 eq.) to a saturated solution of NH4OAc in EtOH provided a 
marked improvement in both selectivity and monomer yield (4:1, 4:14, 80%, 
Entry 11). Further optimisation via the addition of 60 equivalents of ammonia 
(Entry 12), resulted in almost exclusive formation of amine 4 and in excellent 
isolated yield (95%). 
 
Due to the absence of protecting groups and the associated water solubility of 
monomer 4, removal of the excess ammonium acetate was initially problematic. 
Optimal conditions were found when a solution of HCl in iso-propanol was added 
to the reaction mixture. Reaction of NH4OAc with HCl gave NH4Cl and AcOH. 
The AcOH could then be evaporated, and the resulting mixture dissolved in 
EtOH. NH4Cl is much less soluble in ethanol than NH4OAc, and could be 
removed by filtration through celite. Following silica gel flash column 
chromatography, monomer 4 was isolated in a 95% yield (as its HCl salt) and 
subsequently cyclised to carbamate 7, in a quantitative yield. To the best of our 
knowledge, this methodology provides the first efficient synthesis of a primary 
amine via reductive amination without any need for functional group protection. 
The use of this remarkably efficient transformation, in combination with the 
carbamate annulation, is ably demonstrated by the five step synthesis of azasugar 
8, in 57% overall yield, the best reported yield to date.  
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4.3 Conclusion 
Herein we have reported a novel, stereoselective, five step strategy for the 
synthesis of 1,4-dideoxy-1,4-imino-D-xylitol (8) in 57% yield. This strategy is not 
merely competitive in yield and the number of linear steps, but also does not 
require protecting groups. Furthermore, we have identified two novel reaction 
methodologies: the first for the stereoselective formation of cyclic carbamates 
from olefinic amines, and the second for the formation of primary amines without 
the need for protecting groups. Our two new synthetic methodologies are 
important additions to the chemist’s toolbox and we believe that both 
methodologies will find wide application in the synthesis of azasugars and other 
organic molecules.  
 
4.4 Experimental 
General Experimental 
Unless otherwise stated all reactions were performed under atmospheric air.  THF 
(Lab-Scan) was distilled from LiAlH4 prior to use. H2O, MeOH (Pure Science), 
EtOAc (Pure Science), and petroleum ether (Pure Science) were distilled prior to 
use. EtOH (absolute, Pure Science), AcOH (Ajax Finechem), DCM (LabServ), 
30% aqueous NH3 (J. T. Baker Chemical Co.), Et2O (Merck), TFA (Aldrich), D-
xylose (Sigma-Aldrich), AcCl (B&M), PPh3 (Merck), imidazole (Aldrich), I2 
(BDH), triethylsilane (Fluka), NaCNBH3 (Aldrich), aminodiphenylmethane 
(Aldrich), NaOH (Pure Science), and NH4OAc (AnalaR) were used as received. 
Zn dust was activated by the careful addition of conc. H2SO4, washed with EtOH 
(three times) and petroleum ether (three times), and stored under dry hexanes. All 
solvents were removed by evaporation under reduced pressure. Reactions were 
monitored by TLC-analysis on Macherey-Nagel silica gel coated aluminium 
sheets (0.20 mm, silica gel 60) with detection by UV-absorption (254 nm), by 
spraying with 20% H2SO4 in EtOH followed by charring at ~150 °C, by dipping 
in I2 in silica, or by spraying with a solution of ninhydrin (3.3 g) in EtOH (100 
mL) followed by charring at ~150 °C. Column chromatography was performed on 
Pure Science silica gel (40-63 micron). Dowex® W50-X8 acidic resin (Sigma) and 
Dowex® 1X4-50 basic resin (Sigma) were used for ion exchange chromatography 
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and HP-20 (Supelco) for reverse phase chromatography. High-resolution mass 
spectra were recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer 
using positive electro-spray ionisation. Optical rotations were recorded using a 
Perkin-Elmer 241 polarimeter at the sodium D-line. Infrared spectra were 
recorded as thin films using a Bruker Tensor 27 FTIR spectrometer, equipped 
with an Attenuated Total Reflectance (ATR) sampling accessory, and are reported 
in wave numbers (cm-1). Nuclear magnetic resonance spectra were recorded at 20 
°C in D2O or CDCl3 using either a Varian Unity-INOVA operating at 300 MHz or 
a Varian Unity operating at 500 MHz. Chemical shifts are given in ppm (!) 
relative to tetramethylsilane. NMR peak assignments were made using COSY, 
HSQC and HMBC experiments.  
 
Methyl 5-deoxy-5-iodo-"/#-D-xyloside (2).  
To a solution of D-xylose (4.16 g, 25.4 mmol) in MeOH (127 
mL), AcCl (380 µL) was added and the reaction was stirred at 
room temperature for 24 h. The reaction was neutralised by the addition of Dowex 
(OH-), filtered and concentrated. The resulting oil could be used without further 
purification or could be purified by flash chromatography (MeOH/EtOAc, 1/9, 
v/v) to give the methyl furanoside. To a solution of methyl xyloside (4.17 g, 25.4 
mmol) in dry THF (140 mL) under an atmosphere of argon, PPh3 (10.0 g, 38.1 
mmol) and imidazole (3.45 g, 50.8 mmol) were added. I2 (9.67 g, 38.1 mmol) in 
dry THF (38 mL) was cannulated into the reaction vessel. The reaction was 
refluxed for 2 h, then cooled, filtered and concentrated under reduced pressure. 
The product was taken up in petroleum ether/EtOAc, 3/1, v/v, and filtered through 
a silica plug to remove excess iodine. The product was further purified by column 
chromatography on reverse phase HP-20 beads (MeOH/water, 5/1, v/v) to give 
xyloside 2 as colourless oil in a 1:1.3 ratio of "- and #-anomers (61%, 4.24 g, 
15.5 mmol).12 Rf = 0.65 (EtOAc/MeOH, 9/1, v/v); ["]D21 = -19.7 (c = 1.5, CHCl3); 
IR (film) 3446, 1216, 770 cm-1. 1H NMR (500 MHz, CDCl3) ! 5.06 (d, J1,2 = 4.4 
Hz, 1H, H-1"), 4.93 (s, 1H, H-1#), 4.60 (dt, J3,4 = 3.9, J4,5a = J4,5b = 7.7 Hz, 1H, 
H-4#), 4.40 (m, 1H, H-4"), 4.29 (dd, J2,3 = 3.3 , J3,4 = 4.6 Hz, 1H, H-3"), 4.28 (s, 
1H, H-2#), 4.17 (dd, J1,2 = 4.4, J2,3 = 3.3 Hz, 1H, H-2"), 4.14 (d, J3,4 = 3.9 Hz, 
1H, H-3#), 3.51 (s, 3H, OMe-"), 3.40 (s, 3H, OMe-#), 3.32 (d, J4,5 = 7.7 Hz, 2H, 
O
I
HO OH
OMe
 105 
H-5), 3.31 (dd, J4,5a = 7.6, J5a,5b = 9.8 Hz, 1H, H-5a"), 3.25 (dd, J4,5b = 6.1, J5a,5b = 
9.8 Hz, 1H, H-5b"), 2.9 (br s, 1H, OH), 2.8 (br s, 1H, OH); 13C NMR (75 MHz, 
CDCl3) 109.0 (C1-#), 102.2 (C1-"), 83.7 (C4-#), 79.7 (C2-#), 79.1 (C4-"), 78.4 
(C2-"), 76.9 (C3-"), 76.0 (C3-#), 56.2 (OMe-"), 55.5 (OMe-#), 1.9 (C5-#), 1.6 
(C5-"); HRMS(ESI) m/z calcd. for [C6H11O4I+Na]+: 296.9594, obsd.: 296.9601. 
 
(2S, 3S)-1-(Diphenylmethyl)amino-pent-4-ene-2,3-
diol (3). To a solution of iodopyranoside 2 (200 mg, 
0.73 mmol) in EtOH (20 mL) was added water (500 
µL), activated Zn (185 mg, 2.92 mmol), 
aminodiphenylmethane (440 µL, 3.5 mmol), NaCNBH3 (137 mg, 2.19 mmol), 
and AcOH (200 µL). The mixture was stirred at reflux for 18 h then cooled and 
the solvent was removed under reduced pressure. The product was dissolved in 
ethanol and dry loaded onto a short silica plug and eluted with 10% methanolic 
ethyl acetate in order to remove zinc and zinc salts. The resulting oil was used 
without further purification. 1H NMR (500 MHz, CDCl3) 7.28 (m, 10H, Ph), 5.59 
(ddd, J3,4 = 6.5, J4,5-cis = 10.7, J4,5-trans = 17.4 Hz, 1H, H-4), 5.39 (s, 1H, CHPh2), 
5.11 (d, J4,5-trans = 17.4 Hz, 1H, H-5-trans), 5.06 (d, J4,5-cis = 10.7 Hz, 1H, H-5-cis), 
3.85 (dd, J2,3 = 5.0, J3,4 = 6.5 Hz, 1H, H-3), 3.77 (ddd, J1b,2 = 3.6, J2,3 = 5.0, J1a,2 = 
9.1 Hz, 1H, H-2), 2.96 (dd, J1b,2 = 3.6, J1a,1b = 13.3 Hz, 1H, H-1b), 2.90 (dd, J1a,2 = 
9.1, J1a,1b = 13.3 Hz, 1H, H-1a). 
 
(2S,3S)-1-Amino-pent-4-ene-2,3-diol trifluoroacetate 
(4). To a solution of (2S, 3S)-1-(diphenylmethyl)amino-
pent-4-ene-2,3-diol 3 (225 mg, 0.79 mmol) in TFA (5 
mL) triethylsilane (232 µL, 1.46 mmol) was added and the mixture stirred at 
reflux for 18 h. The solution was cooled and the solvent removed under reduced 
pressure. The product was dissolved in water (50 mL) and washed with diethyl 
ether (three times 50 mL). The water layer was then concentrated and purified by 
gradient flash chromatography (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, 
v/v/v/v) to give 4 (93% from 2, 158 mg, 0.73 mmol) as the TFA salt. Rf  = 0.32 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); ["]D20 = -25.5 (c = 
0.08, EtOH); IR (film) 3405, 3212, 2888, 1555, 1434, 1183, 1127, 1016, 838 
H
N
OH
OH
NH2
OH
OH
TFA.
 106 
cm-1. 1H NMR (300 MHz, D2O) ! 5.71 (ddd, J3,4 = 6.4, J4,5-cis = 10.4, J4,5-trans = 
17.1 Hz, 1H, H-4), 5.34 (d, J4, 5-trans = 17.1 Hz, 1H, H-5-trans), 5.28 (d, J4,5-cis = 
10.4 Hz, 1H, H-5-cis), 4.10 (dd, J2,3 = 5.0, J3,4 = 6.4 Hz, 1H, H-3), 4.05 (s, 1H, 
NH), 3.81 (ddd, J1a,2 = 3.3, J2,3 = 5.0, J1b,2 = 9.7 Hz, 1H, H-2), 3.15 (dd, J1a,2 = 3.3, 
J1a,1b = 13.2 Hz, 1H, H-1a), 2.98 (dd, J1b,2 = 9.7, J1a,1b = 13.2 Hz, 1H, H-1b); 13C 
NMR (75 MHz, D2O) ! 135.8 (C4), 117.9 (C5), 73.9 (C3), 72.0 (C2), 42.0 (C1); 
HRMS(ESI) m/z calcd. for [C5H11O2N+H]+: 118.0863, obsd.: 118.0871. 
 
 (2S,3S)-1-Amino-pent-4-ene-2,3-diol hydrochloride 
(4). To a solution of iodopyranoside 2 (60.1 mg, 
0.22 mmol) in a saturated solution of NH4OAc in EtOH 
(4.4 mL) was added activated Zn (71.5 mg, 1.1 mmol), NaCNBH3 (41 mg, 
0.66 mmol) and 30% aqueous NH3 (1.8 mL). The mixture was stirred at reflux for 
18 h, cooled to room temperature and concentrated under reduced pressure. The 
residue was redissolved in iPrOH and a solution of 20% HCl in iPrOH was added 
(4.6 g, 27.5 mmol). The suspension was filtered through celite and concentrated 
under reduced pressure. The residue was redissolved in iPrOH (20 mL) and 
filtered. The solution was dry loaded onto silica gel via the addition of silica gel to 
the dissolved material followed by evaporation of the solvent under reduced 
pressure. The silica gel was loaded onto a silica gel column and purified by 
gradient flash chromatography (DCM/EtOH/MeOH/30% aqueous NH3, 25/2/2/1 
to 5/2/2/1, v/v/v/v) to give alkenylamine 4 as the HCl salt (95%, 32 mg, 
0.21 mmol). Rf = 0.37 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); 
["]D20 = -40.0 (c = 0.07, EtOH); IR (film) 3405, 3212, 2888, 1555, 1434, 1016 
cm-1.1H NMR (300 MHz, D2O) ! 5.71 (ddd, J3,4 = 6.4, J4,5-cis = 10.5, J4,5-trans = 
17.1 Hz, 1H, H-4), 5.34 (d, J4, 5-trans = 17.1 Hz, 1H, H-5-trans), 5.28 (d, J4,5-cis = 
10.5 Hz, 1H, H-5-cis), 4.10 (dd, J2,3 = 5.0, J3,4 = 6.4 Hz, 1H, H-3), 4.05 (s, 1H, 
NH), 3.81 (ddd, J1a,2 = 3.3, J2,3 = 5.0, J1b,2 = 9.7 Hz, 1H, H-2), 3.15 (dd, J1a,2 = 3.3, 
J1a,1b = 13.2 Hz, 1H, H-1a), 2.98 (dd, J1b,2 = 9.7, J1a,1b = 13.2 Hz, 1H, H-1b); 13C 
NMR (75 MHz, D2O) ! 135.8 (C4), 117.9 (C5), 73.9 (C3), 72.0 (C2), 42.0 (C1); 
HRMS(ESI) m/z calcd. for [C5H11O2N+H]+: 118.0863, obsd.: 118.0871. 
Dimer: (2S,3S)-1-((2S,3S)-2,3-Dihydroxy-pent-4-
enylamino)-pent-4-ene-2,3-diol (14). Rf = 0.46 
NH2
OH
OH
HCl.
HCl
.HN
OH
OH OH
OH
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(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); 1H NMR (300 MHz, 
D2O) ! 5.86 (ddd, J3,4 = 6.5, J4,5-cis = 10.5, J4,5-trans = 17.3 Hz, 2H, H-4), 5.36 (dt, 
J4,5-trans = 17.3, J3,5-trans = J5-cis,5-trans = 1.3 Hz, 2H, H-5-trans), 5.30 (dt, J4,5-cis = 
10.5, J3,5-cis = J5-cis,5-trans = 1.3 Hz, 2H, H-5-cis), 4.10 (ddt, J2,3 = 4.9, J3,4 = 6.5, J3,5-
cis = J3,5-trans = 1.3 Hz, 2H, H-3), 3.91 (ddd, J1a,2 = 3.3, J2,3 = 4.9, J1b,2 = 9.7 Hz, 
2H, H-2), 3.21 (dd, J1a,2 = 3.3, J1a,1b = 13.0 Hz, 2H, H-1a), 3.11 (dd, J1b,2 = 9.7, 
J1a,1b = 13.0 Hz, 2H, H-1b); 13C NMR (75 MHz, D2O) ! 135.4 (C4), 118.3 (C5), 
73.7 (C3), 68.8 (C2), 49.5 (C1). HRMS(ESI) m/z calcd. for [C10H19O4N+H]+: 
218.1387, obsd.: 218.1386. 
 
 (6S,7S,7aR)-6,7-Dihydroxy-tetrahydro-pyrrolo[1,2-c]oxazol-3-
one (7). To a solution of alkenylamine hydrochloride 4 (41 mg, 0.35 
mmol) in water (1.75 mL) was added NaHCO3 (44 mg, 0.53 mmol) 
and I2 (109 mg, 0.39 mmol). The solution was stirred for 18 h at room 
temperature then filtered and concentrated under reduced pressure. The product 
was purified by silica gel chromatography (EtOAc/MeOH, 95/5, v/v) to give 
carbamate 7 as an amorphous white powder (99%, 55 mg, 0.35 mmol). ["]D19 = -
26.1 (c = 0.4, EtOH); IR (film) 3425, 3243, 3125, 1680, 1435, 1194, 1130, 844, 
799, 717 cm-1. 1H NMR (300 MHz, D2O) ! 4.64 (t, J4,5a = J5a,5b = 9.3 Hz, 1H, H-
5a), 4.51 (dd, J4,5b = 3.7, J5a,5b = 9.3 Hz, 1H, H-5b), 4.40 (d, J1a,2 = 5.3 Hz, 1H, H-
2), 4.31 (dt, J4,5a = 8.5, J4,5b = J3,4 = 3.7 Hz, 1H, H-4), 4.05 (d, J3,4 = 3.7 Hz, 1H, 
H-3), 3.80 (dd, J1a,2 = 5.3, J1a,1b = 12.6 Hz, 1H, H-1a), 3.13 (d, J1a,1b = 12.6 Hz, 
1H, H-1b); 13C NMR (75 MHz, D2O) ! 164.4 (C6), 76.5 (C2), 74.3 (C3), 64.0 
(C5), 62.0 (C4), 52.2 (C1); HRMS(ESI) m/z calcd. for [C6H9O4N+H]+: 160.0604, 
obsd.: 160.0605. 
 
 1,4-Dideoxy-1,4-imino-D-xylitol hydrochloride (8). To a 
solution of carbamate 7 (6.5 mg, 41 !mol) in EtOH (1 mL) 
was added NaOH (16.4 mg, 0.41 mmol). The solution was 
stirred at reflux for 2 h then cooled and purified directly using Dowex (H+). 
Product 8 was eluted in 5 to 15% aqueous NH3, concentrated in vacuo and 
converted to the HCl salt (99%, 7.0 mg, 41 !mol). Rf = 0.9 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); ["]D20 = +6.4 (c = 0.5, 
N
O
O
HO OH
H
N
HO
HO OH
HCl.
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H2O); IR (film) 3334, 3172, 2974, 2886, 1380, 1328, 1088, 1045 cm-1. 1H NMR 
(300 MHz, D2O) ! 4.37 (d, J1a,2 = 4.4 Hz, 1H, H-2), 4.30 (s, 1H, H-3), 4.01 (m, 
1H, H-5a), 3.88 (m, 2H, H-4 and H-5b), 3.64 (dd, J1a,2 = 4.4, J1a,1b = 13.0 Hz, 1H, 
H-1a), 3.28 (d, J1a,1b = 13.0 Hz, 1H, H-1b); 13C NMR (75 MHz, D2O) ! 74.3, 74.2 
(C2, C3), 62.9 (C4), 57.2 (C5), 50.4 (C1). HRMS(ESI) m/z calcd. for 
[C5H11O3N+H]+: 134.0812, obsd.: 134.0818. 
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Chapter 5: Reductive Amination Methodology for 
the Synthesis of Primary Amines1 
5.1 Introduction 
Amines are an important class of compounds and are found in many natural 
products, pharmaceuticals and other valuable organic molecules including dyes 
and agrochemicals.2,3 There are many synthetic transformations that can be used 
to prepare amines,2 however methodology for the selective production of primary 
amines is more limited. Of these, reductive aminations are particularly important 
and well utilised for the synthesis of primary amines.4-6 These reactions often 
utilise molecular hydrogen as the imine reducing agent5 with ruthenium in 
particular proving to be an efficient and selective catalyst.6,7 Though this 
methodology has significant merit, the use of hydrogen gas under high pressure 
and temperature nonetheless limits functional group compatibility as double 
bonds are reduced and aromatic groups removed under these conditions. To 
circumvent this problem, metal hydride reducing agents can be employed, 
however, methodology for selectively forming primary amines via metal hydride 
reductive amination is limited (as discussed in 1.3). 
 
In chapter 4, a procedure for the preparation of primary amines from methyl 
glycosides using a Vasella reductive amination reaction, that did not require the 
use of protecting groups was highlighted.8 For this methodology to have wider 
applicability the scope and limitations of this novel reductive amination protocol 
need to be explored. The results of such studies and insight into factors that may 
be responsible for the observed chemoselectivity of the reductive amination 
methodology are reported herein. More specifically, we wanted to understand the 
 112 
influence that the free hydroxyl substituents had on the chemoselectivity of the 
reaction and whether the reductive amination conditions gave similar results when 
starting with preformed aldehydes (i.e. without the Vasella component of the 
reaction). 
5.2 Results and Discussion 
Vasella Reductive Amination 
Given the importance of primary amines as synthetic products and intermediates, 
we were interested in developing new methodology for the preparation of amines 
from aldehydes without the need for protecting groups. In our protecting group 
free synthesis of amines (Chapter 4), a Vasella reaction9 and a reductive 
amination were used to prepare linear alkenylamines (I) in one step from an alkyl 
halo-glycoside precursor (II), itself readily available from the parent 
monosaccharide (III) in two steps10 (Scheme 5.1). Here, the typical Vasella 
reductive amination protocol8 involved the overnight reflux of a suspension of Zn, 
NH4OAc (excess), NH3, NaCNBH3 and the iodosugar in ethanol. Under these 
conditions the primary mono-alkylamine was produced exclusively (>20:1 
primary:secondary). Excess NH4OAc was crucial to selectively obtain the primary 
amine. 
NH2
OH n
!
O
I
OMe
OH n
!!
O
OH
OH
OH n
!!!  
Scheme 5.1. Retrosynthesis of primary alkenylamines. 
 
To investigate the applicability of this reaction to other methyl iodosugar or 
aldehyde substrates, we wanted to first develop a more efficient strategy for the 
isolation of the amines from the excess NH4OAc. In chapter 4 excess salts were 
precipitated, by converting NH4OAc to NH4Cl and AcOH. This process requires 
HCl in iso-propanol and not all amine products are stable under these conditions. 
In addition, this method usually leaves a small quantity of residual NH4Cl, which 
is subsequently removed by silica gel column chromatography. To improve the 
isolation of the amine products we investigated Dowex-H+ ion exchange 
chromatography as a means to remove the excess salts. Indeed, this methodology 
 113 
proved the most suitable for isolating the amine products from the reaction 
mixture. With greater affinity for the ion exchange resin than the ammonium salts, 
the alkylamine was readily separated by loading the reaction mixture directly onto 
the ion exchange resin and first washing the column with water (to remove the 
salts), then eluting the amine product with aqueous ammonia.  
 
Having developed an improved strategy for the isolation of amines from the 
ammonium salts, we commenced our investigations into the factors responsible 
for primary amine selectivity. To explore the influence of pH on the 
chemoselectivity, we conducted the Vasella reductive amination over a range of 
pH conditions using methyl iodoglycoside 1 as a model substrate, and recorded 
the resulting primary to secondary amine ratio (Table 5.1). A neutral solution, 
obtained by the addition of AcOH (10 eq.), gave the dimeric secondary amine as 
the major product (4.5:5.5, 2:3, Entry 1, Table 5.1). At a pH of 8, when a 
saturated solution of NH4OAc was used without the addition of either AcOH or 
NH3, formation of primary amine 2 was favoured (Entry 2). Increasing the pH of 
the reaction mixture to 10 using NH3 (10 eq.) improved the selectivity even 
further (4:1, 2:3, Entry 3). Having observed the beneficial influence that 
increasing the pH has on chemoselectivity, 60 eq. of NH3 was then added. Under 
these conditions the primary amine was the only product observed by NMR 
(>20:1, 2:3, Entry 4). It is proposed that this pH dependant selectivity relates to 
the beneficial influence of increasing the availability of ammonia. At neutral or 
acidic pH a greater proportion of ammonia will be protonated forming the 
ammonium cation, which will not act as an amine source. As the pH increases, 
however, the availability of ammonia increases favouring primary imine 
formation, and therefore formation of the primary amine. Here it is also important 
to note that though primary amine 2 is more nucleophilic than ammonia, it is also 
more basic. Therefore, while it is important to have NH3 available to react, the 
correct balance of free ammonia to amine product may also be critical in 
optimising the formation of primary amine. At the optimum pH it maybe possible 
to protonate primary amine 2, preventing it from reacting further to give 
secondary amine 3, whilst a proportion of the ammonia remains unprotonated and 
can act effectively as a nucleophile. 
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Table 5.1. Vasella reductive amination under different pH conditions. 
O
I
OMe
HO OH
Zn, EtOH
NH4OAc
NaCNBH3
reflux, 18 h
NH2
OH
OH
21
H
N
OH
OH OH
OH
3  
Entry Conditions pH of the  
reaction mixturea 
Ratiob 
2:3 
1 NH4OAc (sat.), AcOH (10 eq.) 7 4.5:5.5 
2 NH4OAc (sat.) 8 3:2 
3 NH4OAc (sat.), NH3 (10 eq.) 10 4:1 
4 NH4OAc (sat.), NH3 (60 eq.) 12 >20:1 
a pH of the reaction mixture after all reagents have been added, at the start of 
the reaction 
b Ratio obtained from NMR of the crude material 
 
Using our optimised conditions, we investigated the scope of the Vasella 
reductive amination reaction conditions for the synthesis of primary amines from 
other methyl iodoglycosides. Using these conditions alkenylamines 2 and 5 
(Entries 1 and 2, Table 5.2) were synthesised chemoselectively, and in excellent 
yields of 95% and 91%, respectively. Reaction of D-arabinoside 6 (Entry 3, Table 
5.2) also proceeded uneventfully to give the corresponding alkenylamine 7 in 
excellent yield (93%). As anticipated, the stereochemistry around the furanose 
ring had no significant effect on the yield or selectivity of the reaction. Although 
by-products from Vasella reactions have been well documented, with reductive 
dehalogenation and the reduction of the aldehyde to the alcohol being the most 
common degradation products,11 this Vasella reductive amination occurred 
smoothly and with no other products observed. To further investigate the 
applicability of our reaction conditions, 2-deoxy-riboside 8 was subjected to the 
same reductive amination protocol (Entry 4, Table 5.2). Again, exclusive 
formation of the primary alkenylamine was observed, with alkenylamine 9 being 
isolated in good yield (81%). This result indicated that the absence of an !-
hydroxyl function in the aldehyde substrate did not adversely affect the efficiency 
or selectivity of the reaction.  
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Table 5.2. Vasella reductive amination of methyl iodoglycosides. 
O OMe NH2n
Zn, NaCNBH3 
NH4OAc
NH3 (aq), EtOH 
18 h
I
R R
 
Entry Substrate Major Product Ratio
a 
(1°:2° amine) Yield
b 
 1c 
O
I OMe
OHHO  
1 
NH2
OH
OH
 
2 
>20:1 95% 
2 
O
I OMe
OHHO  
4 
NH2
OH
OH
 
5 
>20:1 91% 
3 
O
I OMe
OHHO  
6 
NH2
OH
OH
 
7 
>20:1 93% 
4 
O
I OMe
HO  
8 
NH2
OH  
9 
>20:1 81% 
5 
O
I OMe
OBnBnO  
10 
NH2
OBn
OBn
 
11 
3:1 81% 
6 
O
I OMe
OBnBnO  
12 
NH2
OBn
OBn
 
13 
2:1 98% 
7d 
OI OMe
OH
OH
HO
 
14 
OH
OH
NH2
OH  
15 
9:1 93% 
a Ratio obtained from NMR of the crude material 
b Combined yield of primary and secondary amines following purification 
c See ref. 23 
d See Table 3 
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We then explored the role that the functional group pattern has on the 
chemoselectivity of the reaction. The fully protected methyl iodoglycosides of D-
arabinose 1012 and D-ribose 1210 (Entries 5 and 6) were subjected to the Vasella 
reductive amination conditions. In both instances, the primary amines were the 
major products, although the secondary amine products were also observed. 
Following Dowex-H+ ion exchange chromatography, the relative integrals of the 
corresponding 1H NMR signals were used to determine the ratio of 
primary:secondary amine, and the assignments confirmed after separation of the 
two amine products via silica gel chromatography (DCM ! 
DCM/EtOH/MeOH/30% aq. NH3, 5/2/2/1, v/v/v/v). HRMS allowed for the 
identification of each product, as did the HMBC correlations between the CH2-1 
and the CH2-1´ for the secondary amine product. Here, it is interesting to note that 
the " of C-1 of primary alkenylamines 11 (" = 42.3 ppm) and 13 (" = 42.5 ppm) 
was lower than the corresponding " of C-1 for the secondary amine product by ca. 
8 ppm. This observation was consistent for all primary and secondary amines 
formed and provided a convenient means by which to readily distinguish the two 
products. The reduced selectivity observed for 10 and 12 suggested that the 
functional group pattern of the substrate could affect the chemoselectivity, though 
not as adversely as decreasing the pH of the reaction solution (Table 2). 
 
Next, we turned our attention to the Vasella reductive amination of methyl 6-iodo-
glucoside 14 (Entry 7, Table 5.2) to determine if the methodology was applicable 
to pyranoside sugars. Using the standard reaction concentration, the selectivity for 
primary amine 15 was moderate (9:1, 15:16, Entry 1, Table 5.3) and the overall 
yield was 93%. In an attempt to improve primary amine formation the reaction 
was conducted in more dilute conditions (40 mL sat. NH4OAc in ethanol with 16 
mL 30% aqueous NH3 per mmol). Using these conditions only the desired primary 
amine 15 was produced (Entry 2), however the yield was poor (50%) due to a 
significant amount of degradation. Unfortunately, characterisation of the by-
products proved futile. To further study the effect that concentration had on the 
reaction outcome, more concentrated conditions (5 mL sat. NH4OAc in ethanol 
with 2 mL 30% aqueous NH3 per mmol) were used (Entry 3). These conditions 
led to a reduction in chemoselectivity, producing a 1:1 ratio of primary:secondary 
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amine (15:16), though the overall yield was significantly improved with no 
observed degradation. From these results, it is apparent that over-dilution of the 
reaction mixture leads to increased degradation and poor yields, presumably as a 
consequence of a reduced rate of imine reduction, resulting in imine degradation.  
 
Table 5.3. Vasella reductive amination at different reaction concentrations. 
 
O
OH
OMe
HO OH
I
Zn, EtOH
NH4OAc, NH3
NaCNBH3
reflux, 18 h
NH2
OH
OH
OH
14 15 16
N
HOH
OH
OH OH
OH
OH
 
Entry Concentration Ratioa 
(15:16) 
Yieldb 
1 20 mL sat. NH4OAc in ethanol per mmol 9:1 93% 
2 40 mL sat. NH4OAc in ethanol per mmol > 20:1 50% 
3 5 mL sat. NH4OAc in ethanol per mmol 1:1 99% 
a Ratio obtained from NMR of the crude material 
b Combined yield of primary and secondary amines following purification 
 
Reductive Amination of Aldehydes 
Following our investigations into the Vasella reductive amination methodology, 
we explored the direct reductive amination of several aldehydes to determine 
whether the Vasella step was a requirement for good selectivity. To directly assess 
the effect of the initial Vasella reaction on the chemoselectivity, the benzyl 
protected aldehyde 17 was pre-formed by subjecting methyl iodoglycoside 12 to a 
Vasella reaction, followed by standard work-up procedures. Aldehyde 17 was 
then subjected to the reductive amination conditions to give 13 in a 1:1 ratio 
(primary:secondary amine) in a 97% yield (Entry 1, Table 5.4). Though modest 
chemoselectivity was obtained, this result was nevertheless encouraging as it 
paralleled those observed during the Vasella reductive amination of arabinoside 
10 and riboside 12 (Entries 5 and 6, Table 5.2) and suggests that the Vasella 
reaction has little effect on the chemoselectivity of the reductive amination. We 
then sought to investigate the reductive amination of unfunctionalised aldehydes. 
 118 
Here, nonanal (18) was subject to the reductive amination conditions and primary 
amine 19 was formed exclusively and in an excellent 98% yield (Entry 2, Table 
5.4). This result was significant for it illustrated that hydroxyl substituents were 
not required for the selective reductive amination of aldehydes and therefore 
markedly increased the scope of the reductive amination methodology. These 
results also indicated that the addition of zinc (for the one pot Vasella reductive 
amination reaction) did not significantly alter the outcome of the reaction and 
negates the possibility of boron ester13,14 or zinc chelation15,16 aiding the 
chemoselectivity of the reaction. Unfortunately, the unprotected aldehyde 
products from the Vasella reaction of furanosides 1, 4 and 6 readily polymerised 
into mixtures of acetals and could not be isolated or studied in a reductive 
amination reaction that was independent of the Vasella reaction. 
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Table 5.4. Reductive amination of masked aldehyde (hemi-acetal) and aldehyde 
substrates. 
NaCNBH3, NH4OAc
NH3 (aq), EtOH 
18 h
O
R
NH2
RH  
Entry Substrate Major Product Ratioa 
(1°:2° 
amine) 
Yieldb 
1 O
OBn
OBn  
17 
NH2
OBn
OBn  
13 
1:1 97% 
2 O7  
18 
NH27  
19 
>20:1 98% 
3 
O
HO OH
OHHO  
20 
HO NH2
OH
OH
OH
 
21 
>20:1 85% 
4 
O
HO OH
HO  
22 
HO NH2
OH
OH  
23 
>20:1 86% 
5 
O OH
 
24 
HO NH2  
25 11:1 60% 
6 
O
OH
OH
HO OH
HO
 
26 
HO
NH2
OH
OH
OH
OH  
27 
>20:1 87% 
7 
O OHHO
 
28 
HO NH2
OH  
29 
8:1 65% 
8 
O OH
 
30 
HO NH2  
31 7:1 81% 
a Ratio obtained from NMR of the crude material. 
b Combined yield of primary and secondary amines following purification. 
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We then examined the furanose series of hemiacetals 20, 22, and 24 (Entries 3 to 
5, Table 5.4). Reductive amination of D-xylose (20) and 2-deoxy-D-ribose (22) 
gave the corresponding primary amines, 21 and 23, in excellent selectivity and in 
good yield (>85%). These results parallel those for the furanose Vasella reductive 
amination series (cf. Entries 1-4, Table 5.2) and expand the scope of the reaction 
to hemiacetals. To investigate the influence that the hydroxylation pattern has on 
the chemoselectivity, unsubstituted furanoside 24 was then subjected to the 
reductive amination conditions (Entry 5, Table 5.4). Here, the ratio of 
primary:secondary amine was also good (11:1), although the yield for the reaction 
was reduced (60%). Amine 25 and its dimer were the only products observed 
suggesting that the reduced yield for this reaction was due to the formation of 
non-amine by-products, which could not be extracted from the salts using a 
Dowex-H+ column.  
 
The reductive amination of a series of pyranoses was then explored. First, D-
glucose (26) was treated with a saturated solution of NH4OAc in ethanol, aqueous 
ammonia, and NaCNBH3 to give 1-amino-1-deoxy-D-glucitol (27) in good yield 
(87%) and with excellent selectivity (>20:1, primary:secondary amine) (Entry 6, 
Table 5.4). Hemiacetals with decreasing hydroxylation were then subjected to the 
reductive amination reaction. Hydroxymethylpyranose 28 (Entry 7) provided the 
corresponding amine 29 with good selectivity (8:1), albeit in moderate yield 
(65%), and the absence of the hydroxymethyl group (30, Entry 8) did not 
significantly alter the monomer to dimer ratio (7:1) with the primary amine 31 
being produced in good yield (71%). Though mixtures of primary and secondary 
amines were formed, these could be separated by flash column chromatography 
on silica gel. Again, by comparing the " of C-5 of the primary and secondary 
amine products, the two products could be easily identified by 13C NMR [e.g. C-5 
of 5-amino-pentanol 31 had an upfield 13C NMR chemical shift (" = 39.4 ppm), as 
compared to the C-5 of the secondary amine by-product (" = 47.7 ppm)]. HMBC 
correlations and HRMS were also used to confirm the identity of the primary and 
secondary amines. Taken as a whole, these results demonstrate that our 
methodology is applicable to the synthesis of a variety of primary amines from 
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different aldehyde precursors, and in almost all instances, good chemoselectivity 
was observed.  
5.3 Conclusion 
We have demonstrated that primary amines can be selectively produced from 
aldehydes via metal hydride reductive amination without the need for protecting 
groups. The most important influences on the chemoselectivity are pH, the 
number of amine equivalents, and reaction concentration. The most ideal 
conditions are a pH of approximately 12, a large excess of ammonia, and a 
concentration of 20 mL of saturated NH4OAc in ethanol per mmol of aldehyde. 
Overall, the reductive amination methodology is applicable to a wide range of 
functionalised substrates and the yields of the primary amines are typically good. 
Without requiring the need for protecting groups, the methodology is fast, 
efficient and thus atom-economic, and provides a valuable synthetic tool for the 
selective formation of primary amines. The application of this methodology in the 
protecting group free synthesis of further azasugars is presented in chapter 6.  
 
 
5.4 Experimental 
General experimental 
Unless otherwise stated all reactions were performed under atmospheric air. 
Hemiacetals 24, 28 and 30 were synthesised according to the procedure by 
Tamaru and co-workers.17 Methyl iodoglycosides were synthesised according to 
the procedure by Madsen and co-workers.10 The Zn dust was activated by the 
careful addition of conc. H2SO4, followed by decantation and washing with EtOH 
(three times) and hexanes (three times), and storage under dry hexanes. All 
solvents were removed by evaporation under reduced pressure. Reactions were 
monitored by TLC-analysis on silica gel coated plastic sheets (0.20 mm, 
Polygram SIL G/UV254) with detection by spraying with 20% H2SO4 in EtOH 
followed by charring at ~150 °C, by dipping in I2 in silica, or by spraying with a 
solution of ninhydrin in EtOH followed by charring at ~150 °C. Column 
chromatography was performed on silica gel (40-63 micron). Dowex® W50-X8 
acidic resin was used for ion exchange chromatography. High-resolution mass 
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spectra were recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer 
using positive electro-spray ionisation. Optical rotations were recorded using a 
Perkin-Elmer 241 polarimeter at the sodium D-line. Infrared spectra were 
recorded as thin films using a Bruker Tensor 27 FTIR spectrometer, equipped 
with an Attenuated Total Reflectance (ATR) sampling accessory, and are reported 
in wave numbers (cm-1). Nuclear magnetic resonance spectra were recorded at 20 
°C in D2O or CDCl3 using either a Varian Unity-INOVA operating at 300 MHz or 
a Varian Unity operating at 500 MHz. Chemical shifts are given in ppm (") 
relative to tetramethylsilane. NMR peak assignments were made using COSY, 
HSQC and HMBC experiments. 
 
General procedure for the synthesis of alkenylamines. To a solution of methyl 
iodo-glycoside (1 mmol) in a saturated solution of NH4OAc in EtOH (20 mL) was 
added activated Zn (327 mg, 5 mmol), NaCNBH3 (188 mg, 3 mmol) and 30% 
aqueous NH3 (8 mL). The mixture was stirred at reflux for 18 h, cooled to room 
temperature and concentrated under reduced pressure. The residue was 
redissolved in H2O, loaded on to a Dowex H+ ion exchange resin, and washed 
several times with H2O to remove excess salt. The amine product was then eluted 
with 15 to 30% aqueous NH3. Further purification was achieved using gradient 
flash chromatography (DCM/EtOH/MeOH/30% aqueous NH3, 25/2/2/1 to 
5/2/2/1, v/v/v/v). The alkenylamines were converted to the HCl salts for 
characterization by the addition of two drops of 1M HCl followed by 
concentration under reduced pressure. 
 
NH2
OH
OH
HCl.
 (2S,3S)-1-Amino-pent-4-ene-2,3-diol hydrochloride (2). 
By subjecting xyloside 1 (60.1 mg, 0.22 mmol) to the general procedure for the 
synthesis of alkenylamines, alkenylamine 2 was obtained as the HCl salt (32 mg, 
0.21 mmol, 95%). Rf = 0.37 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, 
v/v/v/v); [#]D20 = -40.0 (c = 0.07, EtOH); IR (film) 3405, 3212, 2888, 1555, 1434, 
1016 cm-1.1H NMR (300 MHz, D2O) " 5.71 (ddd, J3,4 = 6.4, J4,5-cis = 10.5 Hz, J4,5-
trans = 17.1 Hz, 1H, H-4), 5.34 (d, J4, 5-trans = 17.1 Hz, 1H, H-5-trans), 5.28 (d, J4,5-
cis = 10.5 Hz, 1H, H-5-cis), 4.10 (dd, J2,3 = 5.0, J3,4 = 6.4 Hz, 1H, H-3), 4.05 (s, 
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1H, NH), 3.81 (ddd, J1a,2 = 3.3, J2,3 = 5.0, J1b,2 = 9.7 Hz, 1H, H-2), 3.15 (dd, J1a,2 = 
3.3, J1a,1b = 13.2 Hz, 1H, H-1a), 2.98 (dd, J1b,2 = 9.7, J1a,1b = 13.2 Hz, 1H, H-1b); 
13C NMR (75 MHz, D2O) " 135.8 (C4), 117.9 (C5), 73.9 (C3), 72.0 (C2), 42.0 
(C1); HRMS(ESI) m/z calcd. for [C5H11O2N+H]+: 118.0863, obsd.: 118.0871. 
 
NH2
OH
OH
HCl.
 (2S,3R)-1-Amino-pent-4-ene-2,3-diol hydrochloride (5). 
By subjecting riboside 4 (51.2 mg, 0.19 mmol) to the general procedure for the 
synthesis of alkenylamines, alkenylamine 5 was obtained as the HCl salt (26 mg, 
0.17 mmol, 91%). Rf = 0.41 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, 
v/v/v/v); [#]D18 = +8.2 (c = 0.28, EtOH); IR (film) 3345, 2946, 2835, 1651, 1450, 
1018 cm-1. 1H NMR (300 MHz, D2O) " 5.88 (ddd, J3,4 = 6.6, J4,5-cis = 10.5, J4,5-trans 
= 17.1 Hz, 1H, H-4), 5.35 (d, J4,5-trans = 17.1 Hz, 1H, H-5-trans), 5.31 (d, J4,5-cis = 
10.5 Hz, 1H, H-5-cis), 4.12 (dd, J2,3 = 5.6, J3,4 = 6.6 Hz, 1H, H-3), 3.81 (ddd, J1a,2 
= 3.0, J2,3 = 5.6, J1b,2 = 9.7 Hz, 1H, H-2), 3.23 (dd, J1a,2 = 3.0, J1a,1b = 13.2 Hz, 1H, 
H-1a), 2.95 (dd, J1b,2 = 9.7, J1a,1b = 13.2 Hz, 1H, H-1b); 13C NMR (75 MHz, D2O) 
" 135.4 (C4), 118.3 (C5), 74.0 (C3), 69.8 (C2), 41.1 (C1); HRMS(ESI) m/z calcd. 
for [C5H11O2N+H]+: 118.0863, obsd.: 118.0873. 
 
NH2
OH
OH
HCl.
 (2R,3R)-1-Amino-pent-4-ene-2,3-diol hydrochloride (7). 
By subjecting arabinoside 6 (274 mg, 1 mmol) to the general procedure for the 
synthesis of alkenylamines, alkenylamine 7 was obtained as the HCl salt (143 mg, 
93 mmol, 93%). Rf = 0.61 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, 
v/v/v/v); [#]D20 = +50.6 (c = 1.0, EtOH); IR (film) 3412, 3252, 3045, 1632, 1432, 
1013 cm-1. 1H NMR (500 MHz, D2O) " 5.74 (ddd, J3,4 = 5.3, J4,5-cis = 10.5, J4,5-trans 
= 17.3 Hz, 1H, H-4), 5.23 (d, J4,5-trans = 17.3 Hz, 1H, H-5-trans), 5.17 (d, J4,5-cis = 
10.5 Hz, 1H, H-5-cis), 3.99 (t, J3,4 = J2,3 = 5.3 Hz, 1H, H-3), 3.70 (ddd, J1a,2 = 2.8, 
J2,3 = 5.3, J1b,2 = 9.9 Hz, 1H, H-2), 3.03 (dd, J1a,2 = 9.9, J1a,1b = 13.1 Hz, 1H, H-
1a), 2.87 (dd, J1a,2 = 2.8, J1a,1b = 13.1 Hz, 1H, H-1b); 13C NMR (125 MHz, D2O) " 
135.4 (C4), 118.2 (C5), 73.7 (C3), 69.7 (C2), 41.5 (C1). HRMS(ESI) m/z calcd. 
for [C5H11O2N+H]+: 118.0863, obsd: 118.0869. 
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NH2
OH
HCl.
 (R)-5-Amino-pent-1-en-3-ol hydrochloride (9). By 
subjecting deoxyriboside 8 (100 mg, 0.38 mmol) to the general procedure for the 
synthesis of alkenylamines, alkenylamine 9 was obtained as the HCl salt (42 mg, 
0.31 mmol, 81%). Rf = 0.4 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, 
v/v/v/v); [#]D17 = -3.2 (c = 0.1, EtOH); IR (film), 3359, 3047, 2955, 2927, 2854, 
1635, 1428, 1134, 1056 cm-1; 1H NMR (500 MHz, D2O) " 5.35 (ddd, J3,4 = 6.1, 
J4,5b =10.5, J4,5a = 17.3 Hz, 1H, H4), 5.06 (dd, J5a,5b = 1.3, J4,5a = 17.3 Hz, 1H, H-
5a), 5.04 (dd, J5a,5b = 1.3, J4,5b = 10.5 Hz, 1H, H-5b), 4.04 (ddd, J3,4 = 6.1, J2a,3 = 
5.2, J2b,3 = 7.3 Hz, 1H, H-3), 2.96 (m, 2H, H-1), 1.38 (m, 2H, H-2); 13C NMR 
(125 MHz, D2O) " 138.8 (C4), 115.8 (C5), 70.1 (C3), 36.3 (C1), 32.9 (C2). 
HRMS(ESI) m/z calcd. for [C5H11NO+H]+: 102.0919, obsd.: 102.0921. 
 
NH2
OBn
HCl.
OBn
 (2S,3S)-2,3-Bis-benzyloxy-pent-4-enylamine 
hydrochloride (11). To a solution of methyl arabinoside 10 (50.0 mg, 0.110 
mmol) in a saturated solution of NH4OAc in EtOH (2.2 mL) was added activated 
Zn (36 mg, 0.550 mmol), NaCNBH3 (21 mg, 0.330 mmol) and 30% aqueous NH3 
(0.88 mL). The mixture was stirred at reflux for 18 h, cooled to room temperature 
and concentrated under reduced pressure. The residue was redissolved in 10 mL 
EtOAc and made basic using 1M NaOH. The layers were separated, and the 
aqueous layer extracted with EtOAc. Organic extracts were combined and washed 
with brine, dried (MgSO4), and concentrated under reduced pressure to obtain 
alkenylamine 11 together with dimer, in a 3:1 ratio (monomer:dimer), as a 
colourless oil (29 mg, 0.096 mmol, 81%). Amine 11 was purified using gradient 
flash chromatography (DCM/EtOH/MeOH/30% aqueous NH3, 475/2/2/1 to 
95/2/2/1, v/v/v/v), then converted to the HCl salt. Monomer: Rf = 0.31 
(DCM/EtOH/MeOH/30% aqueous NH3, 95/2/2/1, v/v/v/v); [#]D20 = + 6.0 (c = 
0.3, CHCl3); IR (film) 3371, 3087, 3064, 3030, 2924, 2866, 2054, 1955, 1641, 
1586, 1496, 1454, 1390, 1352, 1307, 1207, 1088, 996, 927, 734, 697 cm-1. 1H 
NMR (500 MHz, CDCl3) " 7.38 - 7.27 (m, 10H, CH Ph), 5.84 (ddd, J3,4 = 7.5, 
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J4,5-cis = 10.6, J4,5-trans = 17.1 Hz, 1H, H-4), 5.34 (d, J4,5-cis = 10.6 Hz, 1H, H-5cis), 
5.33 (d, J4,5-trans = 17.1 Hz, 1H, H-5trans), 4.81 (d, JHa,Hb = 11.5 Hz, 1H, CHaHb 
Bn), 4.65 (d, JHa,Hb = 11.9 Hz, 1H, CHaHb Bn), 4.62 (d, JHa,Hb = 11.5 Hz, 1H, 
CHaHb Bn), 4.41 (d, JHa,Hb = 11.5 Hz, 1H, CHaHb Bn), 3.96 (dd, J2,3 = 5.7, J3,4 = 
7.5 Hz, 1H, H-3), 3.50 (ddd, J1a,2 = 3.8, J2,3 = 5.7, J1b,2 = 7.7 Hz, 1H, H-2), 2.87 
(dd, J1a,2 = 3.8, J1a,1b = 13.2 Hz, 1H, H-1a), 2.73 (dd, J1b,2 = 7.7, J1a,1b = 13.2 Hz, 
1H, H-1b); 13C NMR (125 MHz, CDCl3) " 138.6, 138.4 (Cq Ph), 135.0 (C4), 
128.4 - 127.6 (CH Ph), 119.0 (C5), 82.8 (C2), 81.5 (C3), 73.6 (CH2 Bn on C2), 
70.6 (CH2 Bn on C3), 42.5 (C1); HRMS(ESI) m/z calcd. for [C19H23NO2+H]+: 
298.1807, obsd.: 298.1808. 
 
NH2
OBn
HCl.
OBn
 (2S,3R)-2,3-Bis-benzyloxy-pent-4-enylamine 
hydrochloride (13). To a solution of methyl riboside 12 (305 mg, 0.671 mmol) in 
a saturated solution of NH4OAc in EtOH (13 mL) was added activated Zn (219 
mg, 3.36 mmol), NaCNBH3 (125 mg, 2.011 mmol) and 30% aqueous NH3 (5.3 
mL). The mixture was stirred at reflux for 18 h, cooled to room temperature and 
concentrated under reduced pressure. The residue was redissolved in 20 mL 
EtOAc and made basic using 1M NaOH. The layers were separated, and the 
aqueous layer extracted with ethyl acetate (twice with 20 mL). Organic extracts 
were combined and washed with brine, dried (MgSO4), and concentrated under 
reduced pressure to obtain alkenylamine 13 together with dimer, in a 3:1 ratio 
(monomer:dimer), as a colourless oil (218 mg, 0.655 mmol, 98%). Amine 13 was 
purified using gradient flash chromatography (DCM/EtOH/MeOH/30% aqueous 
NH3, 475/2/2/1 to 95/2/2/1, v/v/v/v), then converted to the HCl salt. Monomer: Rf 
= 0.23 (DCM/EtOH/MeOH/30% aqueous NH3, 95/2/2/1, v/v/v/v); [#]D21 = - 40.4 
(c = 1, CHCl3); IR (film) 3379, 3064, 3030, 2865, 1952, 1675, 1586, 1454, 1349, 
1206, 1089, 1066, 994, 927, 734, 696 cm-1. 1H NMR (500 MHz, CDCl3) " 7.36 - 
7.27 (m, 10H, CH Ph), 5.89 (ddd, J3,4 = 7.7, J4,5-cis = 10.5, J4,5-trans = 17.2 Hz, 1H, 
H-4), 5.37 (d, J4,5-cis = 10.5 Hz, 1H, H-5-cis), 5.34 (d, J4,5-trans = 17.2 Hz, 1H, H-5-
trans), 4.70 (d, JHa,Hb = 11.4 Hz, 1H, CHaHb Bn), 4.65 (d, JHa,Hb = 11.9 Hz, 1H, 
CHaHb Bn), 4.56 (d, JHa,Hb = 11.4 Hz, 1H, CHaHb Bn), 4.38 (d, JHa,Hb = 11.9 Hz, 
1H, CHaHb Bn), 3.89 (dd, J2,3 = 5.3, J3,4 = 7.7 Hz, 1H, H-3), 3.47 (ddd, J1b,2 = 4.1, 
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J2,3 = 5.3, J1a,1b = 5.6 Hz, 1H, H-2), 5.89 - 5.82 (m, 2H, H-1a and H-1b); 13C NMR 
(125 MHz, CDCl3) " 138.5, 138.3 (Cq Ph), 135.8 (C4), 128.4 - 127.6 (CH Ph), 
119.2 (C5), 82.8 (C2), 80.5 (C3), 72.8 (CH2 Bn on C2), 70.3 (CH2 Bn on C3), 
42.3 (C1); HRMS(ESI) m/z calcd. for [C19H23NO2+H]+: 298.1807, obsd.: 
298.1804. Dimer: Rf = 0.72 (DCM/EtOH/MeOH/30% aqueous NH3, 95/2/2/1, 
v/v/v/v); HRMS(ESI) m/z calcd. for [C38H43NO4+H]+: 578.3265, obsd.: 578.3263. 
 
OH
OH
NH2
OH
HCl.
 (2S,3S,4R)-1-Amino-hex-5-ene-2,3,4-triol 
hydrochloride (15). By subjecting glucoside 14 (890 mg, 2.93 mmol) to the 
general procedure for the synthesis of alkenylamines, alkenylamine 15 was 
obtained as the HCl salt (501 mg, 2.74 mmol, 93%). Rf = 0.20 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); [#]D17 = + 6.6 (c = 1.0, 
EtOH); IR (film) 3320, 3227, 3046, 2925, 1622, 1550, 1409, 1342, 1127, 1066, 
1016, 935, 840, 737 cm-1. 1H NMR (500 MHz, D2O) " 5.71 (ddd, J4,5 = 6.9, J5,6-cis 
= 10.6, J5,6-trans = 17.2 Hz, 1H, H-5), 5.21 (d, J5,6-trans = 17.2 Hz, 1H, H-6-trans), 
5.14 (d, J5,6-cis = 10.6 Hz, 1H, H-6-cis), 4.05 (dd, J3,4 = 6.7, J4,5 = 6.9 Hz, 1H, H-
4), 3.80 (ddd, J2,3 = 2.9, J1a,2 = 4.8, J1b,2 = 7.6 Hz, 1H, H-2), 3.36 (dd, J2,3 = 2.9, 
J3,4 = 6.7 Hz, 1H, H-3), 2.98 (m, 2H, H-1a and H-1b); 13C NMR (125 MHz, D2O) 
" 135.8 (C5), 118.4 (C6), 74.2 (C3), 73.2 (C4), 67.0 (C2), 42.3 (C1); HRMS(ESI) 
m/z calcd. for [C6H13NO3+H]+: 148.0974, obsd.: 148.0977. 
 
General procedure for the synthesis of glycamines. To a solution of hemiacetal 
(1 mmol) in a saturated solution of NH4OAc in EtOH (20 mL) was added 
NaCNBH3 (188 mg, 3 mmol) and 30% aqueous NH3 (8 mL). The mixture was 
stirred at reflux for 18 h, cooled to room temperature and concentrated under 
reduced pressure. The residue was redissolved in H2O, loaded on to a Dowex H+ 
ion exchange resin, and washed several times with H2O to remove excess salt. 
The amine product was then eluted with 15 to 30% aqueous NH3 and the eluent 
was concentrated under reduced pressure. 
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NH27 HCl
.
 Nonylamine hydrochloride (19). By subjecting aldehyde 18 
(430 mg, 3.03 mmol) to the general procedure for the synthesis of glycamines, 
nonylamine 19 was obtained as the acetate salt, which was then converted into the 
HCl salt by the addition of 1M HCl and compound 19 was obtained in 98% yield 
(534 mg, 2.97 mmol). All spectroscopic data was in full agreement with that of a 
commercial sample (Aldrich). 
 
HO NH2
OH
OH
OH
HCl.
 1-Amino-1-deoxy-D-arabinitol hydrochloride (21). 
By subjection of arabinose (20) (150 mg, 1 mmol) to the general procedure for the 
synthesis of glycamines, glycamine 21 was obtained as the acetate salt. Addition 
of HCl (1M), followed by concentration gave the HCl salt of 21 (128 mg, 0.85 
mmol, 85%). Rf = 0.01 (DCM/EtOH/MeOH/NH3 (aq.), 5/2/2/1, v/v/v/v); [#]D16 = 
+14.8 (c = 1.2, H2O); IR (film), 3372, 3364, 2967, 2943, 1634, 1070, 1032 cm-1; 
1H NMR (500 MHz, D2O) " 3.99 (ddd, J2,3 = 1.8, J1a,2 = 5.4, J1b,2 = 7.4 Hz, 1H, H-
2), 3.68, (dd, J4,5a = 2.9, J5a.5b = 11.8 Hz, 1H, H-5a), 3.57 (ddd, J4,5a = 2.9, J4,5b = 
5.9, J3,4 = 8.9 Hz, 1H, H-4), 3.51 (dd, J4,5b = 5.9, J5a,5b = 11.8 Hz, 1H, H-5b), 3.27 
(dd, J2,3 = 1.8, J3,4 = 8.9 Hz, 1H, H-3), 3.01 (m, 2H, H-1); 13C NMR (125 MHz, 
D2O) " 71.0 (C2), 70.3 (C3), 66.2 (C4), 62.6 (C5), 42.4 (C1). HRMS(ESI) m/z 
calcd. for [C5H13NO4+H]+: 152.0923, obsd.: 152.0918. 
 
HCl.HO NH2
OH
OH  1-Amino-1,2-dideoxy-D-ribitol hydrochloride (23). 
By subjecting 2-deoxyribose (22) (134 mg, 1 mmol) to the general procedure for 
the synthesis of glycamines, glycamine 23 was obtained as the acetate salt. 
Addition of HCl (1M), followed by concentration gave HCl salt 23 (117 mg, 0.87 
mmol, 87%). Rf = 0.02 (DCM/EtOH/MeOH/NH3 (aq), 5/2/2/1, v/v/v/v); [#]D16 = 
+16.3 (c = 1.0, H2O); IR (film), 3375, 3342, 3297, 2948, 2917, 1471, 1014 cm-1; 
1H NMR (500 MHz, D2O) " 3.57 (m, 2H, H-3, and H-5a), 3.48 (m, 2H, H-4, and 
H-5b), 3.04 (m, 2H, H-1), 1.83 (dddd, J = 2.9, J = 6.2, J = 8.8, J2a,2b = 14.5 Hz, 
1H, H-2a), 1.64 (dddd, J = 6.6, J = 8.2, J = 9.8, J2a,2b = 14.5 Hz, 1H, H-2b); 13C 
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NMR (125 MHz, D2O) " 74.2 (C4), 69.5 (C3), 62.2 (C5), 37.1 (C1), 29.2 (C2). 
HRMS(ESI) m/z calcd. for [C5H13NO3+H]+: 136.0974, obsd.: 136.0972. 
 
 
HO NH2 HCl
.
 4-Amino-butan-1-ol hydrochloride (25). By subjecting 
furanol 24 (470 mg, 5.34 mmol) to the general procedure for the synthesis of 
glycamines, glycamine 25 was obtained as the acetate salt together with its dimer 
in a 11:1 ratio (monomer:dimer). Addition of HCl (1M), followed by 
concentration gave a mixture of the corresponding HCl salts (401 mg, 3.21 mmol, 
60%). Monomer and dimer were separated using gradient flash chromatography 
(DCM/EtOH/MeOH/30% aqueous NH3, 95/2/2/1 to 10/2/2/1, v/v/v/v) and 
converted to the HCl salt for characterisation. Monomer 25: Rf = 0.24 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); IR (film) 3374, 3280, 
3042, 2982, 2844, 1634, 1443, 1405, 1054, 1033, 1015, 907, 698 cm-1.1H NMR 
(500 MHz, D2O) ! 3.58 (t, J1,2 = 6.5 Hz, 2H, H-1), 2.98 (t, J3,4 = 7.4 Hz, 2H, H-4), 
1.67 (tt, J3,4 = 7.4 J2,3 = 7.6 Hz, 2H, H-3), 1.57 (tt, J1,2 = 6.5, J2,3 = 7.6 Hz, 2H, H-
2); 13C NMR (125 MHz, D2O) " 60.9 (C1), 39.3 (C4), 28.2 (C2), 23.4 (C3); 
HRMS(ESI) m/z calcd. for [C4H11ON+H]+: 90.0913, obsd.: 90.0911.  
Bis-(5-hydroxy-butyl)-amine hydrochloride (dimer): Rf = 0.45 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); HRMS(ESI) m/z calcd. 
for [C8H19O2N+H]+: 162.1494, obsd.: 162.1492.  
 
HO
NH2
OH
OH
OH
OH
HCl.
 1-Amino-1-deoxy-D-glucitol hydrochloride (27). 
By subjecting 26 (180 mg, 1 mmol) to the general procedure for the synthesis of 
glycamines, glycamine 27 was obtained as the acetate salt. Addition of HCl (1M), 
followed by concentration gave HCl salt of 27 (156 mg, 0.86 mmol, 86%). Rf = 
0.01 (DCM/EtOH/MeOH/NH3 (aq), 5/2/2/1, v/v/v/v); [#]D16 = -6.1 (c = 1.5, 
H2O); IR (film), 3431, 3388, 2975, 2947, 1633, 1090, 1054, 1014 cm-1; 1H NMR 
(500 MHz, D2O) " 3.87 (ddd J1a,2 = 3.2, J2,3 = 5.2, J1b,2 = 9.5 Hz, 1H, H-2), 3.65 
(m, 2H, H-6a, H-3) 3.58 (m, 1H, H-5), 3.48 (m, 2H, H-6b, H-4), 3.06 (dd, J1a,2 = 
3.2, J1a,1b = 13.1 Hz, 1H, H-1a), 2.91 (dd, J1b,2 = 9.5, J1a,1b = 13.1 Hz, 1H, H-1b); 
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13C NMR (125 MHz, D2O) " 70.7 (C5), 70.6 (C4), 70.5 (C3), 69.9 (C2), 62.5 
(C6), 41.8 (C1). HRMS(ESI) m/z calcd. for [C6H15NO5+H]+: 182.1028, obsd.: 
182.1028. 
 
HO NH2
OH
HCl.
 6-Amino-hexane-1,2-diol hydrochloride (29). By 
subjecting pyranose 28 (100 mg, 0.763 mmol) to the general procedure for the 
synthesis of glycamines, glycamine 29 was obtained together with dimer in a 8:1 
ratio (monomer:dimer) as the acetate salts. Addition of HCl (1M), followed by 
concentration gave the HCl salts of 29 together with the corresponding dimer 
(83.7 mg, 0.495 mmol, 65%). Monomer 29: Rf = 0.18 (DCM/EtOH/MeOH/30% 
(aq) NH3, 5/2/2/1, v/v/v/v); IR (film) 3353, 3204, 2928, 2856, 1710, 1662, 1393, 
1267, 1125, 1073, 1046, 1013, 883, 740 cm-1.1H NMR (500 MHz, D2O) " 3.68 
(ddd, J1a,2 = 3.9, J1b,2 = 6.8, J2,3 = 10.9 Hz, 1H, H-2), 3.56 (dd, J1a,2 = 3.9, J1a,1b = 
11.7 Hz, 1H, H-1a), 3.45 (dd, J1b,2 = 6.8, J1a,1b = 11.7 Hz, 1H, H-1b), 2.98 (t, J5,6 = 
7.7 Hz, 2H, H-6), 1.67 (m, 2H, H-5), 1.50 (m, 2H, H-3), 1.41 (m, 2H, H4) ; 13C 
NMR (125 MHz, D2O) " 71.3 (C2), 65.2 (C1), 39.3 (C6), 31.5 (C3), 26.6 (C5), 
21.7 (C4); HRMS(ESI) m/z calcd. for [C6H15NO2+H]+: 134.1176, obsd.: 
134.1175.  
6-(5,6-Dihydroxy-hexylamino)-hexane-1,2-diol hydrochloride (dimer): Rf = 
0.34 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); 1H NMR (500 
MHz, D2O) " 3.68 (ddd, J1a,2 = 3.9, J1b,2 = 6.8, J2,3 = 10.9 Hz, 2H, H-2), 3.56 (dd, 
J1a,2 = 3.9, J1a,1b = 11.7 Hz, 2H, H-1a), 3.45 (dd, J1b,2 = 6.8, J1a,1b = 11.7 Hz, 2H, H-
1b), 3.02 (t, J5,6 = 7.9 Hz, 4H, H-6), 1.67 (m, 4H, H-5), 1.50 (m, 4H, H-3), 1.41 
(m, 4H, H4); 13C NMR (125 MHz, D2O) " 71.3 (C2), 65.2 (C1), 47.3 (C6), 31.5 
(C3), 25.4 (C5), 21.8 (C4); HRMS(ESI) m/z calcd. for [C12H27NO4+H]+: 
250.2018, obsd.: 250.2020. 
 
HCl.HO NH2  5-Amino-pentan-1-ol hydrochloride (31). By 
subjecting pyranose 30 (400 mg, 3.92 mmol) to the general procedure for the 
synthesis of glycamines, glycamine 31 was obtained as the acetate salt together 
with dimer in a 7:1 ratio (monomer:dimer) then converted to the HCl salt (515 
mg, 3.18 mmol, 81%). Monomer and dimer were then separated using gradient 
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flash chromatography (DCM/EtOH/MeOH/30% aqueous NH3, 95/2/2/1 to 
10/2/2/1, v/v/v/v) and converted to the HCl salts for characterisation. Monomer 
31: Rf = 0.44 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); IR (film) 
3425, 3294, 2935, 2868, 1623, 1517, 1472, 1208, 1130, 1022, 951, 736, 699 cm-
1.1H NMR (500 MHz, D2O) " 3.58 (t, J1,2 = 6.7 Hz, 2H, H-1), 2.95 (t, J5,4 = 7.6 
Hz, 2H, H-5), 1.64 (tt, J3,4 = 7.6, J4,5 = 7.6 Hz, 2H, H-4), 1.55 (tt, J1,2 = 6.7, J2,3 = 
7.5 Hz, 2H, H-2), 1.39 (tt, J2,3 = 7.5, J3,4 = 7.6 Hz, 2H, H-3); 13C NMR (125 MHz, 
D2O) " 61.2 (C1), 39.4 (C5), 30.6 (C2), 26.7 (C4), 21.9 (C3); HRMS(ESI) m/z 
calcd. for [C5H13ON+H]+: 104.1075, obsd.: 104.1070.  
5-(5-Hydroxy-pentylamino)-pentan-1-ol hydrochloride (dimer): Rf = 0.63 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); IR (film) 3309, 3117, 
2934, 2862, 1496, 1369, 1207, 1079, 1022, 734, 697 cm-1.1H NMR (500 MHz, 
D2O) " 3.58 (t, J1,2 = 6.5 Hz, 4H, H-1), 2.82 (t, J4,5 = 7.3 Hz, 4H, H-5), 1.59 (tt, 
J3,4 = 7.3, J4,5 = 7.3 Hz, 4H, H-4 ), 1.55 (tt, J1,2 = 6.5, J2,3 = 7.6 Hz, 4H, H-2), 1.36 
(tt, J2,3 = 7.6, J3,4 = 7.3 Hz, 4H, H-3) ; 13C NMR (125 MHz, D2O) " 61.3 (C1), 
47.7 (C5), 30.7 (C2), 26.4 (C4), 22.5 (C3); HRMS(ESI) m/z calcd. for 
[C10H23O2N+H]+: 190.1807, obsd.: 190.1801. 
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Chapter 6: Investigations into the Carbamate 
Annulation Reaction for the Synthesis of Five and 
Six Membered Azasugars1,2 
6.1 Introduction 
The methodology developed (Chapter 4) for the synthesis of azasugars involved a 
protecting group free strategy whereby D-xylose was transformed into 1,4-
dideoxy-1,4-imino-D-xylitol (1) via the use of a Vasella reductive amination3 and 
a novel carbamate annulation reaction.4 To illustrate the versatility of this 
methodology and its application in the synthesis of azasugars, we wanted to 
explore the potential of our new methodology for the synthesis of three additional 
five membered azasugars 2, 3, and 4, 1,2 and three six membered azasugars 5, 6, 
and 7 (Figure 6.1). This would enable us to develop an azasugar library, which 
could be screened at a later date to elucidate the biological activities that each 
azasugar possesses. 1,4-Dideoxy-1,4-imino-D-xylitol (1) is a known glycogen 
phosphorylase b inhibitor,5 however the biological activities of azasugars 2, 3 and 
4 are currently unknown. DGJ (5) is an !-galactosidase inhibitor, and a weak "-
galactosidase inhibitor (see Chapter 1).6 Although 4-epi-fagomine (7) has not 
been found in nature, it was first obtained by transformation from fagomine, and 
was shown to be an !-galactosidase inhibitor.7,8  
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Figure 6.1. Target five and six membered azasugars. 
 
6.2 Results and Discussion 
Synthesis of five membered azasugars 
To extend the scope of the protecting group free strategy to the synthesis of 
additional azasugars we set out to synthesise 1,4-dideoxy-1,4-imino-L-lyxitol 2 
(Scheme 6.1). D-Ribose (8) was converted into to iodoglycoside 9 (67%) using 
Fischer glycosidation followed by treatment with I2 and PPh3.9 Vasella reductive 
amination proceeded smoothly to give olefinic amine 10 (91%). 
Halocyclisation/carbonylation using our iodine-promoted annulation methodology 
gave carbamate 11 in 93% yield, and as a single diastereomer (>20:1 d.s.), as 
determined by 1H NMR of the crude reaction mixture. (See chapter 6 for 
discussions concerning the diastereoselectivity of the reaction.) Carbamate 11 was 
subsequently hydrolysed to give 3,4-cis 1,4-dideoxy-1,4-imino-L-lyxitol (2) in a 
97% yield, the data was in full agreement with those published.10 Overall 1,4-
dideoxy-1,4-imino-L-lyxitol was synthesised in five steps in 55% yield, the 
highest reported to date.  
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Scheme 6.1. Synthesis of 1,4-dideoxy-1,4-imino-L-lyxitol (2) from D-ribose. 
 
The next target was 1,4-dideoxy-1,4-imino-L-xylitol (3), this synthesis 
commenced with the transformation of D-arabinose 12 into the corresponding 
methyl glycoside 13 and subsequent conversion to methyl iodoglycoside 14 
(Scheme 6.2).9 Glycoside 14 was then subjected to the Vasella reductive 
amination protocol to give the corresponding linear alkenylamine 15 in excellent 
yield (91%). Alkenylamine 15 was then cyclised using the iodine-mediated 
carbamate annulation methodology, providing carbamate 16, again in an excellent 
93% yield and as the only diastereomer. Hydrolysis of carbamate 16, and 
comparison of the NMR spectral data and optical rotation values of the 
hydrolysed product with those in the literature11,12 confirmed the identity of the 
resulting azasugar to be that of 1,4-dideoxy-1,4-imino-L-xylitol (3).  With an 
overall yield of 54%, this 5-step synthesis is remarkably efficient. Similar 
methodology was subsequently applied to the synthesis of 1,4-dideoxy-1,4-imino-
D-lyxitol (not shown).2 
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Scheme 6.2. Protecting group free synthesis of 1,4-dideoxy-1,4-imino-L-xylitol 
(3). 
 
To prepare 1,2,4-trideoxy-1,4-imino-L-xylitol (4) and explore the effect that the 
hydroxylation pattern had on the carbamate annulation, 2-deoxy-D-ribose (17) 
was subjected to Fischer glycosidation to generate the desired methyl glycoside 
18 (Scheme 6.3). Given the propensity of 2-deoxy-D-ribose to form the 
thermodynamically more stable pyranose ring, short reaction times were required 
to favour formation of the desired furanoside. Thus, 2-deoxy-D-ribose was stirred 
with 1% AcCl in MeOH for 15 min., according to the procedure by Hoffer and 
co-workers.13 This resulted in almost exclusive formation of 2-deoxy-D-
ribofuranoside 17 with only trace amounts (ca. 5%) of the pyranose structural 
isomer. Longer reaction times resulted in the increase formation of the pyranose 
product. Installation of an iodide at the primary position was then attempted by 
refluxing a solution of methyl 2-deoxy-D-ribose 18, triphenylphosphine, I2 and 
imidazole in THF for 2 h. Unfortunately, these conditions led to significant 
degradation. Milder reaction conditions, however, whereby the solution was 
stirred at room temperature for 18 h,14 allowed for the preparation of methyl 2,5-
dideoxy-5-iodo-D-riboside (19) in satisfactory yield (73%). Vasella reductive 
amination of iodoriboside 19 gave linear alkenylamine 20 in good (81%) yield. 
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Scheme 6.3. Synthesis of 1,2,4-trideoxy-1,4-imino-L-xylitol. 
 
Alkenylamine 20 was then subjected to the iodine-promoted carbamate annulation 
(Scheme 6.3). This reaction proceeded smoothly and gave the desired carbamate 
21 in 90% yield and with a diastereoselectively of greater than 20:1 in favour of 
the 3,4-cis isomer, as determined by 1H NMR of the crude reaction mixture. This 
demonstrated that the absence of the C-2 hydroxyl did not alter the stereochemical 
outcome of the cyclisation. Hydrolysis of carbamate 21, using NaOH, proceeded 
uneventfully and gave the desired azasugar 4 in a quantative yield, as confirmed 
via comparison of spectral data with that previously reported.15-18 In sum, 1,2,4-
trideoxy-1,4-iminol-L-xylitol was prepared in 5 steps and in an overall yield of 
48%, the best reported to date.16 
 
Synthesis of six membered 1-deoxyazasugars 
With the objective of extending our carbamate methodology to the synthesis of 
six membered azasugars, we embarked on a synthesis of deoxygalactonojirimycin 
(DGJ, 5, Scheme 6.4), which is currently under investigation for the treatment of 
Fabry’s disease. Our strategy began with the selective iodination of the 6 position 
of methyl galactoside 22 (commercially available) using iodine and 
triphenylphosphine. Under these conditions, however, only a modest (49%) yield 
of methyl iodoglycoside 23 was obtained and the other major product observed 
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was bicyclic compound 24. This by-product is most likely formed via 
nucleophilic attack of the 3-hydroxyl on the carbon at the 6-position, once the 
positively charged triphenylphosphine adduct has formed. To improve this yield 
and develop a more scalable synthesis of iodoglycoside 23, an alternative route 
was then developed. To this end, D-galactose (25) was treated with acetone and 
ZnCl2 to give the corresponding diacetonide in excellent (92%) yield following 
distillation.19,20 The iodide was then installed using standard conditions, the 
triphenylphosphine oxide was removed via trituration with MeOH and filtration, 
and the crude iodide 26 was treated with HCl and MeOH to afford triol 23, which 
readily crystallised from MeOH.21 Though 2-steps longer than the protecting 
group free approach, (or one-step if diacetone galactose is commercially sourced), 
this second strategy gave an improved overall yield (72%, from D-galactose) and 
had more efficient purification procedures as no column chromatography was 
required. Accordingly, we considered this the more appropriate route when 
preparing gram quantities of key intermediate iodide 23. With 23 in hand we 
proceeded to use our modified Vasella reductive amination protocol for the 
formation of linear alkenylamine 27. Applying these conditions to iodide 23 led to 
a smooth transformation into primary alkenylamine 27 (85% yield), with only 
minor amounts (ca.10%) of the dimeric secondary amine observed. The two 
products, easily discernable via the 13C NMR chemical shift of CNH2, can be 
readily separated by column chromatography.  
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Scheme 6.4. Synthesis of DGJ 
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Key in our strategy for the synthesis of DGJ was the applicability of the 
iodine-promoted carbamate annulation protocol to the formation of six 
membered azasugars. Though highly reliable for the formation of five 
membered azasugars, the formation of six membered rings includes hurdles 
such as the possible formation of furanose rings (e.g. 29 and 31, Scheme 6.4) 
and/or the formation of azasugar diastereomers (e.g. 28a, 28b). Given this, we 
spent some time optimising our carbamate annulation strategy to favour the 
formation of DGJ-precursor 28a.  
 
Following the original protocol, the first carbamate annulation reaction of 
alkenylamine 27 was carried out using 1.5 eq. NaHCO3 and iodine in water at 
room temperature (Entry 1, Table 6.1). This reaction was sluggish (>7 days), 
therefore a saturated solution of NaHCO3 was used and the reaction mixture was 
warmed to 40 °C (Entry 2). This improved the reaction rate and gave a 3:1:1 ratio 
of 28a:28b:31. Next, in an attempted to favour the formation of 28a the more 
basic sodium carbonate salt was used, instead of sodium bicarbonate. To a 
solution of alkenylamine 27 in water, 20 eq. Na2CO3 and iodine were added, and 
the resulting mixture stirred for 3 days at rt (Entry 3), or 2 days at 40 °C (Entry 4). 
Concentration of the reaction mixtures in vacuo, and subsequent NMR analysis 
revealed that both conditions gave approximately a 3:1:1 mixture of 28a:28b:31, 
and no improvement in the yield of 28a was observed. It is interesting to note that 
reaction of alkenylamine 27 in a 1:1 mixture of sat. aq. NaHCO3:MeOH gave only 
a primary iodide product (Entry 5), thought it was difficult to conclusively 
determine whether this was furan 29 or the six membered iodide 30. In this 
example, it is presumed that the lack of carbamate product is due to the decreased 
solubility of carbonate in MeOH. This result suggests that furan 31 is formed via 
reaction of alkenylamine 27 with I2 giving iodide 29 which subsequently reacts 
with ‘CO2’ to give the corresponding carbamate. 
 
As cyclisation reactions forming five membered rings are kinetically favoured 
over cyclisations forming six membered rings, reaction of alkenylamine 27 with I2 
and NaHCO3 was slower than cyclisation of the pentenylamines to form five 
membered azasugars. In addition, cyclisation of amine 27 also gave a 
 141 
considerable amount of ‘O’ cyclised furan product 31. However in general, we 
were encouraged by the significant formation of the ‘N’ cyclised 6 membered ring 
product. Carbamate annulation to form the six membered azasugar also gave a 
mixture of diastereomers. (Discussions around stereochemical outcomes for the 
cyclisation reaction are at the end of Chapter 6.) Overall the best reaction outcome 
that could be achieved was a 3:1:1 ratio of 28a:28b:31.  
 
Table 6.1. Cyclisation of alkenylamine 27. 
NH3
OH
OH
OH
27
N
HO
OH
OH
28a
O
O
N
HO
OH
OH
O
O
+
28b
Base
Conditions
O
HO OH
O NH
O
3129
O
HO OH
I NH2 HN
I
HO
OH
OH
30
or +
Cl
 
Entry Base/solvent Temp. I2 Time Product(s) 
1 NaHCO3 (1.5 eq.) rt 1.5 > 7 days Reaction 
incomplete 
2 NaHCO3 (sat. aq.) 40 °C Excess* 3 days 3:1:1, 
28a: 28b:31 
3 Na2CO3 (20 eq.) rt 1.5 eq. 3 days 3:1:1, 
28a: 28b:31 
4 Na2CO3 (20 eq.) 40 °C Excess* 2 days 3:1:1, 
28a: 28b:31 
5 1:1, MeOH:NaHCO3 
(sat. aq.) 
rt 8 eq. 3 days Major product: 
29 or 30 
* Added in portions (5 x 1.5 eq.) 
 
Diastereomers 28a and 28b could be separated using gradient silical gel 
chromatography (EtOAc/MeOH, 99/1 to 95/5, v/v), with 28b emerging from the 
column first. However, it was not possible to separate 28a from 31. Diastereomer 
28a could be identified by the presence of a doublet of doublets at about 2.8 ppm 
in the 1H NMR, corresponding to H-1b. In contrast H-1b of 28b appeared as a 
doublet at 3.2 ppm. Carbamate 28a was then hydrolysed using NaOH in EtOH to 
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give DGJ (5) in 99% yield. Overall DGJ was synthesised in six steps with a yield 
of 26%, the shortest route to date. 
 
With a successful strategy in place for the synthesis of DGJ (5) we wanted to 
apply our protecting group free methodology to the synthesis of 1,5-dideoxy-1,5-
imino-L-iditol (6) from D-glucose (Scheme 6.5). To this end, a solution of methyl 
!-D-glucopyranoside (32) in THF was subjected to triphenylphosphine, imidazole 
and iodine to give the corresponding iodosugar 33 in 98% yield and, in contrast to 
galactose, without any observable by-products. The subsequent Vasella reductive 
amination reaction of iodosugar 33 also occurred smoothly to give linear 
alkenylamine 34 (93% yield) with only a minor amount (5%) of the secondary 
amine by-product. Alkenylamine 34 was then treated with I2 and NaHCO3 in 
anticipation that carbamate 38 would be synthesised, however, the only observed 
product contained a CH2I group as indicated by the presence of a methylene 
carbon at -0.3 ppm in the 13C NMR. Extensive NMR (1H, 13C, COSY, HMBC, 
HSQC) and mass spectrometric analysis indicated that the product was either 
furan 35 or pyran 36. However while all carbon and proton NMR peaks could be 
assigned, the ring size could not be determined due to the lack of HMBC 
correlation between either 1 and 5 (indicating a six membered ring) or 2 and 5 
(indicating a five membered ring) in D2O or CD3OD. Attempts to purify the 
material by silical gel flash column chromatography or Dowex H+ ion exchange 
lead to degradation of the material. Full characterisation was achieved via 
acetylation using acetic anhydride and pyridine. The spectral data for this 
compound revealed the presence of an NH peak in the 1H NMR, which possessed 
a COSY correlation to both H-1a and H-1b and no correlation to H-5. This 
indicated that the acetylated product was indeed that of furan 37, as acetylation of 
pyran 36 would protect the amine centre, and no NH group would remain. 
Identifying furan 37 indicates that the product formed during I2, NaHCO3 
promoted cyclisation was furan 35. In an attempt to favour ‘N’ attack and form 
carbamate 38 a stronger base, Na2CO3, was used. After stirring at room 
temperature overnight no starting material remained, however, concentration and 
NMR analysis of the crude reaction mixture revealed that again only a furan 
product had been synthesised. This time, furan 39, formed via “CO2” absorption 
on the primary amine, was observed as indicated by 1H and 13C NMR.22,23 Next 
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the reaction temperature was varied. Alkenylamine 34 was stirred with I2, and sat. 
aq. Na2CO3 overnight at either 2 °C or reflux. Under these conditions there was 
still no observable carbamate formation, therefore this route to carbamate 38 was 
abandoned, as it appears that ‘N’ attack cannot be favoured for this alkenylamine.  
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Scheme 6.5. Attempted synthesis of 1,5-dideoxy-1,5-imino-L-iditol (6) from 
methyl !-D-glucopyranoside. 
 
Given the success in forming carbamate 28a from alkenylamine 27 (Scheme 6.4), 
we envisaged synthesising carbamate 38 from alkenylamine 34 (Scheme 6.5). 
However, when alkenylamine 34 was subjected to iodocyclisation conditions only 
furan 35 was observed. Iodocyclisation reactions are irreversible and accordingly 
product formation is under kinetic (rather than thermodynamic) control.24 When a 
reaction is under kinetic control, product formation is dependant only on the 
relative activation energies of the respective transition states. Therefore, to 
understand the products formed from the cyclisation reactions of alkenylamines 
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27 and 34 the transition state energies must be considered. The lower the 
transition state energy, the faster the reaction rate. A number of examples of 
intramolecular cyclisation reactions have served to establish a rough correlation 
between reaction rate and the size of the ring being formed. In general, 
intramolecular cyclisation reactions resulting in the formation of six membered 
rings are much slower than cyclisation reactions to form five membered rings.25 
Mandolini and co-workers rationalised that the decrease in reaction rate is due to a 
combination of decreased entropy, resulting from a decrease in rotational 
freedom, and the relatively greater transition state strain energy, resulting from the 
1,3-diaxial-type interactions in a six membered transition state.26 These 1,3-
diaxial-type interactions are much less severe in five membered transition states. 
In addition, the nucleophile type also affects the rate of intramolecular cyclisation, 
this relationship is not as well studied as the effect of ring size. Although nitrogen 
is generally a better nucleophile than oxygen, there is evidence to suggest that 
intramolecular ring closure reactions with oxygen nucleophiles are faster than 
those with nitrogen nucleophiles.27 An explanation for this is that internal oxygen 
nucleophiles have increased directional flexibility compared to amine 
nucleophiles. A neutral amine nucleophile has three covalent bonds with a fixed 
orientation for the non-bonded electron pair, therefore, an amine nucleophile has 
specific directional requirements. In contrast, an oxygen nucleophile has two lone 
pairs this increases the directional flexibility and the reaction rate.27 Therefore, it 
is not so much that the formation of furan 35 is unusual, but more that the 
formation of carbamate 28a is extraordinary. 
 
In the iodocyclisation of glucose-derived alkenylamine 34 there are four possible 
products that can theoretically be made (Scheme 6.6). According to the transition 
state models of Chamberlin et al.,28 and Gouverneur and co-workers,29 O-in-plane 
transition states are favoured over H-in-plane transition states (discussed in 
subsequent paragraphs), therefore, the transition state energy of B is much greater 
than A (B >> A) (Scheme 6.6). As mentioned, cyclisation reactions that afford 
five membered rings are much faster than those affording six membered rings.25,26 
Accordingly, the transition state energies shown in Scheme 6.6 are as follows: C 
and D >> A and only five membered ring formation is observed (Scheme 6.5). As 
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a result, the only product observed from the iodocyclisation of alkenylamine 34 is 
furan 35. 
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Scheme 6.6. Set of theoretical products and preceding transitions states in the 
iodocyclisation of glucose derived hexenylamine 34. 
 
If we now turn our attention to the cyclisation of galactose derived alkenylamine 
27 we must presume that the rate of the iodocyclisation reaction to form the five 
membered product 29b is, in this case, similar to the reaction rate leading to the 
six membered products 30a and 30b i.e. that transition states B, C, and D are 
roughly similar in energy (Scheme 6.7). (Again according to the transition state 
models by Chamberlin et al.,28 and Gouverneur and co-workers29 we presume that 
the transition state energy of A, where H is in plane, is much greater in energy 
than B, when O is in plane [A >> B]). The question of reaction outcomes for 
alkenylamines 27 vs 34 then becomes why does the order of the relative transition 
state energies change for the two different substrates? In transition state B 
(Scheme 6.7) all of the ring substituents are in a relative cis configuration. This 
configuration involves a high degree of steric and electronic strain. In addition, all 
of the electron withdrawing substitutents are aligned, which is also destabilising. 
Overall these factors could elevate the transition state energy of B to such an 
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extent that the five membered transition state B is no longer significantly lower in 
energy than the six membered transition states (C and D). As a consequence both 
the five and six membered iodocyclisation products are observed. It is also worth 
mentioning that in transition states C and D (Scheme 6.7) the hydroxyl 
substitutents at positions two and three are equatorial. This also decreases the 
energies of these transitions states and contributes to the change in relative 
transition state energies.  
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Scheme 6.7. Set of theoretical products and preceding transitions states in the 
iodocyclisation of galactose derived hexenylamine 27. 
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Synthesis of six membered 1,2-dideoxyazasugars 
To further extend the carbamate annulation methodology, 2-deoxy hexoses were 
utilised, as these cannot form furan rings during the annulation, due to the absence 
of a C-2 hydroxyl. Accordingly, the synthesis of 4-epi-fagomine 7 began with the 
anomeric methylation of 2-dexoy-D-galactose (40) using AcCl and MeOH 
(Scheme 6.8). Under these conditions, only 40% of the desired methyl glycoside 
41 was obtained, with the major products being the kinetically favoured furans. 
The reaction was not optimised at this stage, for it was deemed more important to 
first determine whether iodination of the unprotected methyl glycoside, to form 
45, was plausible. Methyl glycoside 41 was subjected to iodination using I2 and 
triphenylphosphine. Unfortunately, none of the desired methyl iodoglycoside 45 
was observed and the major product was that of the bi-cyclic structure 42, in 
which nucleophilic attack of the 3-OH at C-6 occurs. This was not entirely 
unexpected given that similar results were observed en route to DGJ (Scheme 
6.4). An alternate strategy for the preparation of iodoglycoside 45 was then 
developed, whereby 2-deoxy-D-galactose (40) was converted to the 
isopropylidene protected methyl glycoside 43 and subsequently iodinated to give 
protected methyl iodoglycoside 44 in a 73% yield from 2-deoxy-D-galactose. 
Although the installation of the isopropylidene protecting group was not ideal, it 
only added one additional step to the synthesis. The isopropylidene protecting 
group could then be removed in acidic methanol to give the desired methyl 
iodoglycoside 45 to be used in the subsequent Vasella reductive amination. 
Gratifyingly, when 45 was refluxed with Zn, NH3, NH4OAc and NaCNBH3, only 
the desired primary alkenylamine 46 was synthesised (99% yield). 
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Scheme 6.8. Synthesis of 4-epi-fagomine 7. 
 
With alkenylamine 46 in hand, we set about to cyclise this derivative. The 
cyclisation of alkenylamine 46, using excess I2 and NaHCO3 in water at 50 °C 
was complete after 24 h. NMR analysis of the crude product mixture revealed a 
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3:1 mixture of two products, which were determined to be diastereomers 47a and 
47b. 
 
Though outside the scope of my involvement in this project, it is interesting to 
note that subsequent experimentation by others in the group30 illustrated that 47a 
could be selectively synthesised (>20:1, 47a: 47b) by stirring alkenylamine 46 in 
a solution sat. aq. NaHCO3 with I2 at 35 °C for 5 days giving carbamate 47a in a 
86% yield. Carbamate 47a was subsequently hydrolysed, using NaOH in ethanol, 
to provide 4-epi-fagomine (7) in a 92% yield. Overall 4-epi-fagomine (7) was 
synthesised in six steps with a yield of 54% yield, the most efficient total 
synthesis to date. The total synthesis of 4-epi-fagomine (7) has only been 
conducted twice before, once in 2003 (14% yield over 7 steps),31 and in 2009 
(35% yield over 6 steps, from an advanced carbohydrate precursor).32 
 
Diastereoselectivity of the carbamate annulation reaction 
Perhaps one of the most remarkable features of our strategy for the synthesis of 
azasugars are the high yield and diastereoselectivity observed in the carbamate 
annulation reaction. The diastereoselectivity is in favour of the 3,4-cis (five 
membered) or 4,5-cis (six membered) isomers, as illustrated by the entries in 
Table 2. Cyclisation of the pentenylamines (Entries 1 to 4) gave the 3,4-cis 
carbamates exclusively, while cyclisation of hexenylamines (entries 5 and 6) 
favoured the 4,5-cis products, albeit with reduced selectivity. From these results it 
is apparent that the stereochemistry at the C-3 (five membered) or C-4 (six 
membered) position exerts stereocontrol on the cyclisation reaction and that this is 
unaffected by the chirality, or lack of chirality, at the adjacent centres. 
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Table 2. Diastereoselectivity of iodine-promoted carbamate annulation. 
N
O
O
I2, NaHCO3
H2OOH
NH2
R
n
R = OH or H HO R
n
 
Entry Alkenylamine Carbamate 
Diastereoselectivity 
cis:trans 
Yielda 
1 NH2
OH
OH
 
N
O
O
HO OH  
>20:1 99% 
2 NH2
OH
OH
 
N
O
O
HO OH  
>20:1 93% 
3 NH2
OH
OH
 
N
O
O
HO OH  
>20:1 93% 
4 
NH2
OH  
N
O
O
HO  
> 20:1 95% 
5 NH2
OH
OH
OH  
N
O
HO
OH
OH
O
 
3:1 56% 
6 NH2
OH
OH
 
N
O
HO
OH
O
 
3:1 86% 
a Isolated yield.  
 
The high diastereoselectivity observed in these cyclisation reactions can be 
explained via a transition state model originally proposed by Chamberlin et al.,28 
which is in accordance with subsequent theoretical studies by Gouverneur and co-
workers.29 Here it is proposed that during electrophilic cyclisations, the stereo 
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directing hydroxyl can be positioned either in the plane of the double bond (A, O-
in-plane), or almost perpendicular to that plane (B, H-in-plane) (Figure 2). Of 
these two transition states, A has minimal overlap between the electron-
withdrawing 
! 
"C-O
*  and reacting CC=!  orbitals, thereby forming the lowest energy 
transition state. The H-in-plane conformation (B) has overlapping hydroxyl 
! 
"C-O
*  
and double bond CC=!  orbitals, which destabilises the I2–# complex and hence is 
disfavoured. 
 
R H
HO
!"
A: O in Plane
Nu
II#
RHO
H
!"
B: H in plane
I I
Nu
#
Favoured Disfavoured  
Figure 2. O in Plane vs. H in plane. 
 
During the cyclisation to form five membered azasugars, attack of the amine on 
the I2–ethylene complex is envisioned to take place via a five membered ring 
transition structure, in which the ring nitrogen approaches the double bond in an 
NE (envelope) conformation and follows a Bürgi-Dunitz-like trajectory33 (Figure 
3). Considering the two envelope transition states that can occur, it is apparent 
that where O is in plane, this transition state (A) leads to the 3,4-cis product, and 
the less favoured H in plane transition state (B) leads to the 3,4-trans product 
(Figure 3).  
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Figure 3. Proposed transition state for the iodine-promoted cyclisation of 
alkenylamines leading to the formation of five membered azasugar carbamates. 
 
In the formation of six membered azasugars, the amine is likely to attack the I2–
ethylene complex via a six membered chair transition state (Figure 4). There are 
four possible chair transition states. Two in which O is in plane (A and B), and 
two where H is in plane (C an D). As discussed, the O-in-plane transition state is 
considered lower in energy, however, in the case of the six membered cyclisation, 
one of the O-in-plane transition states (A) leads to the 4,5-cis product, while the 
other (B) gives the trans product. Therefore, the stereochemical outcome of the 
reaction can no longer be accounted for solely on the basis of O vs. H-in-plane 
and it is necessary to also consider the position of the ring substituents in the 
transition state. During transition state A, the hydroxyl substituent is in an axial 
position, while the reacting double bond is in a more favored pseudo equatorial 
orientation. In contrast, during transition state B both the hydroxyl and the double 
bond substituents are in axial orientations, and are therefore subject to 
unfavourable 1,3-diaxial interactions. Transition state A is, therefore, likely to be 
lower in energy, and thus account for the observed 4,5-cis stereoselectivity 
observed during the six membered cyclisation. The 4,5-trans products can be 
formed from either transition state B or C. In general it is difficult to predict 
which of these transition states lead to the trans product, however, based on our 
observations these transitions states are higher in energy than A, and therefore the 
cis product predominates.  
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Figure 4. Proposed general transition state for iodine-promoted annulation for the 
formation of six membered azasugar carbamates. 
  
6.3 Conclusions 
In summary, we have achieved an efficient, high yielding and diastereoselective 
protecting group free strategy for the synthesis of a number of five membered 
azasugars and have extended this methodology for this synthesis of six membered 
azasugars. During the course of this work we have shed light on the mechanisms 
behind the remarkable stereoselectivity observed during the cyclisation reaction. 
In this chapter, each of the five membered azasugars were prepared in 5 steps, in 
good overall yield, and without the need for protecting groups. 1,4-Dideoxy-1,4-
imino-L-lyxitol (2) was synthesised in five steps, with an overall yield of 55%. 
The overall yield for the formation of 1,4-dideoxy-1,4-imino-L-xylitol (3) was 
54% and supersedes that of the next most efficient synthesis (3 steps, 48% total 
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yield, commencing from 2,3,5-tri-O-benzyl-D   -arabinofuranose).12   The overall 
yield for the synthesis of 1,2,4-trideoxy-1,4-imino-L-xylitol (4) was 48% over the 
5 steps. Progress was also made toward the synthesis of six membered azasugars. 
When galactose (Scheme 6.4) or 2-dexoygalactose (Scheme 6.8) were used as 
starting materials, alternative protecting group methodology was required for the 
synthesis of key methyl iodoglycosides. However, DGJ (5) was prepared in six 
steps with an overall 33% yield. This thesis highlights the progress made towards 
the synthesis of 4-epi-fagomine 7, which was subsequently completed. 
Unfortunately, when the alkenylamine derived from D  -glucose was used as the 
starting material, only cyclisation to the furan was observed. Overall, this 
carbamate annulation methodology shows great potential for the synthesis of 
azasugars, however, competition between 5 and 6 membered cyclisation can limit 
the scope of the methodology.  
 
6.4 Experimental 
General methods 
Unless otherwise stated all reactions were performed under atmospheric air. THF 
(Lab-Scan) was distilled from LiAlH4 prior to use. H2O, MeOH (Pure Science), 
and EtOAc (Pure Science), were distilled prior to use. EtOH (absolute, Pure 
Science), DCM (LabServ), 30% aqueous NH3 (J. T. Baker Chemical Co.), Ribose 
(BDH), arabinose (Sigma-Aldrich), lyxose (Sigma-Aldrich), methyl D-
galactopyranoside (Sigma), methyl D-glucopyranoside (Sigma), 2-deoxy-D-
galactose (Fluka), AcCl (B&M), PPh3 (Merck), imidazole (Aldrich), I2 (BDH), 
NaCNBH3 (Aldrich), !-picoline borane (Aldrich), NaOH (Pure Science), and 
NH4OAc (AnalaR) were used as received. Zn dust was activated by the careful 
addition of conc. H2SO4 washed with EtOH (3x) and hexanes (3x), and stored 
under dry hexanes. All solvents were removed by evaporation under reduced 
pressure. Reactions were monitored by TLC-analysis on Macherey-Nagel silica 
gel coated aluminium sheets (0.20 mm, silica gel 60) with detection by UV-
absorption (254 nm), by spraying with 20% H2SO4 in EtOH followed by charring 
at ~150 °C, by dipping in I2 in silica, or by spraying with a solution of ninhydrin 
in EtOH followed by charring at ~150 °C. Column chromatography was 
 155 
performed on Pure Science silica gel (40-63 micron). Dowex® W50-X8 acidic 
resin (Sigma) and Dowex® 1X4-50 basic resin (Sigma) were used for ion 
exchange chromatography and HP-20 (Supelco) for reverse phase 
chromatography. High-resolution mass spectra were recorded on a Waters Q-TOF 
PremierTM Tandem Mass Spectrometer using positive electro-spray ionisation. 
Optical rotations were recorded using a Perkin-Elmer 241 polarimeter at the 
sodium D-line. Infrared spectra were recorded as thin films using a Bruker Tensor 
27 FTIR spectrometer, equipped with an Attenuated Total Reflectance (ATR) 
sampling accessory, and are reported in wave numbers (cm-1). Nuclear magnetic 
resonance spectra were recorded at 20 °C in D2O, CD3OD or CDCl3 using either a 
Varian Unity-INOVA operating at 300 MHz or a Varian Unity operating at 500 
MHz. Chemical shifts are given in ppm ($) relative to tetramethylsilane. NMR 
peak assignments were made using COSY, HSQC and HMBC 2D experiments. 
 
For the synthesis of compounds 10 (5), 15 (7), 20 (9), and 34 (15) in chapter 6 
please refer to chapter 5, numbering for these compounds in chapter 5 is in 
brackets. 
 
General procedure for the synthesis of methyl furanosides.  
To a solution of pentose (150 mg, 1 mmol) in MeOH (5 mL), AcCl (15 µL) was 
added and the reaction was stirred at room temperature for 18 h. The reaction was 
quenched by the addition of Dowex (OH-), filtered and concentrated. The 
resulting oil was purified by flash chromatography to give the pure methyl 
furanosides. 
 
O
OH
OMe
HO
HO
 Methyl D-arabinofuranoside (13). By subjecting D-
arabinose 12 (20.1 g, 134 mmol) to the general procedure for the synthesis of 
methyl furanosides, methyl D-arabinofuranoside (13) was isolated as a colourless 
oil (19.1 g, 118 mmol, 88%). Rf = 0.48 and 0.36 for ! and " respectively (10% 
MeOH in EtOAc); [!]D19 = +91.0 (c = 1.0, MeOH); IR (film), 3356, 2924, 2481, 
1455, 1119, 972, 824 cm-1; 1H NMR (500 MHz, CD3OD) $ 4.88 (d, J1,2 = 1.5 Hz, 
1H, H-1!), 3.94 (dd, J1,2 = 1.5, J2,3 = 3.5 Hz, 1H, H-2!), 3.91 (ddd, J4,5a = 3.3, 
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J4,5b 5.3, J3,4 = 6.1 Hz, 1H, H-4!), 3.83 (dd, J2,3 = 1.5, J3,4 = 6.1 Hz, 1H, H-3!), 
3.75 (dd, J4,5a = 3.3, J5a,5b = 11.6 Hz, 1H, H-5a!), 3.64 (dd, J4,5b = 5.3, J5a,5b = 11.6 
Hz, 1H, H-5b!), 3.37 (s, 3H, OMe); 13C NMR (125 MHz, CD3OD) $ 109.2 (C1), 
84.1 (C4), 82.0 (C2), 77.3 (C3), 61.6 (C5), 53.9 (OMe); HRMS(ESI) m/z calcd. 
for [C6H12O5+Na]+: 187.0577, obsd.: 187.0581. 
 
O OMe
HO
HO
 Methyl 2-deoxy-!/"-D-riboside (18). To a solution of 2-
deoxy-D-ribose (17) (200 mg, 1.5 mmol) in methanol (7.5 mL) AcCl (75 µL) was 
added and the solution stirred 15 min. at room temperature. The reaction was 
quenched by the addition of Dowex (OH-), filtered and concentrated. The 
resulting oil was purified by gradient flash chromatography (EtOAc % 
MeOH/EtOAc, 1/9, v/v) to give methyl furanoside 18 (203 mg, 1.37 mmol, 91%). 
Rf = 0.7 (15% MeOH in EtOAc); [!]D18 = +5.20 (c = 1.0, EtOH); IR (film), 3372, 
2942, 1448, 1358, 1031, 1009 cm-1; 1H NMR (500 MHz, CDCl3) $ 5.17 (dd, J1,2a 
= 2.1, J1,2b = 5.5 Hz, 1H, H-1"), 5.12 (dd, J1,2b = 2.3, J1,2a = 4.4 Hz 1H, H-1!), 
4.55 (br s, 1H, H-3"), 4.16 (m, 2H, H-3! and H-4!), 4.09 (m, 1H, H-4"), 3.78-
3.59 (m, 4H, H-5a!, H-5b!, H-5a", and H-5b"), 3.41 (s, 3H, OMe-!), 3.40 (s, 3H, 
OMe-"), 2.32 (ddd, J1,2a = 2.3, J2a,3 = 4.9, J2a,2b = 14.0 Hz, 1H, H-2a!), 2.18-2.09 
(m, 2H, H-2b!, H-2a"), 2.05-2.02 (m, 1H, H-2b"); 13C NMR (125 MHz, CDCl3) 
$ 105.7 (C1-"), 105.6 (C1-!), 87.8 (C4-"), 87.6 (C4-!), 73.0 (C3-"), 72.3 (C3-!), 
63.6 (C5-"), 63.3 (C5-!), 55.6 (OMe-"), 55.0 (OMe-!), 42.8 (C2-"), 41.7 (C2-!); 
HRMS(ESI) m/z calcd. for [C6H12O4+Na]+:171.0628, obsd.:171.0631. 
 
General procedure for the synthesis of methyl iodo-glycosides.  
To a solution of methyl glycoside (164 mg, 1 mmol) in dry THF (5.5 mL) under 
an atmosphere of N2, PPh3 (393 mg, 1.5 mmol) and imidazole (136 mg, 2 mmol) 
were added. I2 (380 mg, 1.5 mmol) in dry THF (1.5 mL) was cannulated into the 
reaction vessel. The reaction was refluxed for 2 h, then cooled, filtered and 
concentrated. The product was taken up in Petroleum ether/EtOAc, 3/1, v/v, and 
filtered through a silica plug to removed excess iodine, then purified by column 
chromatography on reverse phase HP-20 beads (MeOH/water, 5/1, v/v) to give 
the methyl iodo-D-glycosides. 
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O OMe
HO
I
OH Methyl 5-deoxy-5-iodo-!/"-D-riboside (9). By subjecting D-
ribose (8) (1.02 g, 6.22 mmol) to the general procedure for the formation of 
methyl iodo-glycosides,  riboside 9 was obtained as an amorphous white solid in a 
1:9 ratio of !- and "- anomers (1.14 g, 4.15 mmol, 67%). Rf = 0.63 
(EtOAc/MeOH, 9/1, v/v); [!]D19 = -61.0 (c = 0.8, CHCl3); IR (film) 3423, 1218, 
770 cm-1. 1H NMR (500 MHz, CDCl3) $ 4.87 (s, 1H, H-1), 4.23 (dd, J2,3 = 5.0, 
J3,4 = 5.9 Hz, 1H, H-3), 4.12 (d, J2,3 = 5.0 Hz, 1H, H-2), 4.06 (dt, J4,5b = 7.4, J3,4  = 
J4,5a = 5.9 Hz, 1H, H-4), 3.39 (s, 3H, OMe), 3.35 (dd, J4,5a = 5.9, J5a,5b = 10.1 Hz, 
1H, H-5a), 3.30 (dd, J4,5b = 7.4, J5a,5b = 10.1 Hz, 1H, H-5b) 2.8 (br s, 1H, OH), 2.7 
(br s, 1H, OH); 13C NMR (125 MHz, CDCl3) $ 108.2 (C1), 82.8 (C4), 75.7 (C2), 
75.6 (C3), 55.3 (OMe), 7.9 (C5); HRMS(ESI) m/z calcd. for [C6H11O4I+Na]+: 
296.9594, obsd.: 296.9595. 
 
O OMe
HO
I
OH Methyl 5-deoxy-5-iodo-D-arabinofuranoside (14).  By 
subjecting methyl D-arabinoside 13 (4.20 g, 28 mmol) to the general procedure 
for the synthesis of methyl iodo-glycosides, arabinoside 14 was obtained as a 
colourless oil (5.62 g, 20.5 mmol, 73%). Rf = 0.60 (15% MeOH in EtOAc); [!]D20 
= +37.0 (c = 2.2, CHCl3); IR (film), 3435, 1216, 770 cm-1; 1H NMR (500 MHz, 
CDCl3): $ 4.96 (s, 1H, H-1!), 4.86 (d, J1",2" = 4.6 Hz, 1H, H-1"), 4.17 (d, J2!,3! = 
1.9 Hz, 1H, H-2!), 4.12 (dd, J1",2" = 4.6, J2",3" = 7.0 Hz, 1H, H-2"), 4.07 (dt, J3!,4! 
= 3.9, J4!,5a! = J4!,5a! = 5.8 Hz, 1H, H-4!), 4.04 (ddd, J3",4" = 3.2, J4",5a" = 6.1, 
J4",5b" = 7.0 Hz, 1H, H-4"), 3.95 (dd, J3",4" = 3.2, J2",3" = 7.0 Hz, 1H, H-3"), 3.91 
(dd, J2!,3! = 1.9, J3!,4! = 3.9 Hz, 1H, H-3!) 3.48 (s, 3H, "-OMe), 3.42 (s, 3H, !-
OMe), 3.41 (dd, J4!,5a! = 5.8, J5a!,5b! = 10.5 Hz, 1H, H-5a!), 3.37 (dd, J4!,5b! = 5.8, 
J5a!,5b! = 10.5 Hz, 1H, H-5b!), 3.33 (dd, J4",5a" = 6.1, J5a",5b" = 10.0 Hz, H-5a"), 
3.30 (dd, J4",5b" = 7.0, J5a",5b" = 10.0 Hz, H-5a!); 13C NMR (125 MHz, CDCl3) $ 
108.9 (C1-!), 101.9 (C1-"), 84.7 (C4-!), 81.5 (C3-"), 81.0 (C3-!), 80.8 (C2-!), 
80.6 (C4-"), 78.6 (C2-"), 55.6 (C6-"), 55.2 (C6-!), 8.0 (C5-"), 6.6 (C5-!); 
HRMS(ESI) m/z calcd. for [C6H11O4I+Na]+: 296.9594, obsd.: 296.9598. 
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O OMe
HO
I
Methyl 2,5-dideoxy-5-iodo-!/"-D-riboside (19). By subjecting 
methyl 2-deoxy-!/"-D-riboside (18, 201 mg, 1.36 mmol) to the general procedure 
for the synthesis of methyl iodo-glycosides, except stirring at room temperature 
for 18 h (rather than 2 h at reflux), methyl 2,5-iodo-D-riboside 19 was obtained as 
an oil (257 mg, 0.99 mmol, 73%). Rf = 0.6 (15% MeOH in EtOAc); [!]D17 = -2.05 
(c = 1.0, CHCl3); IR (film), 3475, 2986, 2874, 2829, 1416, 1441, 1062, 1016 cm-1; 
1H NMR (500 MHz, CDCl3) $ 5.14 (d, J1,2b = 4.5 Hz, 1H, H-1"), 5.12 (dd, J1,2b = 
1.6, J1,2a = 5.2 Hz 1H, H-1!), 4.49 (ddd, J2a,3 = 4.1, J2b,3 = 6.6, J3,4 = 10.7 Hz, 1H, 
H-3"), 4.14 (m, 3H, H-3!, H-4", H-4!), 3.39 (s, 3H, OMe-"), 3.36 (s, 3H, OMe-
!), 3.32 (dd, J4,5a = 5.8, J5a,5b = 9.5 Hz, 1H, H-5a"), 3.26 (dd, J5a,4 = 4.9, J5a,5b = 
10.5 Hz, 1H, H-5a!), 3.20 (t, J5a,5b = J4,5b = 9.5 Hz, 1H, H-5b"), 3.18 (dd, J4,5b = 
6.3, J5a,5b = 10.5 Hz, 1H, H-5b!), 2.32 (ddd, J1,2b = 1.6, J2b,3 = 6.8, J2a,2b = 13.5 
Hz, 1H, H-2a!), 2.23 (ddd, J1,2b = 4.5, J2b,3 = 6.6, J2a,2b = 14.2 Hz, 1H, H-2b"), 
2.13 (td, J1,2a = J2a,3 = 5.2, J2a,2b = 13.5 Hz, 1H, H-2b!), 2.00 (dd, J2a,3 = 4.1, J2a,2b 
= 14.2 Hz, 1H, H-2a"); 13C NMR (125 MHz, CDCl3) $ 105.8 (C1-"), 105.4 (C1-
!), 86.2 (C4-"), 86.0 (C4-!), 75.8 (C3-"), 75.6 (C3-!), 55.3 (OMe-"), 55.1 (OMe-
!), 41.9 (C2-"), 40.9 (C2-!), 7.9 (C5-"), 6.7 (C5-!); HRMS(ESI) m/z calcd. for 
[C6H11O3I+Na]+: 280.9645, obsd.: 280.9655. 
 
O
HO
OH
OMe
I
OH
Methyl 6-deoxy-6-iodo-!-D-galactopyranose (23). To a 
mixture of 1,2:3,4-O-di-isopropyl-!-D-galactopyanose (2.6 g, 10 mmol), PPh3 
(3.93 g, 15 mmol) and imidazole (1.36 g, 20 mmol) in dry THF (100 mL), was 
added iodine (3.81 g, 15 mmol) in small portions. After refluxing for 1h, the 
reaction mixture was cooled to rt, and quenched by the addition of 10% aq. 
Na2S2O4. The product was extracted with EtOAc, and the combined organic 
layers were washed with brine, dried (MgSO4), filtered and concentrated. 
Distillation of the residue gave 6-deoxy-6-iodo-1,2:3,4-O-di-isopropyl-!-D-
galactopyranose   as a yellow oil (3.14 g, 8.48 mmol, 85%). AcCl (1.8 mL) was 
added drop wise to a mixture of 6-deoxy-6-iodo-1,2:3,4-O-di-isopropyl-!-D-
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galactopyranose (3.14 g, 8.48 mmol) in MeOH (60 mL). After stirring for 2 days, 
the mixture was concentrated in vacuo and the residue crystallised from MeOH, to 
give the title compound (2.37 g, 7.80 mmol, 92%) as white crystals. Mp 175.0–
175.6 °C; Rf = 0.43 (MeOH/EtOAc, 1/9, v/v); IR (film) 3354, 3227, 3007, 2953, 
2935, 2906, 2836, 1454, 1417, 1360, 1347, 1297, 1257, 1200, 1145, 1132, 1102, 
1078, 1026, 999, 935, 886, 854, 790, 721, 691, 657 cm-1; 1H NMR (500 MHz, 
D2O) $ 4.69 (d, J1,2 = 3.6 Hz, 1H, H-1), 3.97 (dd, J3,4 = 3.3, J4,5 = 1.2 Hz, 1H, H-
4), 3.90 (ddd, J4,5 = 1.2 Hz, J5,6a = 5.3, J5,6b = 8.0 Hz 1H, H-5), 3.75 (dd, J1,2 = 3.6, 
J2,3 = 10.2 Hz, 1H, H-2), 3.69 (dd, J2,3 = 10.2, J3,4 = 3.3 Hz, 1H, H-3), 3.46 (s, 3H, 
OMe), 3.37 (dd, J5,6a = 5.3, J6a,6b = 10.2 Hz, 1H, H-6a), 3.33 (dd, J5,6b = 8.0, J6a,6b 
= 10.2 Hz, 1H, H-6b); 13C NMR (125 MHz, D2O) $ 100.2 (C1), 71.4 (C5), 70.4 
(C4), 69.9 (C2), 68.4 (C3), 54.6 (OMe), 2.3 (C6). HRMS(ESI) m/z calcd. for 
[C7H13IO5+Na]+: 326.9700, obsd.: 326.9709. 
 
O
HO
OH
OMe
I
OH
Methyl 6-deoxy-6-iodo-!-D-glucopyranose (33). By 
subjecting methyl D-glucose 32 (6.0 g, 30.9 mmol) to the general procedure 
for the synthesis of methyl iodo-glycosides, and then crystallising from 
ethanol, glucoside 33 was obtained as white crystals (9.2 g, 30.3 mmol, 
98%). Mp 147.2–148.2 °C; Rf = 0.5 (EtOAc/MeOH, 85/15, v/v); IR (film) 
3337, 2916, 2840, 1626, 1455, 1410, 1371, 1313, 1195, 1011, 932, 883, 748, cm-
1; 1H NMR (500 MHz, D2O) $ 4.67 (d, J1,2 = 3.9 Hz, 1H, H-1), 3.57 (dd, J3,4 = 
9.1, J2,3 9.8 Hz, 1H, H-3), 3.51 (dd, J5,6 = 2.1, J6a,6b = 10.7 Hz, 1H, H-6a), 3.46 
(dd, J1,2 = 3.9, J2,3 = 9.8 Hz, 1H, H-2), 3.34 (s, 3H, OMe), 3.32 (ddd, J5,6a = 2.1, 
J5,6b = 6.4, J4,5 = 9.1 Hz, 1H, H-5), 3.28 (dd, J5,6b = 6.4, J6a,6b = 10.7 Hz, 1H, H-
6b), 3.20 (t, J3,4 = J4,5 = 9.1 Hz, 1H, H-4); 13C NMR (125 MHz, D2O) $ 99.3 (C1), 
73.4 (C4), 72.4 (C3), 71.2 (C2), 70.1 (C5), 55.3 (OMe), 6.6 (C6); HRMS(ESI) 
m/z calcd. for [C7H13IO5+Na]+: 326.9700, obsd.: 326.9706. 
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O
O
O
OMe
I
Methyl 2,6-dideoxy-6-iodo-3,4-O-isopropylidene-!/"-D-
galactopyranoside (44). To a solution of 2-deoxy-D-galatose (200 mg, 0.61 
mmol) in MeOH/Acetone/dimethoxypropane (2/2/2 mL) AcCl (180 µL) was 
added and the solution stirred 18 h at room temperature. The reaction was 
quenched with basic dowex, filtered and concentrated. The resulting oil was used 
without purification. Rf = 0.13 (Ethyl Acetate/Petroleum Ether, 1/1, v/v); 1H NMR 
(500 MHz, CDCl3) $ 4.86 (dd, J1,2a = 5.1, J1,2b = 6.0 Hz, 1H, H-1), 4.47 (ddd, J2b,3 
= 4.1, J2a,3 = 5.1, J3,4 = 6.9 Hz, 1H, H-3), 4.16 (dd, J4,5 = 1.7, J3,4 = 6.9 Hz, 1H, H-
4), 3.89 (dd, J5,6a = 5.6, J6a,6b = 10.6 Hz, 1H, H-6a), 3.80 (ddd, J4,5 = 1.7, J5,6b = 
4.3, J5,6a = 5.6 Hz, 1H, H-5), 3.77 (dd, J5,6b = 4.3, J6a,6b = 10.6 Hz, 1H, H-6b), 3.37 
(s, 3H, OMe), 2.17 (dt, J2a,2b = 14.8, J1,2a = J2a,3 = 5.1 Hz, 1H, H-2a), 1.73 (ddd, 
J2b,3 = 4.1, J1,2b = 6.0, J2a,2b = 14.8 Hz, 1H, H-2b), 1.47 (s, iPr), 1.31 (s, iPr); 13C 
NMR (75 MHz, CDCl3) 109.2 (iPr-C(CH3)2) 97.4 (C1), 73.4 (C4), 70.5 (C3), 68.5 
(C5), 62.8 (C6), 55.0 (OMe), 30.8 (C2), 26.8, 25.3 (iPr-C(CH3)2); HRMS(ESI) 
m/z calcd. for [C10H18O5+Na]+: 241.1046, obsd.: 241.1046. To a solution of 43 
(0.61 mmol) in THF (7 mL) was added PPh3 (456 mg, 1.74 mmol), imidazole 
(180 mg, 2.62 mmol) and I2 (442 mg, 174 mmol). The mixture was stirred at 
reflux for 18 h, then cooled and concentrated. The syrup was redissolved in Ethyl 
Acetate (20 mL) and washed sat. aq. Na2S2O3 (2 x 15 mL) Brine (20 mL), dried 
MgSO4, filtered and concentrated. The resulting oil was purified by flash column 
chromatography (Petroleum Ether/EtOAc, 15/1, v/v) then crystallised from 
hexanes to give 44 as white crystals (142 mg, 0.434 mmol, 72% from 2-dexoy-D-
galactose), Rf = 0.77 (Petroleum Ether/EtOAc, 1/1, v/v); Mp 91-92 °C; [!]D21 = 
+72.4 (c = 1.0, CHCl3); IR (film) 2982, 2936, 2912, 2833, 1439, 1373, 1246, 
1214, 1186, 1088, 1047, 969, 880, 738 cm-1. 1H NMR (500 MHz, CDCl3) $ 4.86 
(dd, J1,2a = 5.4, J1,2b = 6.6 Hz, 1H, H-1), 4.49 (ddd, J2b,3 = 3.7, J2a,3 = 4.6, J3,4 = 7.3 
Hz, 1H, H-3), 4.26 (dd, J4,5 = 2.0, J3,4 = 7.3 Hz, 1H, H-4), 3.86 (ddd, J5,4 = 2.0, 
J5,6a = 5.8, J5,6b = 8.1 Hz, 1H, H-5), 3.47 (s, 3H, OMe), 3.34 (dd, J5,6a = 5.8, J6a,6b 
= 10.2 Hz, 1H, H-6a), 3.28 (dd, J5,6b = 8.1, J6a,6b = 10.2 Hz, 1H, H-6b), 2.24 (ddd, 
J2a,3 = 4.6, J1,2a = 5.4, J2a,2b = 15.1 Hz, 1H, H-2a), 1.64 (ddd, J2b,3 = 3.7, J1,2b = 6.6, 
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J2a,2b = 15.1 Hz, 1H, H-2b), 1.48 (s, 3H, iPr), 1.34 (s, 3H, iPr); 13C NMR (75 
MHz, CDCl3) 109.3 (iPr-C(CH3)2) 97.6 (C1), 73.4 (C4), 70.9 (C3), 70.0 (C5), 
55.2 (OMe), 30.2 (C2), 26.6, 25.2 (iPr-C(CH3)2), 3.2 (C6); HRMS(ESI) m/z calcd. 
for [C10H17O4I+Na]+: 351.0064, obsd.: 351.0072. 
 
 
O
HO
OH
OMe
I
 Methyl 2,6-dideoxy-6-iodo-!/"-D-galactopyranoside (45). To 
a solution of iodo-galactoside 44 (237 mg, 0.79 mmol) in MeOH (10 ml), at 0 °C 
AcCl (200 #l) was added. The reaction was stirred at room temperature for 5 
days, quenched with Dowex (OH-) and then concentrated in vacuo. The product 
was purified via gradient flash column chromatography (Petroleum Ether/EtOAc, 
3/1 to 1/1, v/v) to provide galactoside 45 as a colourless oil (200 mg, 0.69 mmol, 
94%). Rf = 0.11 (EtOAc); [!]D21 = +0.11 (c = 1.0, MeOH); IR (film) 3292, 2925, 
2854, 1735, 1457, 1209, 1130, 1034, 668 cm-1; 1H NMR (500 MHz, CD3OD) $ 
4.71 (d, J1,2a = 3.6 Hz, 1H, H-1), 3.81 (ddd, J3,4 = 3.2, J2b,3 = 4.1, J2b,3 = 12.6 Hz, 
1H, H-3), 3.78-3.72 (m, 2H, H-4 and H-5), 3.31 (s, 1H, OCH3), 3.30-3.22 (m, 2H, 
H-6a and H-6b), 1.82 (td, J2a,2b = J2a,3 = 12.6, J1,2a = 3.6, Hz, 1H, H-2a), 1.62 (dd, 
J2b,3 = 5.1, J2a,2b = 12.6 Hz, 1H, H-2b); 13C NMR (125 MHz, CD3OD) $ 100.3 
(C1), 72.9 (C4), 70.5 (C5), 66.7 (C3), 55.5 (OCH3), 33.1 (C2), 4.5 (C6); 
HRMS(ESI)  m/z calcd. for [C7H13O4I+Na]+: 310.9751, obsd.: 310.9756. 
 
General procedure for the synthesis of alkenylamines. 
To a solution of methyl iodo-glycoside (274 mg, 1 mmol) in a saturated solution 
of NH4OAc in EtOH (20 mL) was added activated Zn (327 mg, 5 mmol), 
NaCNBH3 (3 mmol) and 30% aqueous NH3 (8 mL). The mixture was stirred at 
reflux for 18 h, cooled to room temperature, filtered to remove excess zinc, and 
concentrated under reduced pressure. The residue was redissolved in H2O, loaded 
on to a Dowex H+ ion exchange resin, and washed several times with H2O to 
remove excess salt. The amine product was then eluted with 15 to 30% aqueous 
NH3. The eluent was concentrated under reduced pressure then converted to the 
HCl salt using 1M HCl. If necessary, further purification could be achieved using 
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gradient flash chromatography (DCM/EtOH/MeOH/30% aqueous NH3, 25/2/2/1 
to 5/2/2/1, v/v/v/v). 
 
NH2
OH
OH
OH  (2S,3S,4S)-1-Amino-hex-5-ene-2,3,4-triol (27). By 
subjecting triol 23 (520 mg, 1.71 mmol) to the general procedure for the synthesis 
of alkenylamines, alkenylamine 27 was obtained as the HCl salt (215 mg, 1.46 
mmol, 86%). Rf = 0.14 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); 
[!]D20 = -20.3 (c = 1.0, EtOH); IR (film) 3304, 2922, 1624, 1507, 1424, 1298, 
1032, 998, 932, 836 cm-1; 1H NMR (500 MHz, D2O) $ 5.93 (ddd, J4,5 = 7.0, J5,6-cis 
= 10.5, J5,6-trans = 17.4 Hz, 1H, H-5), 5.35 (dt, J5,6-trans = 17.4, J4,6-trans = J6-cis,6-trans 
= 1.2 Hz, 1H, H-6-trans), 5.29 (dt, J5,6-cis = 10.5, J4,6-cis = J6-cis,6-trans = 1.2 Hz 1H, 
H-6-cis), 4.12 (dd, J3,4 = 8.0, J4,5 = 7.1 Hz, 1H, H-4), 4.10 (ddd, J2,3 = 2.4, J1a,2 = 
7.5, J1b,2 = 7.5 Hz, 1H, H-2), 3.44 (dd, J2,3 = 2.4, J3,4 = 8.0 Hz, 1H, H-3), 3.13 (m, 
2H, H-1a and H-1b); 13C NMR (125 MHz, D2O) $ 136.8 (C5), 118.3 (C6), 73.7 
(C3), 72.0 (C4), 66.3 (C2), 42.4 (C1). HRMS(ESI) m/z calcd. for 
[C6H13NO3+H]+:148.0968, obsd.:148.0973. 
 
NH2
OH
OH
 (3S,4R)-1-Amino-hex-5-ene-3,4-diol (46).  By subjecting 
methyl iodoglycoside 45 to the general procedure for the synthesis of 
alkenylamines, alkenylamine 46 was obtained as the HCl salt (35 mg, 0.211 
mmol, 99%). Rf  = 0.11 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); 
[!]D25 = -114 (c = 0.1, EtOH); IR (film) 3370, 3321, 2962, 2836, 1642, 1504, 
1435, 1378, 1025, 652 cm-1. 1H NMR (500 MHz, D2O) $ 5.74 (ddd, J4,5 = 6.2, 
J5,6-cis = 10.3, J5,6-trans = 17.1 Hz, 1H, H-5), 5.17 (d, J5,6-trans = 17.1 Hz, 1H, H-6-
cis), 5.14 (d, J5,6-cis = 10.3 Hz, 1H, H-6-trans), 3.90 (dd, J3,4 = 4.6, J4,5 = 6.2 Hz, 
1H, H-4), 3.56 (ddd, J2a,3 = 3.2, J3,4 = 4.6, J2b,3 = 9.6 Hz, 1H, H-3), 2.71 (dd, J1a,2b 
= 5.9, J1a,2a = 8.5, J1a,1b = 12.8 Hz, 1H, H-1a), 2.64 (ddd, J1b,2a = 7.0, J1b,2b = 8.0, 
J1a,1b = 12.8 Hz, 1H, H-1b), 1.59 (dddd, J2a,3 = 3.2, J1b,2a = 7.0, J1a,2a = 8.5, J2a,2b = 
17.5 Hz, 1H, H-2a), 1.42 (dddd, J1a,2b = 5.9, J1b,2b = 8.0, J2b,3 = 9.6, J2a,2b = 17.5 
Hz, 1H, H-2b) ; 13C NMR (75 MHz, D2O) $ 135.5 (C5), 118.0 (C6), 75.4 (C4), 
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71.6 (C3), 37.1 (C1), 28.9 (C2); HRMS(ESI) m/z calcd. for [C6H14O2N+H]+: 
132.1019, obsd.: 132.1022. 
 
General Procedure for the iodo-cyclisation/carbamate formation. 
To a solution of the alkenylamine hydrochloride (154 mg, 1 mmol) in water (5 
mL) was added NaHCO3 (126 mg, 1.5 mmol) and I2 (279 mg, 1.1 mmol). The 
solution was stirred 18 h at room temperature, filtered and concentrated under 
reduced pressure. The product was purified by silica gel chromatography (1-5% 
MeOH in EtOAc, v/v). 
 
N
HO
O
O
OH  (6S,7R,7aS)-6,7-Dihydroxy-tetrahydro-pyrrolo[1,2-c]oxazol-
3(1H)-one (24). By subjecting alkenylamine 23  (30 mg, 0.20 mmol) to the 
general procedure for the iodo-cyclisation/carbamate formation, carbamate 24 was 
isolated as an amorphous white powder (29 mg, 0.18 mmol, 93%). 
Characterisation data was in accordance with literature values.34 [!]D19 = +32.2 (c 
= 0.3, EtOH); IR (film) 3332, 2977, 1717, 1474, 1411, 1250, 1130, 1068 cm-1. 1H 
NMR (500 MHz, D2O) $ 4.52 (m, 3H, H-2, H-5a and H-5b), 4.14 (ddd, J3,4 = 3.1, 
J4,5a = 5.0, J4,5b = 7.9 Hz, 1H, H-4), 4.01 (dd, J3,4 = 3.1, J2,3 = 3.3 Hz, 1H, H-3), 
3.51 (dd, J1a,2 = 8.1, J1a,1b = 10.8 Hz, 1H, H-1a), 3.15 (dd, J1b,2 = 7.9, J1a,1b = 10.8 
Hz, 1H, H-1b); 13C NMR (75 MHz, D2O) $ 164.1 (C6), 73.2 (C2), 70.6 (C3), 64.3 
(C5), 61.5 (C4), 48.6 (C1); HRMS(ESI) m/z calcd. for [C6H9O4N+Na]+: 
182.0424, obsd.: 182.0429. 
N
HO
O
O
OH  (6R,7R,7aS)-6,7-Dihydroxy-tetrahydro-pyrrolo[1,2-c]oxazol-3 
(1H)-one (16).  By subjecting alkenylamine 15 (40 mg, 0.26 mmol) to the general 
procedure for the iodo-cyclisation/carbamate formation, carbamate 16 was 
isolated as an amorphous white powder (38.5 mg, 0.24 mmol, 93%). [!]D18 = 
+20.1 (c = 0.6, EtOH); IR (film) 3372, 2954, 2845, 1715, 1635, 1416, 1253, 1079, 
955 cm-1; 1H NMR (500 MHz, D2O) $ 4.51 (t, J4,5a = J5a,5b = 9.2 Hz, 1H, H-5a) 
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4.38 (dd, J4,5b = 2.9, J5a,5b = 9.2 Hz, 1H, H-5b), 4.27 (d, J1a,2 = 5.1 Hz, 1H, H-2), 
4.17 (dt, J4,5a = 9.2, J4,5b = J3,4 = 2.9 Hz, 1H, H-4), 3.90 (d, J3,4 = 2.9 Hz, 1H, H-3), 
3.67 (dd, J1a,2 = 5.1, J1a,1b = 12.5 Hz, 1H, H-1a), 3.01 (d, J1a,1b = 12.5 Hz, 1H, H-
1b); 13C NMR (125 MHz, D2O) $ 164.4 (C=O), 76.5 (C2), 74.3 (C3), 64.0 (C5), 
62.0 (C4), 52.2 (C1); HRMS(ESI) m/z calcd. for [C6H9O4N+Na]+: 182.0429, 
obsd.: 182.0424. 
 
N
HO
O
O
 (7S,7aS)-7-Hydroxy-tetrahydro-pyrrolo[1,2-c]oxazol-3(1H)-one (21). 
By subjecting alkenylamine 20 (30 mg, 0.21 mmol) to the general procedure for 
iodo-cyclisation, carbamate 21 was obtained as an amorphous white powder (27 
mg, 0.19 mmol, 90%). [!]D17 = +7.0 (c = 0.1, EtOH); IR (film), 3419, 3385, 3047, 
2986, 2931, 1730, 1448, 1087 cm-1; 1H NMR (500 MHz, D2O) $ 4.42 (t, J4,5a = 
J5a,5b = 9.2 Hz, 1H, H-5a), 4.34 (dd, J4,5b = 3.6, J5a,5b = 9.2 Hz, 1H, H-5b), 4.08 (t, 
J3,4 = J2a,3 = 3.6 Hz, 1H, H-3), 3.90 (td, J3,4 = J4,5b = 3.6, J4,5a = 9.2 Hz, 1H, H-4), 
3.37 (ddd, J1a,2b = 8.1, J1a,2a = 9.5, J1a,1b = 10.9 Hz, 1H, H-1a), 3.15 (ddd, J1b,2b = 
2.2, J1b,2a = 10.0, J1a,1b = 10.9 Hz, 1H, H-1b), 2.06 (ddd, J1a,2a = 9.5, J1b,2a = 10.0, 
J2a,2b = 14.2 Hz, 1H, H-2a), 1.93 (ddd, J1b,2b = 2.2, J1a,2b = 8.1, J2a,2b = 14.2 Hz, 
1H, H-2b); 13C NMR (125 MHz, D2O) $ 171.0 (C=O), 69.6 (C3), 64.4 (C4), 64.3 
(C5), 43.0 (C1), 33.7 (C2). HRMS(ESI) m/z calcd. for [C6H9NO3+Na]+:166.0475 
obsd.:166.0480. 
 
 
N
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31   
(6S,7R,8S,8aR)-6,7,8-Trihydroxy-hexahydro-oxazolo[3,4-a]pyridin-3(5H)-
one (28a), (6S,7R,8S,8aS)-6,7,8-Trihydroxy-hexahydro-oxazolo[3,4-a]pyridin-
3(5H)-one (28b) and (1R,7S,8S,9R)-8,9-Dihydroxy-3,10-dioxa-5-aza-
bicyclo[5.2.1]decan-4-one (31). A suspension of alkenylamine hydrochloride 27 
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(79 mg, 0.50 mmol) and I2 (0.59 g, 2.3 mmol) in sat. aq. NaHCO3 (2 mL) was 
stirred for 3 d at 40 °C, filtered and concentrated under reduced pressure. The 
residue was taken up in EtOH, subsequently passed through Dowex-H+ and 
Dowex-OH- resin columns by eluting with EtOH, concentrated and purified by 
silica gel chromatography (EtOAc/MeOH, 100/0 to 97/3, v/v) to obtain carbamate 
28b (20 mg, 0.12 mmol, 25%) and a mixture of 28a and 31 (60 mg, 0.36 mmol, 
75%) as amorphous white powders. Carbamate 28a: Rf = 0.21 (MeOH/EtOAc, 
2/8, v/v); IR (film): 3419, 3385, 2928, 2856, 1710, 1662, 1393, 1267, 1125, 1073, 
1046, 1013, 883, 740 cm-1; 1H NMR (500 MHz, D2O) $ 4.47 (t, J5,6a = J6a,6b = 9.0 
Hz, 1H, H-6a), 4.35 (dd, J5,6b = 5.0, J6a,6b = 9.0 Hz, 1H, H-6b), 4.05 (ddd, J4,5 = 
1.9, J5,6b = 5.0, J5,6a = 9.0 Hz, 1H, H-5), 3.96 (dd, J4,5 = 1.9, J3,4 = 2.3 Hz, 1H, H-
4), 3.90 (dd, J1a,2 = 6.1, J1a,1b = 13.1 Hz, 1H, H-1a), 3.79 (ddd, J1a,2 = 6.1,  J2,3 = 
9.7, J1b,2 = 10.5 Hz, 1H, H-2), 3.57 (dd, J3,4 = 2.3, J2,3 = 9.7 Hz, 1H, H-3), 2.82 
(dd, J1b,2 = 10.5, J1a,1b = 13.1 Hz, 1H, H-1b); 13C NMR (125 MHz, D2O) $ 159.7 
(C7), 73.6 (C3), 69.0 (C4), 65.0 (C2), 63.9 (C6), 56.6 (C5), 44.0 (C1). 
HRMS(ESI) m/z calcd. for [C7H11O5N+Na]+: 212.0535, obsd.: 212.0532. 
Carbamate 28b: Rf = 0.28 (MeOH/EtOAc, 2/8, v/v); IR (film): 3353, 3204, 2931, 
2856, 1730, 1448, 1262, 1124, 1087, 1046, 1013, 996 cm-1; 1H NMR (500 MHz, 
D2O) $ 4.43 (t, J5,6a = J6a,6b = 8.8 Hz, 1H, H-6a), 4.18 (dd, J5,6b = 5.1, J6a,6b = 8.8 
Hz, 1H, H-6b), 3.89-3.85 (m, 2H, H-2 and H-3), 3.80 (ddd, J4,5 = 10.2, J5,6a = 8.8, 
J5,6b = 5.1 Hz, 1H, H-5), 3.71 (dd, J4,5 = 10.2, J3,4 = 2.5 Hz, 1H, H-4), 3.90 (bd, 
J1a,1b = 14.3 Hz, 1H, H-1a), 3.21 (dd, J1a,1b = 14.3, J1b,2 = 1.6 Hz, 1H, H-1b); 13C 
NMR (100MHz, D2O) $ 159.7 (C=O), 70.0 (C3), 68.3 (C2), 67.7 (C4), 67.0 (C6), 
53.4 (C5), 41.7 (C1); HRMS(ESI) m/z calcd. for [C7H11O5N+Na]+: 212.0535, 
obsd.: 212.0529. Carbamate 31: Rf = 0.21 (MeOH/EtOAc, 2/8, v/v); IR (film): 
3419, 3385, 2928, 2856, 1710, 1662, 1393, 1267, 1125, 1073, 1046, 1013, 883, 
740 cm-1; 1H NMR (500 MHz, D2O) $ 4.23-4.21 (m, 1H, H-6a), 4.14 (d, J1a,2 = 
4.6 Hz, 1H, H-2), 4.12 (d, J3,4 = 2.8 Hz, 1H, H-3), 4.02-3.95 (m, 2H, H-5 and H-
6b), 3.62 (dd, J1a,1b = 12.6, J1a,2 = 4.6 Hz, 1H, H-1a), 3.61-3.58 (m, 1H, H-4), 3.23 
(brd, J1a,1b = 12.6 Hz, 1H, H-1a); 13C NMR (125 MHz, D2O) $ 155.0 (C=O), 73.6 
(C2), 72.5 (C3), 69.1 (C6), 62.8 (C4), 58.7 (C5), 53.0 (C1); HRMS(ESI) m/z 
calcd. for [C7H11O5N+Na]+: 212.0533, obsd.: 212.0529. 
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N
O
HO
OH
O
 (7R,8S,8aR)-7,8-Dihydroxy-hexahydro-oxazolo[3,4-a]pyridin-
3(5H)-one (47a). To a solution of alkenylamine hydrochloride 46 (17 mg, 0.13 
mmol) in sat. aq. NaHCO3 (0.6 ml), I2 (32 mg, 0.25 mmol) was added. The 
solution was stirred 24 h at 50 °C then filtered and concentrated in vacuo. 
Purification by flash chromatography (EtOAc/MeOH, 99/1, v/v) yielded 
carbamate 47a. (15.1 mg, 0.0873 mmol, 86 %). [!]D19 = + 4.0 (c = 1.0, MeOH); 
IR (film) 3338, 2945, 2360, 2342, 1653, 1449, 1417, 1114, 1021 cm-1; 1H NMR 
(500 MHz, D2O) $ 4.34 (t, J5,6 = J6a,6b= 9.0 Hz, 1H, H-6a), 4.22 (dd, J5,6 = 5.5, 
J6a,6b = 9.0 Hz, 1H, H-6b), 3.89 (ddd, J4,5 = 1.8, J5,6b = 5.5, J5,6a = 9.0 Hz, 1H, H-
5), 3.75 (br s, 1H, H-4), 3.72 (ddd, J3,4 = 2.5, J2b,3 = 5.5, J2a,3 = 11.1 Hz, 1H, H-3), 
3.63 (ddd, J1a,2b = 1.9, J1a,2a = 5.3, J1a,1b = 13.6 Hz,  1H, H-1a), 2.92 (ddd, J1b,2b = 
4.5 J1b,2a = 12.0, J1a,1b = 13.6 Hz, 1H, H-1b), 1.62 (m, 2H, H-2a and H-2b). 13C 
NMR (125 MHz, D2O) $ 159.5 (C=O) 68.6 (C3), 67.9 (C4), 64.1 (C6), 57.0 (C5), 
38.5 (C1), 25.1 (C2); HRMS(ESI)  m/z calcd. For [C7H11NO4+Na]+: 196.0580, 
obsd.: 196.0590. 
  
General procedure for the synthesis of azasugars. 
To a solution of carbamate (159 mg, 1 mmol) in EtOH (5 mL) was added NaOH 
(400 mg, 10 mmol). The solution was stirred at reflux for 2 h then cooled and 
purified directly using Dowex (H+). The product was eluted in 5 to 15% aqueous 
NH3 and concentrated under reduced pressure. The isolated compound was 
converted to the HCl salt, using 1M HCl, for characterisation. 
H
N
HO
HO
OH  1,4-dideoxy-1,4-imino-L-lyxitol (2). By subjecting cyclic 
carbamate 11  (6.4 mg, 40 #mol) to the general procedure for the synthesis of 
azasugars, 2 was isolated as the HCl salt (6.6 mg, 39 #mol, 97%). Rf = 0.11 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); [!]D19 = -22.4 (c = 0.3, 
H2O); IR (film) 3369, 3198, 2956, 2857, 1456, 1266, 1127, 1056 cm-1. 1H NMR 
(500 MHz, D2O) $ 4.47 (dt, J2,3 = 4.1, J1a,2 = J1b,2 = 7.4 Hz, 1H, H-2), 4.32 (t, J2,3 
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= J3,4 = 4.2 Hz, 1H, H-3), 3.96 (dd, J4,5a = 5.0, J5a,5b = 12.1 Hz, 1H, H-5a), 3.86 
(dd, J4,5b = 8.4, J5a,5b = 12.1 Hz, 1H, H-5b), 3.71 (ddd, J3,4 = 4.2, J4,5a = 5.0, J4,5b = 
8.4 Hz, 1H, H-4), 3.50 (dd, J1a,2 = 7.4, J1a,1b = 12.2 Hz, 1H, H-1a), 3.18 (dd, J1b,2 = 
7.4, J1a,1b = 12.2 Hz, 1H, H-1b); 13C NMR (125 MHz, D2O) $ 69.9 (C2), 69.7 
(C3), 62.4 (C4), 57.6 (C5), 46.9 (C1); HRMS(ESI) m/z calcd. for 
[C5H11O3N+H]+: 134.0812, obsd.: 134.0813. 
 
H
N
HO
HO
OH  1,4-dideoxy-1,4-imino-L-xylitol (3).  By subjecting cyclic 
carbamate 16 (13 mg, 0.082 mmol) to the general procedure for the synthesis of 
azasugars, 3 was isolated as the HCl salt (13 mg, 0.077 mmol, 97%). Rf = 0.21 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); [!]D20 = +8.2 (c = 0.5, 
H2O); IR (film) 3317, 2944, 2832, 1654, 1449, 1415, 1113, 1021 cm-1; 1H NMR 
(500 MHz, D2O) $ 4.26 (d, J1a,2 = 4.5 Hz, 1H, H-2), 4.19 (d, J3,4 = 3.8 Hz, 1H, H-
3), 3.89 (dd, J4,5a = 5.5, J5a,5b = 11.5 Hz, 1H, H-5a), 3.77 (dd, J4,5b = 7.7, J5a,5b = 
11.5 Hz, 1H, H-5b), 3.62 (ddd, J3,4 = 3.8, J4,5a = 5.5, J4,5b = 7.7 Hz, 1H, H-4), 3.46 
(dd, J1a,2 = 4.5, J1a,1b = 12.8 Hz, 1H, H-1a), 3.04 (d, J1a,1b = 12.8 Hz, 1H, H-1b); 
13C NMR (125 MHz, D2O) $ 74.6 (C2), 74.5 (C3), 62.5 (C4), 57.6 (C5), 50.4 
(C1); HRMS(ESI) m/z calcd. For [C5H11O3N+H]+: 134.0812, obsd.: 134.0817. 
 
H
N
HO
HO
 1,2,4-trideoxy-1,4-imino-L-arabinitol (4). By subjecting carbamate 
21 (10 mg, 0.07 mmol) to the general procedure for the synthesis of azasugars, 4 
was isolated as the HCl salt (8.2 mg, 0.07 mmol, 99%). Rf = 0.1 
(DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); [!]D17 = +10.0 (c = 
0.09, MeOH); IR (film), 3397, 3364, 2960, 2932, 2874, 1720, 1601, 1168, 1064 
cm-1; 1H NMR (500 MHz, D2O) $ 4.27 (dt, J2b,3 = 1.5, J2a,3 = J3,4 = 4.9 Hz, 1H, H-
3), 3.98 (dd, J4,5a = 4.9, J5a,5b = 12.1 Hz, 1H, H-5a), 3.83 (dd, J4,5b = 8.5, J5a,5b = 
12.1 Hz, 1H, H-5b), 3.31 (td, J3,4 = J4,5a = 4.9, J4,5b = 8.5 Hz, 1H, H-4), 3.25 (ddd, 
J1a,2b = 7.6, J1a,2a = 9.6, J1a,1b = 11.6 Hz, 1H, H-1a), 3.21 (ddd, J1b,2b = 3.4, J1b,2a = 
9.9, J1a,1b = 11.6 Hz, 1H, H-1b), 2.13 (dddd, J2a,3 = 4.9, J2a,1a = 9.6, J2a,1b = 9.9, 
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J2a,2b = 14.1 Hz, 1H, H-2a), 2.05 (dddd, J2b,3 = 1.5, J2b,1b = 3.4, J2b,1a = 7.6, J2a,2b = 
14.1 Hz, 1H, H-2b); 13C NMR (125 MHz, D2O) $ 70.8 (C3), 64.1 (C4), 59.0 (C5), 
42.9 (C2), 33.3 (C1). HRMS(ESI) m/z calcd. for [C5H11NO2+H]+: 118.0863 obsd.: 
118.0870. 
 
H
N
HO
OH
OH
HO
 Deoxygalactonojirimycin (5). A 1:1 mixture of carbamates 
28a and 31 (20 mg, 0.12 mmol) and NaOH (200 mg) were dissolved in EtOH and 
refluxed for 2 h. The reaction was cooled to rt, loaded onto a Dowex-H+ column, 
eluted with 50% conc. aq. NH3 in EtOH and concentrated. Purification of the 
residue by column chromatography gave the title compound (10 mg, 0.06 mmol, 
quant.) as a white solid. Rf = 0.1 (DCM/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, 
v/v/v/v); 1H NMR (300 MHz, D2O) $ 4.13 (dd, J4,5 = 1.4, J3,4 = 3.2 Hz, 1H, H-4), 
4.04 (ddd, J1a,2 = 5.4, J1b,2 = 10.9 Hz, J2,3 = 9.7 Hz, 1H, H-2), 3.85 (dd, J5,6a = 6.7, 
J6a,6b = 11.2 Hz, 1H, H-6a), 3.77 (dd, J5,6b = 6.7, J6a,6b = 11.2 Hz, 1H, H-6b), 3.60 
(dd, J2,3 = 9.7, J3,4 = 3.2 Hz, 1H, H-3), 3.48 (dd, J1a,2 = 5.4,  J1a,1b = 12.7 Hz, 1H, 
H-1a), 3.39 (dt, J4,5 = 1.4, J5,6a = J5,6b = 6.7 Hz, 1H, H-5), 2.84 (dd, J1a,1b = 12.7, 
J1b,2 = 10.9 Hz, 1H, H-1b); HRMS(ESI) m/z calcd. for [C6H13O4N+H]+: 164.0917, 
obsd.: 164.0916. 
 
 
 
O
HO OH
I NH2
1-Amino-2,5-anhydro-1,6-dideoxy-6-iodo-L-iditol (35). 
To a solution of alkenylamine 34 (310 mg, 1.69 mmol) in sat. aq. NaHCO3 (7 mL) 
was added I2 (645 mg, 2.54 mmol) and the solution was stirred 7 days. The 
reaction mixture was concentrated and used without further purification. Rf = 0.23 
(DCM/EtOH/MeOH/30% aq. NH3, 5/2/2/1, v/v/v/v); 1H NMR (500 MHz, D2O) $ 
4.45 (dt, J4,5 = 3.1, J5,6a = J5,6b = 7.3 Hz, 1H, H-5), 4.40 (ddd, J2,3 = 3.8, J1a,2 = 4.4, 
J1b,2 = 5.6 Hz, 1H, H-2), 4.38 (dd, J3,4 = 1.3, J2,3 = 3.8 Hz, 1H, H-3), 4.28 (dd, J3,4 
= 1.3, J4,5 = 3.1 Hz, 1H, H-4), 3.27 (dd, J5,6a = 7.3, J6a,6b = 9.8 Hz, 1H, H-6a), 3.26 
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(dd, J5,6b = 7.3, J6a,6b = 9.8 Hz, 1H, H-6b), 3.258 (dd, J1a,2 = 4.4, J1a,1b = 13.6 Hz, 
1H, H-1a), 3.23 (dd, J1b,2 = 5.6, J1a,1b = 13.6 Hz, 1H, H-1b); 13C NMR (125 MHz, 
D2O) $ 81.7 (C5), 77.5 (C3), 76.52, 76.50 (C2 and C4), 39.4 (C1), 0.6 (C6); 
HRMS(ESI) m/z calcd. for [C6H12O3NI+H]+: 273.9935, obsd.: 273.9938. 
 
O
AcO OAc
I NHAc
 1-Acetamido-3,4-di-O-acetyl-2,5-anhydro-1,6-dideoxy-6-
iodo-L-iditol (37). A solution of iditol 35 was stirred over night at rt in a solution 
of Acetic anhydride (4 mL) and pyridine (4 mL). The reaction mixture was 
concentrated, the dissolved in EtOAc and washed sat. aq. NaHCO3 and brine, 
dried MgSO4, filtered and concentrated in vacuo to give acetylated iditol 37 as the 
major product. Rf = 0.12 (EtOAc); 1H NMR (500 MHz, CDCl3) $ 5.84 (t, J1a,NH = 
J1b,NH = 6.2 Hz, 1H, NH), 5.38 (dd, J3,4, = 1.4, J4,5 = 4.0 Hz, 1H, H-4), 5.27 (dd, 
J3,4, = 1.4, J2,3 = 3.4 Hz, 1H, H-3), 4.52 (ddd, J4,5 = 4.0, J5,6a = 6.3, J5,6b = 8.8 Hz, 
1H, H-5), 4.30 (ddd, J2,3 = 3.4, J1b,2 = 6.2, J1a,2 = 7.3 Hz, 1H, H-2), 3.47 (ddd, 
J1a,NH = 6.2, , J1a,2 = 7.3, J1a,1b = 14.0 Hz, 1H, H-1a), 3.27 (td, J1b,NH = J1b,2 = 6.2, 
J1a,1b = 14.0 Hz, 1H, H-1b), 3.21 (dd, J5,6a = 6.3, J6a,6b = 9.7 Hz, 1H, H-6a), 3.17 
(dd, J5,6b = 8.8, J6a,6b = 9.7 Hz, 1H, H-6b); 13C NMR (125 MHz, CDCl3) $ 79.6 
(C5), 78.9 (C2), 76.4 (C3), 76.1 (C4), 38.1 (C1), -0.6 (C6); HRMS(ESI) m/z 
calcd. for [C12H19O6NI+Na]+: 422.0071, obsd.: 422.0076. 
 
O
O
HO OMe  Methyl 3,6-anhydro-2-deoxy-!-D-galactopyranoside (42). 
Rf = 0.3 (EtOAc/MeOH, 98/2, v/v); 1H NMR (500 MHz, D2O) $ 4.69 (d, J1,2b = 
6.2 Hz, 1H, H-1), 4.31-4.32 (m, 2H, H-3 and H-6a), 4.27-4.28 (m, 1H, H-5), 4.02 
(d, J3,4 = 1.8 Hz, 1H, H-4), 3.98 (dd, J5,6b = 3.4, J6a,6b = 9.9 Hz, 1H, H-6b), 3.40 (s, 
3H, OMe), 2.19 (dd, J2a,3 = 4.6, J2a,2b =14.5 Hz, 1H, H-2a), 2.02 (ddd, J2b,3 = 1.6, 
J1,2b = 6.2, J2a,2b = 14.5 Hz, 1H, H-2b); 13C NMR (125 MHz, D2O) $ 97.2 (C1), 
77.8 (C3), 77.3 (C5), 74.8 (C4), 70.2 (C6), 55.7 (OMe), 37.6 (C2); HRMS(ESI) 
m/z calcd. for [C7H12O4+Na]+: 183.0633, obsd.: 183.0631. 
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Chapter 7: Anti-Tubercular Activity of Azasugars 
and Linear Alkenylamines 
7.1 Introduction 
Tuberculosis (Tb) is caused by mycobacteria, most commonly Mycobacterium 
tuberculosis, and continues to be the leading cause of death by infectious disease.1 
Annually, Tb kills more than 1.8 million people world-wide, and in New Zealand, 
there are between 350 and 400 new cases of Tb each year.2 There have been no 
new drugs developed for the treatment of Tb since the late 1960s, and the 
prevalence of multi and extreme drug resistant tuberculosis strains is increasing.3 
An estimated one third of the world’s population are infected with tuberculosis 
and, on average, 10% of infected people will develop active Tb. The high 
incidence of M. tuberculosis infection highlights the importance of new 
treatments to reduce the prevalence of this disease. 
 
Tb is difficult to treat, requiring long courses of multiple antibiotics. Currently, 
the standard short course drug treatment for active tuberculosis is isoniazid, 
rifampin, pyrazinamide and ethambutol for two months, then isoniazid and 
rifampin alone for a further four months.4 A patient is considered cured after these 
six months, however, the relapse rate is 2 to 3%. For latent Tb, the standard 
treatment is six to nine months of isoniazid alone.4 The treatment of active Tb 
always involves a combination of several drugs. Regimens that use only one drug 
result in the rapid development of bacterial resistance and subsequent treatment 
failure.5 Due to the lengthy therapy that relies on several drug combinations, 
patients with TB often do not complete the full drug course.1 Non-compliance 
increases the risk of drug resistant strains developing, thereby threatening the 
ability to treat and control the disease. Currently, there are many multi-drug 
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resistant (MDR) and extreme-drug resistant (XDR) M. tuberculosis strains. MDR 
is defined as resistance to isoniazid and rifampin, two of the most powerful first 
line drugs.6 To treat MDR Tb, healthcare providers use a combination of second-
line drugs, which may have more side effects. Such a treatment is longer and costs 
up to 100 times more.7 XDR Tb occurs when a M. tuberculosis strain is resistant 
to isoniazid, rifampin, a fluoroquinolone, and at least one of kanamycin, 
capreomycin, or amikacin. XDR Tb strains may also be resistant to additional 
drugs, further complicating the treatment. 
 
M. tuberculosis has a thick outer cell wall that plays a critical role in the intrinsic 
resistance of mycobacteria to antibiotics, chemical injury and the immune 
response.8 As a result, a number of drugs act by inhibiting the biosynthesis of this 
protective coating. Some of the abundant constituents of in the cell wall include 
the arabinogalactan (AG) polysaccharides, and the lipophilic mycolic acids. The 
first line drugs used to treat Tb are isoniazid, rifampin, pyrazinamide and 
ethambutol. Isoniazid is a pro-drug, which is activated in mycobacteria, and leads 
to the inhibition of mycolic acid biosynthesis, thereby resulting in bacterial death 
(Figure 7.1).4,9 Rifampin inhibits mRNA synthesis,9 and pyrazinamide, also a pro-
drug, most likely acts by disrupting the bacterial cell membrane potential. 
Ethambutol inhibits arabinosyl transferase enzymes10 responsible for the 
biosynthesis of the arabinan polysaccharides that form vital components of the 
cell wall.9 Disruption of the cell wall biosynthesis prevents mycobacterial growth 
and replication. Some of the more commonly used second line drugs include the 
fluoroquinolones (e.g. moxifloxacin), streptomycin, kanamycin A, B and C, 
amikacin and capreomycin.9 Most of the drugs in this class are broad-spectrum 
antibiotics and target enzymes involved in DNA transcription or translation. A 
summary of key Tb drugs and their modes of action are presented in Figure 7.1. 
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Figure 7.1. Commonly used first and second line Tb drugs and their mode of 
action. 
 
In the quest to develop new Tb drugs we focused our efforts on developing 
potential drugs that could work by targeting cell wall biosynthesis. As azasugars 
can inhibit glycosyl transferase enzymes, there is potential that azasugar mimics 
could be used to inhibit arabinosyl transferase enzymes required for the 
biosynthesis of the protective M. tuberculosis cell wall. In addition, the 
alkenylamine precursors have some similarity to ethambutol, a known AraT 
inhibitor. It is also known that new drugs can be found through screening libraries 
of compounds, therefore it is also worth testing all azasugar products and 
synthetic intermediates made so far. Accordingly, the anti-tubercular activity of 
two target inhibitor series was investigated (Table 7.1). The first was a series of 
substrate like azasugar transition state mimics, and the second, was a series of 
ethambutol like inhibitors.  
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Table 7.1. Target AraT inhibitor series. 
DPA 
Substrate for AraTs 
Azasugars 
Potential substrate-like inhibitors 
OH
HO
O
HO O P O
O
OH 8
 
H
N
HO
HO OH  
 
Ethambutol 
Known AraT inhibitor 
Linear amines 
Potential ethambutol-like 
inhibitors 
HO N
H
H
N OH
 
NH2
OH
OH
 
 
7.2 Results and Discussion 
Optimisation of the BCG alamar blue assay 
To investigate the potential of our compounds to act as Tb drugs, we needed to 
develop an assay to screen for anti-tubercular activity. For this we chose to use a 
Bacillus Calmette-Gérin (BCG) Alamar Blue growth inhibition assay. This robust 
assay is frequently used in the literature and allows for the rapid and safe 
screening of anti-tubercular compounds.11-13 BCG is a strain of Mycobacterium 
bovis that has lost its virulence in humans by being cultured in artificial medium 
for years. Alamar Blue, a redox active dye, is primarily composed of the non-
fluorescent compound resazurin (Figure 7.2, blue in colour) which, when reduced, 
is converted to the pink and highly fluorescent resorufin. Actively dividing cells 
produce NADPH, which reduces resazurin to resorufin. Therefore, if a compound 
inhibits BCG growth, the dye will remain blue and very little fluorescence will be 
observed, however, if no bacterial growth inhibition occurs, the dye will turn pink 
and fluoresce.  
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O
N
OHO
O
 
Figure 7.2. Resazurin. 
 
Though the Alamar Blue assay has been widely used in the literature, it needed to 
be optimised in our laboratory to establish: 1) the initial concentration of bacteria 
that should be used; 2) the number of days the bacteria should be incubated; and 
3) the time (number of hours after the addition of Alamar Blue) that fluorescence 
should be measured at. A titration experiment was established using a 96 well 
black clear bottom plate, where the outside wells were filled with PBS and 
replenished at regular intervals to reduce evaporation. If this was not done, 
inconsistent assay results were obtained. In rows B through to G (Figure 7.3), two 
fold dilutions of bacteria were added, starting with a concentration of 1.28x106 
bacteria* per mL, 20 !L of Alamar Blue was added to rows B and C, and the plate 
was incubated at 37 °C. The fluorescence of rows B and C was read at 19, 24, 26 
and 28 hours after the addition of Alamar Blue. On day 4, 20 !L of Alamar Blue 
was added to rows D and E, and the fluorescence of these rows read at 17, 19, 24 
and 26 hours after Alamar Blue addition. Finally, on day 7, Alamar Blue was 
added to rows F and G and the fluorescence of these rows read at 2, 18, 23 and 26 
hours post addition (Figure 7.4). 
                                                 
* M. bovis BCG Pasteur strain 1173P2 was gifted by AgResearch Wallaceville 
Animal Research Centre, Upper Hutt, New Zealand. 
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                   Decreasing Bacteria Concentration 
  1 2 3 4 5 6 7 8 9 10 11 12 
 A             
B                Day 
0 C                 
D             Day 
4 E             
F             Day 
7 G             
 H             
Figure 7.3. Diagram of plate used for BCG assay. Bacteria were added to the 
plate in two fold dilutions (from 1.28x106 per mL, going down to 5.0x103 bacteria 
per mL). 
 
Titration curves were then plotted to determine the optimal initial concentration of 
BCG, the length of incubation, and the time at which fluorescence should be read 
(Figure 7.4). From these results, we can see that reading the fluorescence 2 hours 
post Alamar Blue addition (day 7, hour 2) gives inconsistent results, and a 
titration curve is not observed. Between 17 and 26 hours post the addition of 
Alamar blue, the fluorescence readings are more consistent (days 0, 4 and 7). 
Therefore, fluorescence was measured at 24 hours post Alamar blue addition in 
subsequent experiments, as this was a convenient time point. To determine the 
initial concentration of bacteria and optimal incubation period required, we 
investigated initial concentrations of bacteria that gave very little fluorescence at 
day 0, and maximum fluorescence after 4 or 7 days. From the titration curve it can 
be observed that an initial concentration of bacteria of 40,000/mL, gave a 
fluorescence reading close to zero on day 0. By day 7 these bacteria had grown to 
such an extent that they produced approximately maximal fluorescence. This 
point on the graph gave the greatest difference between fluorescence on day 0 and 
fluorescence on day 7. Therefore, an initial bacteria concentration of 40,000 
bacteria per mL and an incubation time of 7 days was determined optimum for all 
subsequent assays. 
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Figure 7.4. BCG titration curve. Each bacterial concentration was repeated twice, 
error bars represent SE. 
 
 
These experimental conditions were then assessed by conducting an ethambutol 
titration. Two fold dilutions of ethambutol, in triplicate, were incubated for 7 days 
with 8,000 bacteria per well (40,000 bacteria per mL). The results from this 
experiment were plotted and a dose response curve obtained (Figure 7.5). The 
minimum inhibitory concentration (MIC) was determined to be 29 !M. In the 
literature the MIC of ethambutol against M. tuberculosis (H37Rv) in vitro was 
reported as 2 !M,9 however, the MIC against a BCG strain has been reported as 
7 !M.14 The MIC obtained using this alamar blue assay is, therefore, comparable 
to literature.  
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Figure 7.5. Ethambutol Titration. Each concentration was repeated in triplicate, 
error bars represent SE. 
 
Testing azasugars and linear alkenylamines 
Having established the optimal conditions for the BCG Alamar Blue assay, a 
series of azasugars (1 to 8, Table 7.2) and linear alkenylamines (10 to 15) were 
tested for their ability to inhibit the growth of BCG. Each compound was tested at 
six concentrations, in two fold dilutions beginning at 500 !g/mL, and each of 
these series was repeated in triplicate. On each plate two negative controls (PBS 
only and the compounds being tested in PBS only) and a positive control (bacteria 
in PBS only) and an ethambutol titration control (115 to 4 !M) were included. A 
photograph of the Alamar Blue BCG assay in which alkenylamine 14 was tested 
is given (Figure 7.6). This illustrates the colour change of the blue resazurin to the 
pink resorufin resulting from bacterial production of NADPH. Unfortunately, 
cyclic carbamates 1 to 4 and azasugars 5 to 8 did not demonstrate any inhibitory 
activity (MIC >3.5 mM). (Diphenylmethyl)amine (9) demonstrated modest 
activity with an MIC between 1.36 – 2.73 mM. Alkenylamines 10 to 13 did not 
demonstrate any inhibitory activity, however, (diphenylmethyl)amine 
functionalised alkenylamine 14 (Figure 7.6) and the methylated derivative 15 
demonstrated modest activity, inhibiting bacterial growth at 0.44 – 0.88 mM and 
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0.80 – 1.61 mM, respectively (Table 7.2). This inhibitory activity was greater than 
that observed with (diphenylmethyl)amine (9) alone (1.36 – 2.73 mM).  
 
 
Figure 7.6. Photograph of BCG Alamar Blue assay demonstrating the inhibitory 
activity of 14 in two fold dilutions, beginning at 1.8 mM, repeated in triplicate. 
14 1.8 mM  Ethambutol 
control 
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Table 7.2. Compounds tested in the BCG Alamar Blue assay and their MIC 
values. 
Substrate Like Inhibitors 
N
O
O
HO OH  
1 
N
O
O
HO OH  
2 
N
O
O
HO OH  
3 
> 3.5 mM > 3.5 mM > 3.5 mM 
N
O
O
HO  
4 
 
H
N
HO
HO
OH  
5 
 
H
N
HO
HO
 
6 
> 3.5 mM > 3.5 mM > 3.5 mM 
 
H
N
HO
HO
OH  
7 
 
H
N
HO
HO
OH  
8 
H2N
 
9 
> 3.5 mM > 3.5 mM 1.36 – 2.73 mM 
 
Ethambutol Like Inhibitors 
NH2
OH
OH
 
10 
NH2
OH
OH
 
11 
NH2
OH
OH
 
12 
> 3.5 mM > 3.5 mM > 3.5 mM 
 
NH2
OH  
 
13 
H
N
OH
OH
 
14 
H
N
OMe
OMe
 
15 
> 3.5 mM 0.44 – 0.88 mM 0.80 – 1.61 mM 
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The lack of activity observed for the unprotected azasugars (1 to 8) and 
alkenylamines (10 to 13, Table 7.1) may be due to the hydrophilicity of the 
compounds, making it difficult for them to travel through the high lipid content of 
the bacterial cell wall. Compounds with a hydrophobic moiety, such as 
alkenylamines 14 and 15, may more readily pass through this waxy coating to 
penetrate the cell and inhibit growth. Given this, the addition of a lipid tail to the 
azasugar scaffold is a potentially interesting avenue for further research. 
 
The activity of 14 could, in turn, potentially be improved by altering the lipophilic 
group present on the amine. In the future, a library of alkenylamines with different 
stereochemistry and various lipids could be synthesised and screened for BCG 
inhibition. It would also be valuable to investigate the activity of these compounds 
toward other tuberculosis strains (e.g. M. smegmatis, and M. tuberculosis) and test 
their specificity by investigating their ability to inhibit the growth of other 
bacteria (e.g. Escherichia coli or Staphylococcus aureus). The toxicity of the 
compounds toward human cells should also be investigated as well as their ability 
to inhibit the growth of dormant mycobacteria found in macrophages.  
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7.3 Experimental 
O
HO OH
OH
HO
O
MeO OMe
OMe
HO
4 steps
see ref. 16
I2, PPh3, Imid.
THF, 3 h
O
MeO OMe
OMe
I
Zn, H2NCHPh2
NaCNBH3, EtOH
AcOH
H
N
OMe
OMe
15
D-xylose 16 17
 
Scheme 7.1. Synthesis of methylated alkenylamine 15. 
 
O
MeO OMe
OMe
HO
Methyl 2,3-di-O-methyl-!/"-D-xylofuranoside (16). 
Synthesised in four steps from D-xylose. Data matched that previously reported.15  
 
O
MeO OMe
OMe
I
 Methyl 5-deoxy-2,3-di-O-methyl-5-iodo-!/"-D-
xylofuranoside (17). To a solution of 16 (301 mg, 1.57 mmol) in THF (20 mL) 
was added PPh3 (616 mg, 2.35 mmol), and imidazole (214 mg, 3.14 mmol) and 
the resulting mixture stirred at reflux for 3 h, then cooled filtered and concentrated 
in vacuo. The crude reaction mixture was purified by silica gel flash column 
chromatography (Petroleum Ether/EtOAc, 5/1, v/v) to give 17 as a colourless oil 
(160 mg, 0.53 mmol, 34%). Rf  = 0.71 (EtOAc); 1H NMR (500 MHz, CDCl3) # 
4.98 (d, J1,2 = 4.4 Hz, 1H, H-1!), 4.87 (s, 1H, H-1"), 4.45 (m, 1H, H-4"), 4.37 
(td, J3,4 = J4,5a = 6.2, J4,5b = 7.3 Hz, 1H, H-4!), 3.86 (dd, J2,3 = 5.4, J3,4 =6.2 Hz, 
1H, H-3!), 3.77 (dd, J1,2 = 4.4, J2,3 = 5.4 Hz, 1H, H-2!), 3.74-3.73 (m, 2H, H-2" 
and H-3"), 3.43 (s, 3H, OMe), 3.41 (s, 3H, OMe), 3.36 (dd, J4,5a = 7.3, J5a,5b = 9.7 
Hz, 1H, H-5a"), 3.31 (dd, J4,5a = 6.2, J5a,5b = 10.1 Hz, 1H, H-5a!), 3.27 (dd, J4,5b 
= 7.5, J5a,5b = 9.7 Hz, 1H, H-5b"), 3.16 (dd, J4,5b = 7.3, J5a,5b = 10.1 Hz, 1H, H-
5b!); 13C NMR (125 MHz, CDCl3) # 108.0 (C1"), 100.8 (C1!), 88.1 (C2"), 85.9 
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(C2!), 83.7 (C3"), 83.5 (C3!), 81.9 (C4"), 77.8 (C4!), 60.3 (OMe), 55.5 (OMe), 
3.6 (C5"), 2.4 (C5!); HRMS(ESI) m/z calcd. for [C8H15O4I+Na]+: 324.9907, 
obsd.: 324.9915. 
 
H
N
OMe
OMe
(2S,3S)-1-(Diphenylmethyl)amino-2,3-di-O-methyl-
pent-4-ene-2,3-diol (15). To a solution of methyl iodosugar 17 (144 mg, 
0.48mmol) in EtOH/H2O (15 mL/0.3 mL) was added activated Zn (125 mg, 1.91 
mmol), aminodiphenylmethane (288 µL, 307 mg, 1.67 mmol), NaCNBH3 (102 
mg, 0.96 mmol), and AcOH (50 µL) and the solution was stirred at reflux for 18 
h. The reaction mixture was cooled, and dry loaded onto a silica gel by the 
addition of silica gel to the dissolved material followed by evaporation of the 
solvent under reduced pressure. The silica gel was loaded onto a silica gel column 
for purification by flash column chromatography (Petroleum ether/EtOAc, 10/1, 
v/v) to give alkenylamine 15 as a colourless oil (119 mg, 0.80 mmol, 80%). Rf  = 
0.53 (EtOAc); [!]D17 = -10.0 (c = 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) # 
7.34 – 7.10 (m, 10H, aromatics), 5.68 (ddd, J3,4 = 7.7, J4,5-cis = 10.4, J4,5-trans =  
17.3 Hz, 1H, H-4), 5.29 (d, J4,5-trans =  17.3 Hz, 1H, H-5trans), 5.25 (d, J4,5-cis = 
10.4 Hz, 1H, H-5cis), 4.78 (s, 1H, CH-Ph2), 3.77 (dd, J2,3 = 5.9, J3,4 = 7.7 Hz, 1H, 
H-3), 3.47 (s, 3H, OMe), 3.39 (ddd, J1a,2 = 4.1, J2,3 = 5.9, J1b,2 = 6.8 Hz, 1H, H-2), 
3.30 (s, 3H, OMe), 2.74 (dd, J1a,2 = 4.1, J1a,1b = 12.3 Hz, 1H, H-1a), 2.60 (dd, J1b,2 
= 6.8, J1a,1b = 12.3 Hz, 1H, H-1b); 13C NMR (125 MHz, CDCl3) # 144.2, 143.8 
(aromatics), 134.9 (C4), 128.5, 128.4, 127.6, 127.4, 127.3, 127.0, 126.9, 
(aromatics), 118.8 (C5), 83.8 (C3), 82.7 (C2), 67.7 (CH-Ph2), 58.9 (OMe), 56.7 
(OMe), 47.9 (C1); HRMS(ESI) m/z calcd. for [C20H25NO2+H]+: 312.1958, obsd.: 
312.1959. 
Growing BCG stock 
Preparation of Tween albumin broth (TAB) 
1.3 g Dubos Broth Base was dissolved (Difco, Detroit, Michigan, USA) in 180 
mL deionised H2O in a schott bottle (200 ml). The solution was then sterilised by 
autoclaving, the solution was cooled to below 50˚C and 20 mL oleic albumin 
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dextrose catalase (OADC) growth supplement (Difco)* was added. Note that if 
OADC is added when the media is too hot, the proteins will denature. Though the 
enrichment (OACD) comes “free from contaminating microorganisms” it was 
also filtered before use as an added precaution (using a 0.2 !m filter). 10 mL 
volumes of the prepared TAB were dispensed into 50 mL tissue culture flasks 
(Falcon®, Becton Dickinson Labware).  
 
Growing BCG 
One vial of frozen BCG Pasteur 1173P2 stock was defrosted.** The defrosted 
BCG were inoculated into a 50 mL Falcon tube with 10 mL TAB. The flask was 
incubated at 37 °C until log phase growth was reached (takes up to 7 days – judge 
by eye looking for increased turbidity). Five mL of this media was removed to 
replace stock BCG vial. The remaining 5 mL was made up to a volume of 40 mL 
using TAB. Once this flask reached log phase growth, it was split into 4 times 10 
mL batches, put into 4 times 75 cm3 flasks and each flask made up to 100 mL 
total volume using TAB. Once these flasks had reached log phase growth, they 
were each split in half, to give 8 times 50 mL flasks, and each was made up to 250 
mL total volume using TAB. The BCG were harvested into 50 mL (or larger) 
Falcon tubes, and centrifuged for 30 minutes at 3115 g, 4 °C. The BCG were 
washed twice in sterile PBS (pH 7.4) containing 0.05% Tween 80 
(Polyoxyethylene sorbitol monooleate, Sigma). Finally, the BCG were suspended 
in 10-15 mL of sterile PBS containing 0.05% Tween 80 (Polyoxyethylene sorbitol 
monooleate, Sigma) and vortexed (in hood) vigorously.  Aliquots from 0.25 mL to 
1 mL were prepared in 1.8 mL Cryotubes™ (Nalge Nunc), and kept frozen at -70 
°C until use.   
 
To enumerate viable BCG, a one in ten fold serial dilution of sample aliquots was 
prepared (from 1 to 10-6). A Middlebrook 7H11 agar* with 10% OADC 
enrichment was divided into six sections, and onto one section 3 times 10 µL of 
                                                 
* Difco, Fort Richard Laboratories, Auckland, NZ. 
**M. bovis BCG Pasteur strain 1173P2 was gifted by AgResearch Wallaceville 
Animal Research Centre, Upper Hutt, New Zealand. 
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the 1x10-1 serial dilution was dropped. This was repeated for the remaining 
concentrations (from 1x10-2 to 1x10-6) and the agar was incubated at 37 °C for 21 
days, then the colonies were counted.  To confirm that the batch of BCG was free 
from contaminating micro-organisms, 100 !l of the BCG aliquot was incubated at 
37 °C for 5 days (if it is sterile, nothing should grow).  
 
BCG alamar blue assay 
 
Samples: Compounds were dissolved in sterile PBS (sterile DMSO was added if 
necessary – up to 5%) to make solutions of 1 mg/mL. The samples were then 
filtered (Acrodisc 13 mm syringe filter, with 0.22 µm pore size).  
BCG: BCG were defrosted, then sonicated for 10 seconds, and placed on ice for 
10 seconds, this was repeated twice. Stock BCG solutions were made to 8x104 
bacteria/mL using sterile TAB (pH 6.6) to suspend. 
Assay: In a black clear bottom 96 well plate, two fold serial dilutions of each 
compound in triplicate were added, in volumes of 100 µL, all outer wells were left 
unused. An ethambutol titration (two fold dilutions from 115 to 4 µM) was 
included as a positive control, as well as a positive BCG only control in triplicate, 
and two negative controls (media only and media and compound only) also in 
triplicate. 100 µL of BCG stock was added to the appropriate wells and all the 
other wells were made up to 200 µL using sterile PBS. 200 µL PBS was added to 
the outer wells. The plate was then incubated at 37 °C, 5% CO2 for 7 days (day of 
set up was day 0), the outer wells were filled over the incubation period. On day 
7, 20 µL of Alamar Blue (Invitrogen) was added to all the test wells and the plate 
was incubated a further 24 h. Fluorescence was read using a FLUOstar optima 
plate reader with an excitation filter of 544 nm, and an emission filter of 590 nm. 
Fluorescence values were determined by subtracting the fluorescence of the 
negative control wells from the fluorescence of the test wells. 
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Global Conclusions and Future Prospects 
 
The findings from the work reported in this thesis can be divided into two 
sections. In the first section, two !-GalCer glycolipid analogues were synthesised 
in order to investigate the importance of the 4-hydroxyl for iNKT cell activation. 
Here I found that the activity of the two 4-deoxy !-GalCer analogues was 
species-specific. The 4-deoxy !-GalCer sphinganine and sphingosine analogues 
demonstrated comparable activity to !-GalCer in mice. Toward human iNKT 
cells, however, the 4-deoxy analogues demonstrated significantly reduced iNKT 
cell activity. The reduced activity is attributed to species-specific differences in 
iNKT cell glycolipid recognition rather than reduced CD1d presentation. From 
these results we suggest that glycolipids developed for potent CD1d-iNKT cell 
activity in humans should contain a ceramide base with the 4-hydroxyl present.  
 
A number of !-GalCer analogues with modifications to the lipid portion have 
been synthesised to investigate the structural requirements for CD1d binding and 
iNKT cell activation. However, only a few studies have focused on modifications 
to the carbohydrate head group. In the future it would be valuable to investigate 
the ability of glycolipids with additional carbohydrate groups to bind to CD1d and 
activate iNKT cells. The majority of the carbohydrate-modified glycolipids that 
have been investigated for activity often possess the 4-deoxy sphingosine lipid, 
e.g. iGb3. Therefore, it would be valuable to investigate the activity of 
carbohydrate modified glycolipid analogues containing the phytosphingosine lipid 
base. 
 
The second section of this thesis focused on developing protecting group free 
methodology for the synthesis of azasugars. In this work two new reaction 
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methodologies were discovered. These facilitated the protecting group free 
synthesis of five membered azasugars. The first reaction allowed for the synthesis 
of primary amines directly from aldehydes. The most important factors leading to 
the chemoselective synthesis of primary amines were a pH of approximately 12, a 
large excess of ammonia, and an aldehyde concentration of 20 mL of ethanol per 
mmol. Overall, the reductive amination methodology was applicable to a wide 
range of functionalised substrates. The second reaction was a carbamate 
annulation for the stereoselective synthesis of cyclic carbamates from olefinic 
amines. Overall, this carbamate annulation methodology shows great potential for 
the synthesis of five membered azasugars. However, competition between the 
formation of five and six membered cyclisation products can limit the scope of the 
methodology for the synthesis of six membered azasugars. Our two new synthetic 
methodologies are important additions to the chemist’s toolbox and we believe 
that both methodologies will find wide application in the synthesis of azasugars 
and other organic molecules without using protecting groups.  
 
In the future it would be valuable to investigate the ability for these azasugars to 
inhibit glycosidase and glycosyl transferase enzymes. If specific inhibitory 
activity is observed the active azasugar(s) could be developed to treat a specific 
disease. In addition lead compounds could be modified by the addition of 
lipophilic moieties, this could lead to improved inhibitory activity. The protecting 
group free methodology could also be expanded by developing additional 
reactions that can be conducted in water without the use of protecting groups. 
Specifically, the development of a carbon-carbon bond forming reaction that 
could be performed without the use of protecting groups would be a valuable 
addition to the methodology developed in this thesis. This would enable 
additional classes of molecules to be accessed via protecting group free 
methodology.  
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Appendix – NMR Spectra 
 
Chapter 2: Spectra of final glycolipids 
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Chapter 4: Spectra of carbamate and primary alkenylamine
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